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neurodegeneration.! The! disease! is! a! major! cause! of! neurological! disability! and!
dysfunction!in!young!adults!that!affects!more!than!two!million!people!worldwide.!
In! Spain,! the! prevalence! of! the! disease! is! approximately! 102A160! per! 100,000!
population! according! to! the! current! estimates.! The! disease! typically!manifests! at!
20A40! years! of! age! when! people! are! in! their! full! employment! and! sometimes!
develops!into!an!aggressive!stage!that!alters!the!lives!of!patients!and!their!families.!
Unfortunately!the!current!treatments!are!only!effective!in!preventing!relapses!and!
slowing!down!progression!but! not! completely! ceasing! it! and! the!development! of!
more!effective!treatments!has!been!hindered!by!our! limited!understanding!of!MS!
pathogenesis.!!
Axonal! damage! is! widely! accepted! as! the! major! cause! of! persistent! functional!
disability! in! MS! patients,! although! its! origin! is! unknown.! During! the! relapsingA
remitting! disease! course! the! patient’s! brain! itself! is! capable! of! repairing! the!
damage,! remyelinating! the! axon! and! recovering! the! neurological! function.!
Cerebrospinal! fluid! (CSF)! is! in! contact!with! the! brain! parenchyma! and! ventricles,!
which!can!be!a!site! for!deposition!of!cellular!damage!products! that!can! influence!
the! cellular! physiology! of! neurons,! oligodendrocyte! progenitor! cells! (OPCs)! and!
myelinating!oligodendrocytes.!It!is!a!promising!biofluid!in!the!search!for!biomarkers!
and! disease! associated! proteins! in! MS,! both! with! respect! to! inflammatory! and!
neurodegenerative! processes.! Factors! released! in! CSF! of! MS! patients! including!
apoptotic! factors,! cytokines,! proteolytic! enzymes,! oxidative! products! and! free!





the!effect!of!CSF!on!OPCs,!which! could! contain! factors! that!damage!OPCs!during!
attempts! at! brain! repair.! Identification! of! these! mechanisms! involved! in! axonal!
degenerationAreconstruction!may!shed! light! in!understanding!MS!progression!and!
/or!prognosis.!
Furthermore,! we! were! interested! in! identifying! potential! biomarkers! using!
genomics! based! approach! that! could! differentiate! MS! from! another! similar! but!
totally! distinct! neurological! disease! known! as! Neuromyelitis! optica! (NMO).! NMO!
shares! many! pathological! similarities! with! MS! and! therefore! it! was! previously!
considered! as! its! variant.! For! this! reason! clinicians! often! used! to! encounter!
difficulty!in!distinguishing!MS!from!NMO!and!hence!similar!treatment!was!provided!
to! both! the! category! of! patients.! However! recent! research! shows! that! there! are!
some! NMO! specific! IgG! antibodies! present! in! the! sera! of! NMO! patients! which!
differentiate!both!the!diseases.!
To!study!primary!neuroaxonal!damage!independent!of!secondary!damage!resulting!
from! demyelination,! we! used! a! cellular! model! with! primary! cultures! of!
unmyelinated! granular! neurons! (CGNs)! from! rat! cerebellum.! CGNs! are! small! and!
the!most! numerous!unmyelinated!neurons.!We!employed! these!primary! cultures!
and!treated!them!with!the!CSF!of!distinct!clinical!forms!of!MS!including!oligoclonal!
bands! of! IgG! +! and! IgM! type! –! relapsing! remitting!MS,! primary! progressive!MS,!
NMO! and! neurological! controls.! Previous! data! in! our! laboratory! experienced!
variation! in! sodium! channel! gene(s)! expression! while! normalizing! them! with!
commonly! used! housekeeping! genes! including! ActB! and! Gapdh,! therefore! to!
further!obtain!accurate!gene!expression!data!it!was!first!necessary!to!validate!these!
reference!genes! for! correct!normalization!of! target!mRNA! transcripts.! To!do! this,!
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we! evaluated! certain! reference! genes! during! the! development! of! cerebellar!
granule! neurons! (CGNs)! and!when! CGNs!were! exposed! to! the! CSF! from!MS! and!
NMO!patients.!!!
Unexpectedly,! we! found! that! Gapdh! showed! significant! variation! in! gene!
expression!when!neurons!were!exposed!to!the!CSF!of!MS!and!NMO!patients.! It! is!
well!known!that!GAPDH!plays!a!crucial!role!in!carbohydrate!metabolism,!therefore,!
we!proposed!to! look!for!perturbance! in!expression!of!genes! implicated! in!glucose!
metabolism! in! treated! neurons.! To! do! this,! we! performed! microarray! gene!
expression! profiling! in! both! neurons! and! proliferating! OPCs! exposed! to! the! CSF!
from! MS! patients! and! looked! at! the! genes! involved! particularly! in! glucose!
metabolism.! Furthermore,! the! stability! of! reference! genes! in! treated! OPCs! was!
validated! using! GeNorm! and! NormFinder! algorithms.! Although! very! limited!
research!has!been!carried!out!so!far!that!indicates!a!role!of!metabolic!disturbances!
in! the! pathogenesis! of! axonal! damage! in! MS! there! is! evidence! that! shows! an!
association!of!neurodegenerative!disease!etiology!with!metabolic!impairment.!
The! present! research! shows! a! significant! variation! in! gene! expression! catalyzing!
essential! steps! of! carbohydrate!metabolism! in! neurons! and!OPCs! exposed! to! the!
CSF! of! different! clinical! forms! of!MS! and!NMO!patients! as! compared! to! neurons!
exposed!to!the!CSF!of!neurological!controls.!These!data!suggest!that!factors!in!CSF!
of!MS! and!NMO!patients! cause! a! disturbance! in!metabolic! gene(s)! expression! in!
neurons!and!oligodendrocytes;!and!demonstrates!that!MS!seems!to!be!associated!
with!metabolic! impairment.! ! The! results! allow! us! to! distinguish! different! clinical!
forms!and!aggressivity!in!MS!patients!and!MS!from!NMO!that!is!sometimes!difficult!
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Multiple! sclerosis! (MS)! is! a! chronic,! inflammatory! and! probably! an! autoimmune!
disease!of!the!central!nervous!system!(CNS)!that!causes!damage!to!myelin!sheath!
[Frohman! et) al.,! 2006].! Autoimmunity! means! that! body’s! natural! immunological!
defense!instead!of!destroying!foreign!cells!destroys!the!body’s!native!cells.!!In!MS,!
the! myelin! sheath! or! white! matter! that! surrounds! and! insulates! nerve! cells! is!
destroyed.! Without! the! myelin! sheath,! nerve! cells! lose! their! ability! to! conduct!
nerve!impulse!because!of!which!the!body!loses!its!ability!to!perform!the!functions!
controlled!by!these!cells.!Demyelination!leaves!a!scar!tissue!(“sclerosis”)!or!lesions!
at!numerous!places! in!CNS!(“multiple”).! !These!scars,!or! lesions,!consist!mostly!of!
dead! nerve! cells,! whose! axons! have! been! denuded! of! the! myelin! sheaths.!
Depending!on!the!location!of!the!lesions!and!axonal!injury,!a!variety!of!symptoms!
can!be!observed!with!muscular! control! the!most! visible! symptom!although!many!
other!brain!functions!are!affected!(Figure!1).!Myelin!loss!may!be!a!result!of!immune!




20A40! years,! the! economic! and! social! spheres! of! patients! and! their! families! are!
severely!affected.!In!Europe!and!North!America,!the!prevalence!of!MS!is!1!in!800,!
with! an! annual! incidence! of! 2! to! 10! per! 100,000! individuals.! In! Spain,! the!
prevalence!of!the!disease!is!approximately!102A160!with!a!mean!prevalence!of!120!
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per! 100,000! with! about! 45,000! patients! according! to! the! current! estimates!
[Fernandez!et)al.,!2012].!!
!








a! consequence! of! inflammatory! demyelination! in! neurodegenerative! diseases.!




MS!patients!affected!with!optic!neuritis! further!support! the!notion! that!damaged!
neurons!in!the!retina!contribute!to!the!functional!insufficiencies!in!MS![Tatrai!et)al.,!
2012].! ! Optic! neuritis! is! an! inflammatory! condition! of! the! optic! nerve! that!
undergoes!demyelination!and!neurodegeneration.!!
In! this! thesis,! we! wanted! to! study! primary! neuronal! damage! independent! of!
secondary!damage!resulting!from!demyelination.!Neuronal!and!nonAneuronal!cells!
of!the!brain! including!oligodendrocytes!and!astrocytes,!all!can!be!regarded!as!the!
cellular! “victims”! in!multiple! sclerosis.!When! oligodendrocytes! (OPCs),! which! are!




determine! the! effect! of! CSF! on! OPCs,! which! could! contain! factors! that! damage!
OPCs! during! attempts! at! brain! repair.! During! the! relapsingAremitting! disease!
course,!the!patient’s!brain!itself! is!capable!of!repairing!the!damage,!remyelinating!
the!axon!and!recovering!the!neurological!function.!Furthermore,!the!cerebrospinal!
fluid! (CSF)! is! a! promising! biofluid! in! the! search! for! biomarkers! and! disease!
associated! proteins! in! MS,! both! with! respect! to! inflammatory! and!
neurodegenerative!processes.!!
In! addition,! we! were! interested! to! identify! potential! biomarkers! that! could!
differentiate!MS!from!another!similar!but!completely!distinct!neurological!disease!
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known! as!Neuromyelitis!Optica! (NMO).! Both! diseases! are! similar!with! respect! to!
their! inflammatory,! demyelinating! and! autoimmune! characteristics! they! exhibit.!
NMO,!also!known!as!Devic’s!disease,!is!defined!as!a!severe!monophasic!syndrome!
characterized!by!bilateral!optic!neuritis,!acute!transverse!myelitis!and!inflammatory!
demyelination! of! the! central! nervous! system! (CNS)! that! selectively! affects! the!
spinal! cord!and!optic!nerves!causing!blindness!and!paralysis!and!spares! the!brain!
[Wingerchuk! et) al.,! 1999].! Because! of! common! features,! clinicians! often!
encountered! difficulty! in! distinguishing! MS! from! NMO.! However,! recent!
neuropathologic! studies! demonstrate! that! NMO! is! characterized! by! very! distinct!
vasculocentric! pathology! with! prominent! immunoglobulin! (Ig)! deposition! in! sera!
and! requires! a! different! treatment! approach.! The! identification! of! NMOAIgG!
antibodies!found!specifically!in!the!sera!of!NMO!patients!distinguishes!the!disease!
from!MS! [Lennon!et)al.,! 2004].! These!antibodies!have!also!been! identified! in! the!
sera! of! two! related! neurologic! conditions,! bilateral! optic! neuritis! (ON),! and!
longitudinal!extensive! transverse!myelitis! (LETM)! that!are!generally! considered! to!
lie!within!the!NMO!spectrum!of!diseases.!About!75%!of!people!with!NMO!have!the!
circulating! NMO! IgG! in! their! sera! [Lennon! et) al.,! 2005].! The! antigenic! target! of!




Previous! data! in! our! laboratory! experienced! variation! in! sodium! channel! gene(s)!
expression! while! normalizing! them! with! commonly! used! housekeeping! genes!
including!ActB! and!Gapdh.! Therefore,! to! further! obtain! accurate! gene!expression!
data,! it! was! first! necessary! to! validate! these! reference! genes! for! correct!
normalisation!of!target!mRNA!transcripts!(2010!Thesis!of!Eduardo!Beltran,!Directed!
by! Dr.! Maria! Burgal,! University! of! Valencia).! Several! recent! studies! have!
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documented! that! the! expression! of! housekeeping! genes! may! not! necessarily! be!
stable!in!all!cells/tissues!under!all!conditions.!A!gene!may!show!stable!expression!in!





metabolism! may! contribute! to! the! pathogenesis! of! axonal! injury! in!





The! French! neurologist! JeanAMartin! Charcot! (1825A1893)! was! the! first! person! to!
recognize!multiple! sclerosis! as! a!distinct!disease! in!1868! [Compston!et)al.,! 1988].!
Summarizing! previous! reports! and! adding! his! own! clinical! observations,! Charcot!
called! the! disease! "sclerose) en) plaques".! The! three! signs! of! MS! now! known! as!
Charcot’s! Triad! are! nystagmus,! intention! tremor! and! telegraphic! speech,! though!
these!are!not!unique! to!MS.!Charcot!also!observed! cognition! changes,!describing!
his! patients! as!having! a! "marked)enfeeblement)of) the)memory"! and! "conceptions)
that)formed)slowly"![Charcot!et)al.,!1868].!
Prior!to!Charcot,!Robert!Carswell!(1793–1857),!a!British!professor!of!pathology,!and!




injuries! he! found! as! "a) remarkable) lesion) of) the) spinal) cord) accompanied) with)
atrophy"! [Compston!et)al.,!2008].!Under! the!microscope,!Swiss!pathologist!Georg!
Eduard! Rindfleisch! (1836–1908)! noted! in! 1863! that! the! inflammationAassociated!
lesions!were!distributed!around!blood!vessels![Lassmann!et)al.,!2005].!)
After! Charcot's! description,! Eugene! Devie! (1858–1930),! Jozsef! Balo! (1895–1979),!
Paul! Ferdinand! Schilder! (1886–1940),! and! Otto! Marburg! (1874–1948)! described!
special! cases! of! the! disease.! During! the! 20th! century,! there! was! an! important!




after! the! disease! as! described! by! Charcot.! A! young!woman! called! Halldora,! who!





Augustus! Frederick!d'Este! (1794–1848),! son!of!Prince!Augustus! Frederick!and! the!
grandson!of!George!III!of!the!United!Kingdom,!almost!certainly!suffered!from!MS.!
D'Este! left! a! detailed! diary! describing! his! 22! years! living! with! the! disease.! His!
symptoms!began!at!age!28!with!a!sudden!transient!visual!loss.!During!the!course!of!
his! disease,! he! developed! weakness! of! the! legs,! clumsiness! of! the! hands,!
numbness,! dizziness,! bladder! disturbances,! and! erectile! dysfunction.! In! 1844,! he!
began! to! use! a!wheelchair.! Another! early! account! of!MS!was! kept! by! the! British!
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The! natural! history! of! MS! is! unpredictable! and! has! been! discussed! for! several!
decades.! Overall,! the! clinical! course! of! the! disease! is! composed! of! two! distinct!
types! of! neurological! episodes,! exacerbations! (relapse)! and! progression.! An!
exacerbation! is! the! reappearance! or!worsening! of! neurological! symptoms! lasting!
more! than!24!hours!with!episodes! seperated!by!at! least!one!month.!A! relapse! is!
usually!followed!by!a!remission!although!in!some!cases!concludes!with!permanent!
neurological! deficit.! Progression! is! defined! as! a! continuous! neurological!
deterioration! for! a! minimum! of! six! months.! The! severity! of! MS! is! commonly!
measured! on! the! Expanded!Disability! Status! Scale! (EDSS)! from! 0.0A10.0! [Kurtzke,!








clinical! courses:! relapsing! remitting! (RR),! secondary! progressive! (SP),! primary!
progressive! (PP),! and! progressive! relapsing! (PR)! [Lublin,! 1996].! However,! these!
clinical!course!descriptors!were!based!on!subjective!views!of!MS!experts!and!lacked!
imaging! and! biological! correlates.! Therefore,! in! 2011,! the! Committee! and! other!
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experts! reAexamined! MS! phenotypes,! exploring! clinical,! imaging,! and! biomarker!
advances!through!working!groups!and!literature!searches.!It!was!proposed!that!the!
core! MS! phenotype! descriptions! of! relapsing! and! progressive! disease! should! be!
retained! with! some! modifications! that! include! consideration! of! disease! activity!
(based! on! clinical! relapse! rate! and! lesion! activity! detected! by! CNS! imaging)! and!
disease! progression! over! a! given! time! period.! Evidence! of! disease! activity! and!
clinical!progression,!which!by!current!understanding!reflects!ongoing!inflammatory!




Clinically! isolated! syndrome! (CIS)! was! not! included! in! the! initial! MS! clinical!
descriptors.!CIS!is!now!recognized!as!the!first!clinical!presentation!of!a!disease!that!
shows!characteristics!of!inflammatory!demyelination!that!could!be!MS,!but!has!yet!
to! fulfill! criteria! of! dissemination! in! time! [Miller! et) al.,! 2005].! Use! of! the! 2010!
revisions!to!the!McDonald!MS!diagnostic!criteria!allows!some!patients!with!a!single!
clinical! episode! to! be! diagnosed! with! MS! based! on! the! single! scan! criterion! for!
dissemination! in! time! and! space! [Polman! et) al.,) 2011],! reducing! the! number! of!
patients!who!will!be!categorized!as!CIS.!In!1989,!Miller!et)al.!prospectively!followed!
clinical! status! and!MRI! imaging! in! patients!who! presented!with! clinically! isolated!
lesions!of! the!brainstem!or! spinal! cord.!MS!progression!occurred! in!13!brainstem!
syndrome!patients!(57%)!and!in!14!spinal!cord!syndrome!patients!(42%)!after!mean!
intervals! of! 15! and! 16! months,! respectively.! Oligoclonal! band! (OCB)! in! the! CSF!





In! RRMS,! patients! experience! an! initial! exacerbation! followed! by! complete! or!
incomplete! recovery! (RR,! relapsingAremitting! sequence).! The! 80A90%! of! patients!
with!MS!has!a!RR!course! in! the! following! ten!years!after! initial!presentation.!The!
disease!begins!with!an! initial!attack!(episode!of!symptom!flareAups)!followed!by!a!
period!of!remission!that!could!be!as!long!as!two!years,!a!second!attack!is!followed!
by! either! another! period! of! remission! or! by! progression,! and! this! is! termed!
secondary!progressive!MS!(SPMS).!Eventually,!remissions!are!of!shorter!durations,!
relapses! become! longer! and! finally! the! patient! enters! a! progressive! stage!
[Noseworthy! et) al.,! 2000].! Figure! 2! shows! the! 1996! vs! 2013! MS! phenotype!
descriptions! for! relapsing! disease.! A! patient! with! RRMS! who! had! a! new!
gadoliniumen!enhancing! lesion!on! a! current!MRI!would!be! considered! to!be!RR–
active!(Figure!2).!Conversely,!“not!active”!as!a!phenotype!modifier!could!be!used!in!


















Figure! 2:! The! 1996! vs! 2013! multiple! sclerosis! phenotype!
descriptions! for! relapsing! disease.! ! *Activity! determined! by!
clinical!relapses!and/or!MRI!activity!(contrastAenhancing!lesions;!
new! or! unequivocally! enlarging! T2! lesions! assessed! at! least!
annually);! if! assessments! are! not! available,! activity! is!
“indeterminate.”! **CIS,! if! subsequently! clinically! active! and!
fulfilling! current! multiple! sclerosis! (MS)! diagnostic! criteria,!
becomes!relapsingAremitting!MS!(RRMS)!
!
there! are! no! clear! clinical,! imaging,! immunologic,! or! pathologic! criteria! to!
determine! the! transition! point! when! RRMS! converts! to! SPMS;! the! transition! is!
usually! gradual.! This! has! limited! our! ability! to! study! the! imaging! and! biomarker!
characteristics! that!may!distinguish! this! course.! Figure!3! shows! the!1996!vs!2013!
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MS! phenotype! descriptions! for! relapsing! disease.! A! patient! with! SPMS! who! has!










no! acute! attacks! and! no!MRI! activity! would! be! considered! to! be! PP–not! active.!





in!South!Africa.! In!1967,!he!gave!an! idea!of! the!annual! incidence,!prevalence!and!
mortality!statistics! for!MS! in!white!South!AfricanAborn! individuals!and! immigrants!
to! South! Africa! [Dean) et) al.,! 1994].! He! also! addressed! the! issue! of! the! marked!













Figure! 3:! The! 1996! vs! 2013! multiple! sclerosis! phenotype!
descriptions!for!progressive!disease!!
*Activity! determined! by! clinical! relapses! assessed! at! least!
annually! and/or! MRI! activity! (contrastAenhancing! lesions;! new!
and! unequivocally! enlarging! T2! lesions).! **Progression!
measured! by! clinical! evaluation,! assessed! at! least! annually.! If!
assessments! are! not! available,! activity! and! progression! are!
“indeterminate.”! MS! =! multiple! sclerosis;! PP! =! primary!








! ! !!!!!!transection!plasticity!! ! ! !!!!!!!!!!!!!!!!gliosis!
! ! !!!!!!and!remyelination!
!
Figure! 4:! The! course! of! multiple! sclerosis.! Initial! acute!
inflammatory! outbreaks! can! result! in! disability,! which! the!
patient!may!initially!recover,!but!later!becomes!progressive.!This!
correlates! to! a! reduction! of! the! inflammatory! events! and!









2! The! “SPMS”! or! "Secondary) progressive) MS"! refers! to! a! secondary!
progressive!event.!(Compston!and!Coles,!2002)!
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frequency!as! compared! to! the!older! immigrant!population.!African!blacks!had!no!
MS! whereas! the! rate! was! higher! in! the! mixed! race! population! (African! and!
Caucasians).! Since! then! numerous! studies! have! been! carried! out! on! migrants! in!
different! countries.! In! UK! in! 1997,! Dean! and! Elian! studied! 76! nonACaucasian!





In!1995!Gale!et)al.! reviewed! the! literature!on!migrant! studies,! comparing!
rates! of! MS! in! migrant! populations! with! those! in! the! host! country! and! in! the!
country!of! origin.! In! their! review! they!underscored! the!problems!associated!with!
interpreting! and! drawing! conclusions! from! such! studies.! Migrating! individuals!
rarely! represent! their! original! general! population.! They! are! often! younger,!














account!of!a!black!patient!with!MS! in!South!Africa!was!published.! In!1994,! seven!
cases!of!black!patients! in!South!Africa!and!five! in!Zimbabwe!were!diagnosed!with!
MS! [Dean! et) al.,! 1994].! Six! of! the! 12! patients! had! severe! optic! neuritis! and!
subsequently!became!blind.!Clinical!features!in!these!few!black!patients!resembled!
those! seen! in! oriental! patients! affected! by! MS! rather! than! those! seen! in! white!
South!Africans!or!the!black!people!of!!
North!America!or! the!Caribbean,! indicating! a! real! difference! in! the!phenotype!of!
the! disease! in! the! population! [Dean! et) al.,! 1994].! ! Approximately! 6%! of! North!
American!MS!patients!have!an!affected!family!member!whereas!in!Asia!and!Chile,!
the! figure! is!much! lower.! In! 1979,! Kurtzke! et) al.! studied! 5305!World!War! II! and!
Korean!conflict!veterans!who!were!diagnosed!with!MS!and!matched!to!controls!on!
the!basis!of!age!and!date!of!entry!into!military!service.!Their!findings!indicate!that!
racial! and! genetic! predispositions,! as! well! as! a! geographically! determined!








this! gender! difference! changes! with! the! age! at! onset! [Noseworthy! et) al.,! 2000;!
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Compston! et) al.,! 2002].! A! very! early! onset! of! the! disease! has! been! described! in!
children! under! the! age! of! six! with! even! higher! female! preponderance! of! 3F:M!
[Ruggieri!et)al.,!1999].!The!youngest!of!them!was!a!ten!month!old!girl.!For!patients!
under! thirty! years! of! age,! the! disease! is! typically! characterized! by! periods! of!
inflammation!(relapses)!and!variable!periods!of!remission!(complete!or!incomplete!
remission):! a! relapsing! remitting! pattern! [Trojano!et) al.,! 2002].! Fifteen! to! twenty!
five!years!after!the!first!clinical!onset,!seventy!percent!of!untreated!patients!enter!
the! progressive! phase! known! as! secondary! progressive! MS! [Noseworthy! et) al.,!
2000].! In! patients! over! fifty! years! of! age,! the! disease! often!manifests! as! primary!
progresive!MS,! characterized! by! continuous! progression! of! neurological! disability!
from! the! initial! onset! of! the! disease,! with! only! occasional! plateau! or! temporary!
minor!improvements![Koch!et)al.,!2007;!Clark!et)al.,!1982].!
4.4.!Seasonal!Variations!
It! has! been! suggested! that! environmental! factors! play! an! essential! role! in! the!
aetiology! and! pathogenesis! of! MS.! Several! studies! have! demonstrated! a!
relationship!between!seasons!of!the!year!and!“outbreaks”!of!MS.!AbellaACorral!et)
al.! followed!up!31!patients!over!a!period!between!1997!and!2002!and!calculated!
the! monthly! and! quarterly! rate! of! incidence! of! outbreaks! [AbellaACorral! et) al.,!
2005].!A!higher!incidence!of!outbreaks!in!the!summer!months!(more!in!June)!and!a!








al.,! 2006].!Viral! exposure,! dietary! fatty! acids,! solar!ultraviolet! radiation!exposure,!
organic!solvent!exposure,!and!cigarette!smoking!are!implicated!in!the!pathogenesis!
of! the! disease.! The! risk! of! MS! was! 1.8Afold! higher! among! tobacco! smokers!
compared!with!those!who!had!never!smoked!in!one!study![Riise!et)al.,!2003].!These!
data!further!highlight!the!necessity!of!advising!patients!with!MS!to!quit!smoking.!In!
a! small! nested! caseAcontrol! study,! presence! of! EpsteinABarr! virus! in! plasma! was!




same! geographic! location! and! familial! aggregation! (MS! is! 20A40! times! more!
common! in! firstAdegree! relatives,! dropping! off! rapidly! with! the! degree! of!




Other! than! the!wellAdefined! human! leukocyte! antigen! (HLA)ADRB1*1501A
DQB1*0602!haplotype!on! chromosome!6p21,!multiple! genetic! factors! likely! have!
small!individual!contributions!to!the!etiology!of!MS![Sawcer!S!et)al.,!2003].!Recent!
studies! showed! that! HLA! locus! association! is!with! HLAADRB1! rather! than! the! DO!




the! disease! is! approximately! 70A80! per! 100,000! with! about! 35,000! patients!
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according! to! the! current! estimates.! Prevalence! rates! are! higher! for! women!with!
female:! male! ratio! around! 2.0.! In! northern! part! of! Spain! prevalence! was! 58! per!
100.000!in!1997![Tola!et)al.,!1999],!32!in!1996!in!eastern!Spain![Bufill!et)al.,!1995]!
and!43! in!1998! in!central!Spain! [BenitoALeÅLon!et)al.,!1998].! !The!average!annual!






Even! though! nuclear! magnetic! resonance! (NMR)! was! developed! as! an! imaging!
technique!in!the!1940s,!imaging!humans!became!possible!in!the!1970s!with!the!use!
of!large!bore!magnets.!Shortly!thereafter!in!1981,!the!first!inversion!recovery!scans!






spinal! cord.! CSF! provides! a! vehicle! for! removing! waste! products! of! cellular!
metabolism! from! the! nervous! system! and! is! believed! to! be! nutritive! for! both!
neurons!and!glial!cells!and!to!function!as!a!transport!system!for!biologically!active!






method! of! providing! laboratory! confirmation! of! a! clinical! diagnosis! of!MS.! Since!
then,!study!of! the!CSF!has!played!a!vital! role! in! the! investigation!of! the!aetiology!
and!pathogenesis!of!MS,!due!to!its!direct!contact!with!the!CNS.!
Immunoglobulins! (Ig)! are! produced! by! plasma! cells! that! arise! from! clones! of! BA
lymphocytes.!Kabat!et)al.! in!the!1950s!showed!that!the!proteins! in!the!CSF!of!MS!




in! comparison! to! the! blood! IgG! is! due! to! increased! synthesis! of! IgG! in! the! CNS,!
which!is!also!disproportionately!increased!in!comparison!to!the!CSF!albumin,!this!is!
highly! characteristic! of! MS.! In! some! patients! IgM! and! IgA! are! also! elevated.!
Oligoclonal!bands!(OCB)!are!found!only!in!the!CSF,!and!not!in!the!serum,!in!90%!of!
patients! diagnosed! with! MS! [Freedman! et) al.,! 2005].! Oligoclonal! bands! are!
produced!by!the!overrepresentation!of!particular!antibodies!that!can!be!visualized!
when! CSF! proteins! are! separated! by! gel! electrophoresis! where! they! appear! as!
separate!bands!of!protein!on!a!gel!matrix.!Each!of!the!bands!contains!a!single!type!
of!antibody!produced!by!a!single!clone!of!B!cells.!Oligoclonal!bands!are!typical)for!
the! CSF! of!MS! patients,! but! they! are! not!exclusive! to!MS! patients.! For! example,!
they!are!also!found!in!the!CSF!of!patients!with!other!inflammatory!status,!such!as!
viral! brain! infections.! In! MS,! however,! the! particular! antigens! that! elicit! each!
antibody!band!are!unknown![Thompson,!1995].!Oligoclonal! IgM!and! IgA!may!also!
! 46!
be!noted! in!CSF!of!MS!patients,!but! to!a! lesser!extent! than! IgG! [Keir!et)al.,!1982;!
Grimaldi!et)al.,!1985].In!our!study,!we!have!classified!and!named!inflammatory!MS!
into! “IgM+/H”! and! “IgM+/+) subtype”.! Today! the! vast! majority! of! laboratories!
determine! the! presence! of! OCB! in! the! CSF,! and! they! are! a! part! of! the! diagnosis!
criteria! of! MS! (McDonald! et) al.,! 2001! and! 2005),! but! as! we! will! see! late! the!
presence! of! OCGB! cannot! be! used! as! a! prognosis! factor,! because! nearly! 95%! of!





On! the! first! description! of! the! presence! of! OCMB! in! the! CSF! by! Sharief! et) al.! in!
1991,! a! worse! prognosis! in! this! subtype! of! patients! is! pointed! in! terms! of!
conversion! to! clinical! definitive! MS! (second! relapses)! since! a! clinically! isolated!
syndrome.!This!observations!have!been!confirmed!by!several!authors,!which!have!
studied!the!main!clinical!prognosis!factors!of!MS:!time!to!EDSS!of!4.0,!time!to!SPMS!
diagnosis,! time! to!a! second! relapses,! and! radiologic!prognosis! factors! as!basal! T2!
lesion!volume,!increases!in!T2LV!and!early!brain!atrophy,!and!at!last!patients!which!







in! NMO! patients,! but! other! with! lesions! restricted! to! two! cervical! spinal! cord!
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vertebral! bodies,! and! with! typical! brain! lesions! of! MS.! In! addition,! the! clinical!
relapses!were!not! limited!to!the!optic!nerve!and!spinal!cord!a!difference!to!NMO!
patients.!
Normally,! very! few! T! lymphocytes! are! present! in! the! brain,! making! it!
almost!undetectable!by!immunohistochemical!methods.!In!MS,!these!cells!increase!
in! number! and! are! readily! detectable! in! the! brain! parenchyma.! All! the! CSF!
lymphocytes! are! ultimately! derived! from! the! peripheral! circulation! via!
transmigration!across!the!BBB.!However,!the!distribution!of!lymphocytes!subsets!in!
the! CSF! is! different! from! that! of! peripheral! blood.! In! the! CSF,! atleast! 80%! of! T!








and! neurological! examination,! and! paraclinical! parameters! such! as! MRI,! CSF!
oligoclonal! banding,! and! evoked! potentials.! The! general! diagnostic! criteria,!
established! in! 1965,! state! that! a! diagnosis! of! “clinically! definite”! MS! requires!
clinical! evidence! of! two! or!more! white!matter! lesions! on! at! least! two! occasions!
[Schumacher!et)al.,!1965].!In!1983,!these!criteria!were!expanded!by!Poser!et)al.!to!
include! the! use! of! paraclinical! parameters.! The! most! recent! criteria! for! MS!
diagnosis!is!McDonald's!criteria![McDonald!et)al.,!2001,!Polman!et)al.,!2005],!which!
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incorporated! direct! detection! of! lesions! through! magnetic! resonance! imaging!
(MRI).!!
DiseaseAmodifying! treatments! such! as! interferon! betaA1a! and! 1b,! natalizumab,!




approved! only! for! the! relapsingAremitting! course.! All! of! these! medications! are!
modestly!effective!at!decreasing!the!number!of!attacks!in!RRMS!while!the!capacity!
of! interferons!and!glatiramer!acetate! is!more! controversial.! Studies!of! their! longA
term!effects!are!still!inadequate.!Comparisons!between!immunomodulators!(all!but!
mitoxantrone)! show! that! the! most! effective! is! natalizumab,! both! in! terms! of!
relapse! rate! reduction! and! halting! disability! progression! [Johnson,! 2007].!
Mitoxantrone!may!be! the!most!effective!of! them!all;! however,! it! is! generally!not!
considered!as!a!longAterm!therapy,!as!its!use!may!result!in!severe!secondary!effects!
[Comi,! 2009].! The! earliest! clinical! presentation! of! RRMS! is! the! clinically! isolated!





of! the! disease! and! the! frequency! of! relapses! in! shortAterm! followAup! [Martinelli!






Although! there! is! no! direct! evidence,! MS! is! commonly! considered! to! be! an!
autoimmune!disease.! It! is!believed!that!patient’s!own!immune!system!attacks!the!
nervous! system,! possibly! as! a! result! of! exposure! to! a! molecule! with! a! similar!
structure! to! one! of! its! own! [Compston! et) al.,! 2002].! This! is! called! molecular!




Accumulating! evidence! suggests! that! only! activated! T! cells! can! cross! the!
normally!impermeable!blood!brain!barrier!(BBB)!and!gain!access!to!CNS![Hickey!et)
al.,! 1991].! However,! the! mechanism! and! location! where! the! activation! of!
autoreactive!T!cells!takes!place!in!MS!patients!is!not!apparent.!It!has!been!shown!in!





evidence! of! association! between! MS! and! any! specific! pathogen,! this! molecular!
mimicry! theory! remains! controversial! [Libbey! et) al.,! 2007].! Finally,! although! it!
seems!to!be! the!general!view!that!T!cells!are!activated!prior! to!entry! into!CNS,! it!
has!been!shown! in!experimental!autoimmune!encephalomyelitis! (EAE),!an!animal!
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model! of!MS,! that! naïve! lymphocytes! are! also! able! to! penetrate! the! CNS! if! it! is!
already!inflamed![McMahon!et)al.,!2005].!
Once! lymphocytes! have! penetrated! into! the! CNS,! autoreative! T! cells! are!
thought! to! become! reAactivated! upon! encountering! endogenous!myelin! antigens!








MS! is! defined! as! a! demyelinating! disease! because! the! myelin! sheaths! and! their!
parent!cells,!the!oligodendrocytes,!are!major!targets!of!immuneAmediated!damage!
but! the! direct! cause! of! demyelination! in!MS! is! still! not! apparent! [Conlon! et) al.,!
1999;!Noseworthy,!1999].!Activation!of!the!complement!system,!which!is!a!central!
mechanism!for!removing!pathogens,!may!be!responsible!for!myelin!destruction!as!
suggested! by! presense! of! complement! proteins! in! demyelinated! MS! lesions!
[Compston!et)al.,!1989;!Storch!et)al.,!1998;!Ingram!et)al.,!2009].!Furthermore!nitric!
oxide!(NO)!has!been!shown!to!be!toxic!to!myelin!producing!cells,!oligodendrocytes,!






and! activation! of! cells! recognizing! these! epitopes,! could! be! responsible! for!
chronicity!of!the!inflammatory!reaction!in!MS![Tuohy!and!Kinkel,!2000].!
!7.4!Mechanism!of!axonal!injury!!
The! presence! of! axonal! degeneration! in! MS! was! recognized! in! the! early!
descriptions!of!this!disease!by!Charcot![Charcot,!1868].!Axonal!transection!might!be!
the!structural!basis!for!acquisition!of!permanent!neurological!deficits,!making!it!an!
especially! important! part! of! the! pathology! of!MS! [Davie! et) al.,! 1995;! Lee! et) al.,!
2000;!Lee!et)al.,!2000].! In! recent!years! it!has!become!possible! to!measure!axonal!
injury! effectively.! Using! amyloid! precursor! protein! (APP)! as! a! marker! for! acute!
axonal!injury!a!study!demonstrated!that!massive!axonal!damage!occurs!during!the!
stage! of! active! demyelination! in! fresh! lesions! [Ferguson! et) al.,! 1997].! Similar!
conclusions!were!obtained!by! another! study! that! reported!axonal! transections! in!
MS! lesions! [Trapp! et) al.,! 1998].! In! addition,! these! findings! corroborated! earlier!
observations! that! acute! axonal! injury! was! associated! with! the! degree! of!
macrophage!infiltration!in!the!lesions!and!that!macrophages!were!closely!attached!
to!damaged!axons![Ferguson!et)al.,!1997;!Trapp!et)al.,!1998;!Fraenkel!et)al.,!1913].!




molecular! mechanisms! of! axonal! disintegration:! the! triggers! that! induce! axonal!
damage! and! the! downstream! pathways! of! axonal! disintegration! (Figure! 6).!
Although! the! triggers! of! axonal! injury! seem! to! be! specific! for! inflammatory!
conditions,! such! as! MS,! the! downstream! mechanisms! of! axonal! disintegration!




Figure! 5:! Hypothetic! scenario! of! events! leading! to!





[Neumann! et) al.,! 2002].! Axons! can! be! transsected! by! class! I! MHC! restricted! T!
lymphocytes! in)vitro! in!an!antigen!dependent! immunological!reaction![Medana!et)
al.,! 2001].! Highly! activated! cytotoxic! T! cells! are! often! seen! attached! to!
demyelinated!axons! in! lesions!of!acute!MS.! In!addition,!activated!macrophages!or!
microglia! cells!are!observed! to! interact!with!axons! in! the!course!of!axonal! injury.!
These! cells! are! consistently! found! in! close! proximity! with! degenerating! axons.!
Many!of!their!toxic!effector!molecules!may!lead!to!axonal!injury,!although!a!direct!
detrimental!effect!has!so!far!only!been!shown!for!proteases!and!reactive!nitrogen!
species.! In! particular,! nitric! oxide! (NO)! intermediates! are! particularly! attractive!
candidates.! At! low! concentration! they! may! slowdown! the! action! potential! and!
conduction! ability! of! electrical! impulses! in! the! axons.! At! higher! concentrations!
when! axons! are! electrically! active,! NO! derivatives! may! result! in! irreversible!
destruction! of! axons! [Smith! et) al.,! 2001].! This! may! in! part! be! fulfilled! by! the!
blockade! of! mitochondrial! function! and! the! disturbance! of! energy! metabolism,!
which! can! be! induced! by! NO! radicals! [Bolanos! et) al.,! 1997].! As! nitric! oxide!
intermediates! can! also! contribute! to! oligodendrocyte! damage,! these! molecules!
may!be!important!candidates!in!the!pathogenesis!of!tissue!damage!in!MS![Smith!et)
al.,! 2002].! In! addition! to! toxins! produced! by! T! cells! and! macrophages,! specific!
antibodies!may!be!involved!in!the!initiation!of!axonal!injury.!!
! The!trigger!activates!several!downstream!events,!which!results!in!the!final!
dissolution! of! the! axon.! Axoplasmic! membrane! disturbance! and! energy! failure!
leads! to! uncontrolled! ion! influx! into! the! axoplasm.! Accumulation! of! sodium! ions!
inside! axons! is! then! counteracted! by! a! reverse! operation! of! the! sodium/calcium!
exchanger! (i.e.! sodium! efflux! and! calcium! influx),! resulting! in! excess! intraaxonal!




Triggers!of!axonal!injury! ! ! Axonal!degeneration!
!!!!Cytotoxic!T!cells! ! ! ! !!!!Memberane!disturbance!
! Granzyme/perforin! ! ! !!!!Sodium!influx!
! Fas/FasL! ! ! ! !!!!Energy!failure!
!!!!Macophages/microglia! ! ! !!!!Calcium!influx!
! Reactive!oxygen/nitrogen!species! !!!!Activation!of!proteases!
! Proteases! ! ! ! !!!!Dissolution!of!cytoskeleton!
! Excitotoxins!
!
Figure! 6:! Triggers! of! axonal! injury! and! axonal! degeneration!
(Adapted!from!review!by!Gold!et)al.,!2006)!
!
In! nutshell,! factors! associated! with! axonal! injury! include! cytokines,! nitric!








Remyelination! is! the! spontaneous! repair! process! where! new! myelin!
sheaths! are! generated! around! demyelinated! axons.! ! 40%! of!MS! lesions!manifest!
some!degree!of!remyelination![Barkhof,!2003].!It!could!result!in!partial!restoration!
of! the! conductive! properties! of! demyelinated! axons! [Smith,! 1979;! Jeffery,! 1997].!
The!degree!of!remyelination!depends!on!the!mechanism!and!stage!of!progression!
of! the! lesion! [Lucchinetti! et) al.,! 2000],! although! remyelination! has! been! seen! in!
patients! dying! at! an! old! age! [Patrikios,! 2006].! It! also! depends! on! whether! the!
environment!within!the!plaque!favors!remyelination![Franklin,!2002].!Also!there!is!
a! positive! correlation! between! remyelination! and! the! number! of! surviving!
oligodendrocytes! and! a! negative! one! with! the! presense! of! macrophages! in! the!
lesion![Lucchinetti!et)al.,!1999].!
9.!Neuromyelitis!optica!(NMO)!!
Neuromyelitis! optica! (NMO)! was! first! described! by! Allbutt! (1870)! who!
reported!a!patient!with!a!“sympathetic)disorder)of)the)eye”!after!an!acute!episode!
of!myelitis.! The! disease!was! further! characterized! by! Devic! (1894),!which! is! now!
also! known! as! Devic’s! disease.! NMO! is! described! as! an! idiopathic,! severe,!
inflammatory!demyelinating!disease!that!preferentially!affects!the!optic!nerves!and!
spinal! cord!and! typically! spares! the!brain.!Due! to!many! common! features,! it!was!
assumed! for! many! years! that! NMO! was! simply! a! variant! of! MS.! Infact,! it! was!
reported!in!Japan!that!an!optic!spinal!variant!of!MS,!which!accounts!for!15A40%!of!
all!MS!cases!shares!many!common!features!with!NMO![Misu!et)al.,!2002;!Kira!et)al.,!
2003].! Therefore! the! disease! was! always! mistaken! for! MS! early! in! the! disease!
course.!However,! recent! evidence! suggests! that!NMO! is! a! totally! distinct! disease!
and! requires! a! different! treatment! therapy.! The! identification! of! NMOAIgG!
antibodies! found!specifically! in! the!sera!of!NMO!patients!clearly!distinguishes!the!
disease! from!MS.! These! antibodies! have! also! been! identified! in! the! sera! of! two!
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autoimmune! channelopathy.! AQP4! acts! as! a! channel! that! regulates! water! entry!
into!and!out!of!the!nerve!cells!in!the!CNS!where!it!is!preferentially!localized!within!
astrocytic! end! feet! at! the! bloodAbrain! barrier.! Knockout! studies! in! mice!
demonstrate!that!AQPA4!is!involved!in!maintaining!the!integrity!of!the!blood!brain!
barrier! and! loss! of! this! protein! disrupts! the! integrity! of! the! blood! brain! barrier!
resulting!in!free!translocation!of!molecules!into!the!CNS![Zhou!et)al.,!2008].!Table!1.!
illustrates!the!key!features!exhibited!by!NMO!and!MS.!
Wingerchuck! et) al.! (2007)! at! the! Mayo! Clinic! proposed! a! model! that!
features! the! role! of! antiAAQP4! antibodies! in! the! pathogenesis! of! NMO.! They!
indicated! that! the! pathogenic! antiAAQP4! antibody! binds! to! the! extracellular!
component! of! the! AQP4! protein! and! induces! a! reversible! internalization! of! the!
AQP4AIgG! complex.! AQP4! expression! is! elevated! in! many! conditions! of! brain!
inflammation! and! neurological! diseases! such! as! stroke,! Alzheimer’s,! spongiform!
encephalopathy! and! others! which! do! not! have! an! autoimmune! component.!
Perhaps!the!significance!of!AQP4!for!regulating!brain!edema!suggests!that!when!its!



































stable! expression! in! one! condition! whereas! unstable! in! another.! Invariable!
expression! of! the! soAcalled! housekeeping! genes! has! been! observed! with! cellular!
development! [Maie! Dawoud! et) al.,! 2005]! and! under! distinct! experimental!
conditions![Deindl!et)al.,!2002;!Glare!et)al.,!2002;!Hamalainen!et)al.,!2001;!Radonic!
et)al.,!2004;!Zhong!et)al.,!1999;!Toegel!et)al.,)2007;!Torres!et)al.,!2003;!Gubern!et)
al.,! 2009;! Tricarico! et) al.,! 2002].! Therefore! it! is! indispensible! to! preAvalidate! the!
expression!stability!of!reference!genes!to!accurately!normalize!the!gene!expression!
data.!In!addition,!more!than!one!stably!expressed!gene!is!recommended!for!precise!
normalization! procedure! [Ohl! et) al.,! 2005;! Zhong! et) al.,! 1999;! Hamalainen! et) al.,!
2001;!Vandesompele!!et)al.,!2002].!!!
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10.1.! Glyceraldehyde! 3Aphosphate! dehydrogenase!
(GAPDH)!
GAPDH!has!historically!been!viewed!as!a!housekeeping!cytosol!protein!and!
plays! an! important! role! in! ATP! production.! Recent! studies! have! enhanced! our!
understanding! of! GAPDH! function! and! distribution.! Gapdh! is! found! in! several!
intracellular! locations!and!has!diverse!activities! independent!of! its! traditional! role!
in! glycolysis.! As! a! membrane! protein,! GAPDH! functions! in! endocytosis;! in! the!
cytoplasm,! it! is! involved! in! energy! generation,! polymerization! of! tubulin! into!




of! a! cell,! they! are! presumed! to! express! at! stable! levels.! Therefore,! they! are!
employed! as! common! internal! controls! in! most! of! the! laboratories.! However,!
several! lines! of! evidence! show! that! their! rate! of! transcription! is! influenced! by! a!
variety! of! factors! such! as! epidermal! growth! factor,! transforming! growth! factorAβ!
and!plateletAderived!growth!factor!while!constitutively!expressed![Leof!et)al.,!1986;!
KeskiAOja! et) al.,! 1988;! Elder! et) al.,! 1984].! Therefore,! their! expression! may! not!
necessarily!be!constant!in!all!conditions.!Furthermore,!Gapdh!is!implicated!in!nonA
metabolic! processes! independent! of! its! metabolic! function! such! as! transcription!
activation,! vesicle! transport! from! endoplasmic! reticulum! to! Golgi! apparatus! and!
polymerization!of!tubulin!into!microtubules![Tarze!et)al.,!2007;!Zheng!et)al.,!2003;!
Hara!et)al.,!2005;!Tisdale!et)al.,!2007].!!
The! realization! that! these! reference! genes!may! not! necessarily! express! in! stable!
manner! in! cellular! development! or! under! all! experimental! conditions! has! led! to!
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The! fate! of! dietary! components! after! digestion! and! absorption! constitutes!
metabolism—the! metabolic! pathways! taken! by! individual! biomolecules,! their!
interrelationships,! and! the! mechanisms! that! regulate! the! flow! of! metabolites!
through!the!pathways.!Metabolic!pathways!are!composed!of!three!categories:! (1)!
Anabolic! pathways! are! those! involved! in! the! synthesis! of! compounds.! Protein!
synthesis! is! such! a! pathway,! as! is! the! synthesis! of! fuel! reserves! of! triacylglycerol!
and! glycogen.! Anabolic! pathways! are! endergonic.! (2)! Catabolic! pathways! are!
involved! in! the! breakdown! of! larger! molecules,! commonly! involving! oxidative!
reactions;! they!are!exergonic,!producing! reducing!equivalents!and,!mainly!via! the!
respiratory! chain,!ATP.! (3)!Amphibolic!pathways!act! as! link!between! the!anabolic!
and!catabolic!pathways,!eg,!citric!acid!cycle.!!
The!products!of!digestion!of!dietary!carbohydrate,!lipid,!and!protein!mainly!
glucose,! fatty! acids! and!glycerol,! and!amino!acids,! are!metabolized! to! a! common!
product,! acetylACoA,!which! is! then!oxidized!by! the! citric! acid! cycle.! In! any! tissue,!
glucose! can! follow! various! metabolic! pathways;! in! the! brain,! glucose! is! almost!
entirely!oxidized!to!CO2!and!water!through! its!sequential!processing!by!glycolysis,!
the! tricarboxylic! acid! (TCA)! cycle! and! the! associated! oxidative! phosphorylation,!
which!yield!on!a!molecular!basis,!38!ATP!per!glucose.!
11.1.!Glycolysis!
Glycolysis! is! the! pathway! for! the! breakdown! of! glucose! into! pyruvate.! All! ten!
enzymes! are! in! the! cytosol,! and! all! ten! intermediates! are! phosphorylated!
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compounds!of! three!or! six! carbons.! In! the!preparatory!phase!of!glycolysis,!ATP! is!
invested! to! convert! glucose! to! fructose! 1,6Abiphosphate.! The! bond! between! CA3!
and!CA4! is! then!broken! to! yield! two!molecules!of! triose!phosphate.! In! the!payoff!
phase,! each! of! the! two! molecules! of! glyceraldehyde! 3Aphosphate! derived! from!
glucose! undergoes! oxidation! at! CA1;! the! energy! of! this! oxidation! reaction! is!




to! assure! a! steady! supply! of! ATP.!Hexokinase,! PFKA1,! and! pyruvate! kinase! are! all!
subject! to! allosteric! regulation! that! controls! the! flow! of! carbon! through! the!




conditions! vary! from! cell! to! cell! and! change! within! individual! cells! over! time.!
Therefore,! the! reactions! of! metabolism! must! be! finely! regulated! to! maintain! a!
constant! set! of! conditions! within! cells,! a! condition! called! homeostasis.! Enzymes!
ultimately!determine!which!chemical!reactions!a!cell!can!carry!out!and!the!rate!at!
which! they! can! proceed.! These! chemical! reactions! determine! a! cell's! function.! A!
cell's!functions!are!usually!defined!by!its!chemical!reactions,!so!enzymes!generally!
determine!a!cell's!function!as!well.!By!lowering!the!activation!energy!of!a!chemical!
reaction,! enzymes! promote! chemical! reactions! that! are! specific! to! the! cell's!









to! signals.! Secondly,! the! control! exerted! by! this! enzyme! is! the! effect! that! these!
changes!in!its!activity!have!on!the!overall!rate!of!the!pathway!(the!flux!through!the!
pathway).! For! example,! an! enzyme!may! show! large! changes! in! activity! (i.e.! it! is!
highly!regulated)!but! if! these!changes!have! little!effect!on!the! flux!of!a!metabolic!
pathway,!then!this!enzyme!is!not!involved!in!the!control!of!the!pathway.!
Enzymes!catalyzing!metabolic!reactions!are!regulated!for!the!purpose!of!increased!
efficiency!which! is! crucial! for! the!evolution!of! living!organisms.! There!are! several!
ways! by! which! metabolic! flux! can! be! regulated! including! allosteric! regulation,!
changing! enzyme! or! substrate! concentration,! compartmentalization,! covalent!
modification,! changing! pH! and! specialization! of! organelles! [Srere! and! Mathews,!
1990;!Mendes!et)al.,!1995;!Saks!et)al.,!2008].! In!addition,!glycolytic!enzymes!form!
localized! complexes! and! play! an! important! role! in! allowing! intricate! regulatory!
control! [Clarke! et) al.,! 1975;! Kurganov! et) al.,! 1985].! Other! than! this,! a! glycolytic!
complex! is! involved! in! (i)! increasing! solvation! capacity! with! the! cytosol! and! (ii)!
channeling! of! substrates.! The! channeling! promoted! in! a! complex! would! allow! a!
kinetic! advantage! [Cascante! et) al.,! 1994]! in! addition! to! preserving! the! cytosol!
solvation!capacity!by!limiting!substrate!diffusion.!
This! putative! glycolytic! complex,! although! in! line! with! the! cell’s! propensity! for!
organization!and!consistent!with!considerable!circumstantial!evidence,!has!evaded!
direct!experimental!support![Boiteux!and!Hess,!1981;!Srere,!1987]!and!is!subject!to!
controversial! interpretations! [Brooks! and! Storey,! 1991].! It! is! seen! that! a! larger!





functions,! even! extracellularly! [GomezAArreaza! et) al.,) 2014].! GAPDH! is! a! wellA
researched! example! [Zaffagnini! et) al.,! 2013].! GAPDH! has! been! implicated! in!
regulation!of!gene!expression! [Sirover,!2005],!apoptosis! [Hara!et)al.,!2005;!Sen!et)





The! fundamental! importance! of! understanding! enzymatic! complexes,! especially!




11.1.2.! A! new! hypothesis! on! glycolytic! enzyme!
complexes!
Glycolytic!complex!was! first!proposed!by!Kurganov!et)al.,!1985!and! its! formation,!
excluding!only!hexokinase,!was!proposed!to!take!place!in!three!stages!(Please!see!
Menard! et) al.,! 2014! for! details).! It! was! postulated! that! once! PFK! is! bound! to! a!
support!(e.g.,!FAactin),!PK!and!GPI!would!bind;!followed!by!aldolase!(ALD),!GAPDH,!
LDH;!and!finally,!by!PGK,!PGM,!ENO,!TPI!and!glycerolA3Aphosphate!dehydrogenase!
(GPDH).!However,! support! for!“Kurganov’s!complex”!gradually!abraded! in! light!of!
further!studies![Harris!and!Winzor,!1989].!






of!enzymatic!activity,!or! stabilization,! it! is!hypothesized! that! the! complete,! active!
enzyme! complex! consists! of! three! subcomplexes.! The! summary! table! leaves! out!
HXK! and! PGI! due! to! a! lack! of! data! supporting! interaction! with! other! glycolytic!
enzymes.! The! table! also! excludes! results! from! yeast.! Both! in) vitro! and! in) silico!
studies!imply!that!not!all!glycolytic!enzymes!of!S.!cerevisiae!(a!widely!used!model)!




The! first! of! the! three! subcomplexes! incorporates! two! wellAstudied! glycolytic!
enzymes!in!complex!formation:!ALD!and!GAPDH.!There!have!been!multiple!in)vitro!
studies! supporting! GAPDH! binding! to! actin! [Woztera! et) al.,! 2012;! Schmitz! and!
Bereiter,! 2002]! and! ALD! binding! to! actin! and/or! GAPDH! [Parra! and! Pette,! 1995;!
Woztera! et) al.,! 2012;!Melnikow! et) al.,! 2013].! The! general! consensus! is! that! ALD!
binds!FAactin!predominantly! in!an! inactive! state!and!close! to! its!active! site.!Upon!
substrate! binding,! its! conformation! becomes! unfavorable! for! actin! binding! and! it!
dissociates![Wang!et)al.,!1996;!Schindler!et)al.,!2001].!Similar!to!ALD,!actinAbound!





enzymes! of! the! glycolytic! pathway.! Studies! have! suggested! that! PFK! can! bind!
GAPDH![Commichau!et)al.,!2009]!and!ALD![Srere!and!Mathews,!1990;!Marcondes!
et) al.,! 2011;! Rais! et) al.,! 2000],! although! the! evidence! for! this! binding! is! not! as!
strong! as! the! evidence! supporting! the! ALDAGAPDH! interaction.! Interestingly,! PFK!
dimers!have!been! found! to!be!able! to!be!bound!and!activated!by!ALD!when!PFK!
dimers!would!otherwise!be! inactive! [Marcondes!et)al.,!2011].!This! introduces! the!
interesting! possibility! that,! when! involved! in! a! complex,! PFK! may! be! in! a! dimer!
form,!rather!than!a!tetramer.!!
Table!2:! Interactions!of!glycolytic!enzymes! from!post\1990s! literature,!excluding!
S.! cerevisiae.! A! green! circle! is! indicative! of!modelling! evidence,! a! blue! square! is!
indicative!of!in)vitro!studies!and!an!orange!diamond!is!indicative!of!in)vivo!bacterial!
studies![68].!Color!intensity!is!indicative!of!the!evidence!supporting!an!interaction:!
light! intensity,! one! to! two! published! studies! supporting! an! interaction;! dark!

















11.1.2.3.! Glycolytic! SubcomplexA3! (GlySCx3):! PGM,!
ENO!and!PK!
The! third!proposed!subcomplex! is! composed!of!PGM,!ENO!and!PK!and!possesses!
some! unique! characteristics! that! differentiate! this! complex! from! the! other! two,!





et) al.,! 2013].! Both! PK! and! PGM!have! been! found! to! bind! ENO! [Romagnoli!et) al.,!









than! 1:1:1.! In! fact,! this! seems! extremely! likely.! PFK! first! binds! FAactin,! possibly!
displacing!an!inactive!form!of!ALD.!After!this,!ALD!binds!PFK!and!GAPDH!binds!ALD.!
GAPDH!is!on!the!outskirts!of!this!trifecta!and!there!is!the!possibility!of!there!being!




GAPDH! is! supported!by! crosslinking! studies! [Commichau!et)al.,! 2009].!Depending!
on!the!orientation!of!PGK!binding!GAPDH,!the!orientation!could!permit!TPI,!though!





possibilities,! all! three! subcomplexes! are! in! their! proposed! binding! arrangements!
amongst!themselves!and!PFK!is!anchored!to!FAactin.!There!is!one!GlySCx1!per!every!
two!GlySCx2s!and!two!GlySCx3s!in!the!final!complex.!In!the!first!format!(Figure!6a),!
PFK! is! additionally! binding! GAPDH! and! GlySCx3! is! not! directly! bound! to! either!
GlySCx1! or! 2! but! is! bound! to! either! actin! or! troponin! components! of! the! thin!
filament!by!PK.!In!the!second!format!(Figure!6b),!ENO!is!linking!GlySCx3!to!PFK!and!
both! GAPDH! enzymes! are! still! linking! two! GlySCx2s! to! the! GlySCx1.! This! second!
format! is!an!example!of!how!GlySCx3!may!be!bound! to!GlySCx1!by!ENO,!but! this!
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connection,! for! instance,! could! also!be! formed!with! PGM.! The!positions! of! these!
enzymes! promote! channeling! and! an! important! note! is! the! vicinity! of! PGK! with!
PGM!and!TPI!near!ALD!and!GAPDH.!TPI!and!PGK!are!not!sequential!in!the!glycolytic!
sequence! but! are! shown! binding! each! other! here! such! that! both! of! them! are!
brought!into!close!enough!proximity!for!channeling!to!be!possible.!
The! research! to! date! has! not! been! sufficiently! consistent! to! establish,!
unequivocally,!the!structure!of!a!glycolytic!complex.!Part!of!the!problem!is!that!the!
experiments! have! been! subject! to! a!wide! variety! of! conditions.! The! lack! of! solid!
evidence! highlights! the! need! for! progress! in! this! area.! Most! published! reports!
involving!the!interaction!of!the!glycolytic!enzymes!with!each!other!or!bound!to!FA
actin! or! troponin! supports! the! idea! that! direct! contact! takes! place! among! them,!
even! if! the! reported! evidence! is! not! concrete.! Not! all! of! the! glycolytic! enzymes,!
however,!have!been! researched! to! the! same!extent!or!have!been! reconfirmed! in!
the!same!model!organism.!In!muscle,!many!enzyme–enzyme!interactions!have!not!
been!examined!or!have!been!looked!at!only!indirectly.!Physical!associations!among!
glycolytic! enzymes! are! generally! not! supported! by! protein! interaction! databases!
that! include! highAthroughput! experiments,! such! as!MINT,! and! STRING.! There! is! a!
dire!need!to!examine!the!complex!in!an!in)vivo!context!to!fully!develop!an!accurate!
picture.! Such! an! understanding! is! critical! to! the! way! we! think! about! metabolic!
activity,!regulation!and!its!role!in!pathologies.!
11.2.!Citric!Acid!Cycle!
Pyruvate! from! glycolysis! enters! into! the! citric! acid! cycle.! This! cycle! occurs! in! the!
mitochondria!of!the!cell!in!aerobic!conditions.!The!pyruvate!loses!a!carbon!dioxide!
group,! forming! acetylACoA,! the! compound! that! forms! a! link! for! many! other!
pathways!and!helps!build!other!compounds.!The!citric!acid!cycle!pathway!consists!
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of! eight! reactions! that! process! incoming! molecules! of! Acetyl! CoA.! The! carbon!
atoms! leave! the! cycle! in! the! form!of!molecules! of! carbon! dioxide.! The! hydrogen!
atoms!and!electrons!leave!the!cycle!in!the!form!of!reduced!coenzymes!NADH!and!
FADH2.! The! cycle! is! regulated!by! three! allosteric! enzymes! in! response! to! cellular!
levels!of!ATP.!One!Acetyl!CoA!molecule!entering!the!citric!acid!cycle!produces!three!
molecules!of!NADH,!one!of!FADH2,!and!one!of!GTP.!!
11.3.! Oxidative! Phosphorylation/Electron! Transport!
Chain!
The!electron!transport!chain!is!the!primary!site!for!ATP!synthesis,!and!occurs!in!the!
mitochondria.! In! this!pathway,! the!electrons!produced! from! reducing!equivalents!
i.e.! NADH! and! FADH,! are! transported! through! a! series! of! transition! molecules!
where! they! are! moved! from! one! transition! molecule! in! its! highAenergy! state! to!
another! molecule! in! its! low! energy! state! and! finally! to! molecular! oxygen.! Each!
carrier! in! the! series! has! an! increasing! affinity! for! electrons.! Four! of! the! carriers,!
known! as! cytochromes,! contain! iron,! which! accepts! and! then! transfers! the!
electrons.! Cytochrome! c1! (Cyc1)! is! one! of! the! constituents! of! complex! III,! which!
forms!the!third!proton!pump!in!the!mitochondrial!electron!transport!chain!(ETC).!It!
is!a!subunit!of!the!ETC!protein!Ubiquinol!Cytochrome!c!Reductase!(UQCR,!Complex!
III! or! cytochrome! bc1! complex).! The! general! function! of! the! complex! is! electron!
transfer! between! two! mobile! redox! carriers,! ubiquinol! and! cytochrome! c;! the!
electron!transfer! is!coupled!with!proton!translocation!across!the!membrane,! thus!
generating!protonAmotive!form!in!the!form!of!an!electrochemical!potential!that!can!








experimental! studies1.! Each! circle! represents! an! entire! enzyme!
(i.e.,! all! subunits).! The! grey! bar! represents! a! thin! filament!
composed! of! FAactin,! troponin! and! tropomyosin.! The! three!
subcomplexes! are!designated!by! their! appropriate!borders! and!






possible! GAPDH! in! gray! at! the! two! possible! positions;! GlySCx2! with! members!





two!mitochondrial!membranes.! This! creates!a! concentration!gradient! that! causes!





words,! oxidative! phosphorylation.! Oxidative! phosphorylation! is! the! process! by!
which! NADH! and! FADH2! are! oxidized,!with! concomitant! production! of! ATP.! Two!
molecules!of!ATP!are!produced!when!FADH2! is!oxidized,! and!3!molecules!of!ATP!
are!produced!when!NADH! is!oxidized.!Oxidative!phosphorylation!produces! lots!of!
energy,! but! requires! hydrogen! (NADH! and! FADH2).! The! synthesis! of! ATP! occurs!



















































! The! hypothesis! of! this! work! was! to! elucidate! the!mechanisms! that! are!
involved!in!axonal!degenerationAregeneration!in!MS.!Axonal!damage!is!accepted!as!
a! major! cause! of! persistent! functional! disability.! We! therefore! wanted! to! study!
primary! neuronal! damage,! independent! of! secondary! amage,! resulting! from!
demyelination,! using! primary! cultures! of! cerebellar! granule! neurons! as! a! cellular!
model.! It! is! believable! that! factors,! hitherto! unknown,! present! in! the! CSF! of!MS!
patients! are! able! to! regulate! axonal! destructionArepair,! and! make! a! stable!
remyelination!and!functional!recovery!possible.!Furthermore,!during!the!relapsingA
remitting! disease! course! the! patient’s! brain! alone! is! capable! of! repairing! the!
damage,! remyelinating! the! axon! and! recovering! the! neurological! function.!We!
therefore!decided!to!treat!neurons!and!oligodendrocytes!from!rat!cerebellum!with!
CSF! derived! from! different! clinical! forms! of!MS! and! perform! gene! expression.! In!
addition,!we!were!interested!to!identify!most!stably!expressed!reference!genes!in!




1. To! determine! the! effect! of! CSF! on! cerebellar! granule! neurons! and!
oligodendrocytes!!
2. To! establish! a! relation! between!neuronal! affectation! and! aggressivity! in!
different!clinical!forms!of!multiple!sclerosis!
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3. To! analyze! the! neuronal! affectation! in! primary! culture! of! CGNs! and! in!
OPCs!by!microarray!profiling!
4. To! identify! housekeeping! genes! during! maturation! of! CGNs! and! when!
neurons!and!OPCs!were!exposed!to!the!CSF!from!MS!and!NMO!patients!
5.! To! analyze! variations! in! genes! implicated! in! carbohydrate! metabolism,!
































































and! Hospital! Clinico! (University! of! Valencia)! where! Doctors! Dr.! Bonaventura!
Casanova!and!Dr.!Franscisco!Coret!are!the!clinicians!of!the!study!respectively.!Out!
of! 59! patients,! 21! had! inflammatory! MS! (11! IgM+/+! and! 10! IgM! +/A),! 8! had!
medullary! subtype,! 11! had! PPMS,! 9! had! NMO,! and! 10! were! controls! (NIND!
patients).!In!CSF,!apart!from!factors!related!to!MS!or!NMO,!there!are!factors!from!
other! diseases,! eg.! headache,! diabetes,! genetic! variation! etc.,! that! produce! their!
action.! This! must! be! considered! as! “background) noise”! as! average! population.!
Mixing! of! 11! CSF! samples! from! clinical! forms! such! as! IgM+/+! MS! patients! and!
others!may! sum!up!or! potentiate! the! factors! related! to!MS.! Since!we!wanted! to!
obtain!clear!results!specifically!from!MS!and!NMO,!we!mixed!total!CSF!samples!in!
all!forms.!








Patty! criteria! for! MRI! diagnosis! of! MS.! All! studies! were! performed! during! the!
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According! to! the! clinical! classification,! MS! is! categorized! into! 1)! RRMS!
(inflammatory)! that! later! develops! secondary! progressive! stage! (SPMS);! and,! 2)!
PPMS!(primary!progressive!multiple!sclerosis).!Over!95%!of!patients!with!multiple!
sclerosis!show!oligoclonal!bands!of!IgG!in!CSF!(G+)![Kostulas!et)al.,!1987;!McLean!et)
al.,! 1990;! Villar! et) al.,! 2005]! and! 40%! show! IgM! oligoclonal! bands! in! CSF! (M+)!
related! to! a!more! aggressive! course! of! disease! [Sharief! et) al.,! 1991;! Villar! et) al.,!
2002].!In!our!project!we!also!classified!and!named!inflammatory!MS!into!“IgM+/H”!
and!“IgM+/+)subtype”!(see!below)!on!the!basis!of!aggressivity!and!prognosis!which!
is! more! complete! than! just! RRMS! or! PPMS! and! also! includes! better! or! worse!
prognosis.! In! addition!we! have! studied! separately! a! set! of! patients! with!MS! but!
with! a! predominant! affectation! of! the! spinal! cord,! because! these! patients! have!
some!peculiarities,!and!we!wanted!to!explore!if!they!have!some!differences!in!light!
of!our!experiments.!The!most!aggressive!cases! termed!as!“medullary”!have!more!









  G Age W.C.F. C.F. E.T. A.E.    OCGB OCMB Ac-
AQ4 
T 
  Multiple Sclerosis patients 
1 F 23 
RRMS 
(+/-) 
RRMS 5 1.50 
g+ m- NA IFN, FGM
2 F 21 
RRMS 
(+/-) 
SPMS 18 4.00 
g+ m- NA IFN, MTZ
3 F 36 
RRMS 
(+/-) 
CIS 4 1.50 
g+ m- NA Nt 
4 M 22 
RRMS 
(+/-) 
RRMS 6 1.50 
g+ m- NA IFN, CPX, 
NTZ, 
FGM 
5 F 21 
RRMS 
(+/-) 
RRMS 3 3.00 
g+ m- NA IFN 
6 F 30 
RRMS 
(+/-) 
RRMS 22 4.00 
g+ m- NA IFN, NTZ, 
FGM 
7 F 29 
RRMS 
(+/-) 
RRMS 10 1.50 
g+ m- NA No 
treatment 
8 F 29 
RRMS 
(+/-) 
RRMS 7 1.50 
g+ m- NA IFN, NTZ 
9 F 28 
RRMS 
(+/-) 
RRMS 10 5.50 
g+ m- NA MTZ, IFN
10 F 28 
RRMS 
(+/-) 
RRMS 4 1.00 
g+ m- NA Nt 
11 F 37 
RRMS 
(+/+) 
RRMS 7 3.50 
g> m+ NA IFN, NTZ, 
CPX 
12 M 32 
RRMS 
(+/+) 
RRMS 4 1.00 
g+ m+ NA IvIg 
13 F 44 
RRMS 
(+/+) 
RRMS 5 2.00 
g+ m+ NA Nt 
14 F 26 
RRMS 
(+/+) 
RRMS 5 2.00 
g> m> NA U 
15 F 14 
RRMS 
(+/+) 
RRMS 18 3.50 




16 M 25 
RRMS 
(+/+) 
RRMS 11 2.00 
g+ m+ NA IFN, FGM 
17 F 21 
RRMS 
(+/+) 
SPMS 25 8.50 
g> m+ NA IFN, 
AZA, 
MTZ, IvIg 
18 F 17 
RRMS 
(+/+) 
RRMS 16 2.00 
g+ m+ NA U 
19 F 23 
RRMS 
(+/+) 
SPMS 18 6.50 
g+ m+ NA IFN, IvIg, 
Cy 
20 F 22 
RRMS 
(+/+) 
SPMS 5 4.00 
g+ m+ NA IFN, 
FGM, 
CPX 
21 F 29 
RRMS 
(+/+) 
RRMS 5 2.50 
g+ m+ NA IFN, 
FGM, 
CPX 
22 M 39 
MedMS 
SPMS 10 4.50 
g+ m+ NA IFN, Cy, 
FGM, 
NTZ 
23 F 25 
MedMS 
SPMS 6 7.00 
g+ m- NA IFN, 
MTZ, 
RTX 
24 F 25 
MedMS 
SPMS 14 8.00 
g+ m+ NA IFN, Cy, 
RTX 
25 M 34 MedMS SPMS 9 6.00 g+ m- NA IFN, Cy 
26 M 34 
MedMS 
SPMS 6 6.50 
g+ na NA IFN, 
MTZ, IvIg 
27 F 23 
MedMS 
RRMS 5 4.00 
g- m- NA IFN, NTZ, 
FGM, 
RTX 
28 F 40 
MedMS 
SPMS 10 7.50 
g- m+ NA AZA, 
IvIg, Cy, 
RTX 
29 F 23 
MedMS 
SPMS 28 6.50 
g+ m- NA IFN, 
MTZ, 
RTX 
30 F 54 
PPMS 
PPMS 12 7.00 
g+ m- NA No 
treatment 
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31 M 40 
PPMS 
PPMS 23 6.00 
g+ m- NA MTZ, Cy, 
RTX 
32 F 52 PPMS PPMS 14 5.50 g> m- NA AZA 
33 F 38 PPMS PPMS 11 5.50 g+ m- NA Nt 
34 M 31 PPMS PPMS 24 6.00 g+ m- NA Nt 
35 F 47 PPMS PPMS 14 5.50 g> m- NA Nt 
36 M 49 PPMS PPMS 11 6.00 g- m- NA FGM 
37 F 26 PPMS PPMS 13 6.50 g> m- NA Nt 
38 F 34 PPMS PPMS 6 5.00 g> m- NA Nt 
39 F 39 PPMS PPMS 8 8.50 g- m- NA Cy 
40 M 18 PPMS PPMS 15 8.00 u u NA U 
  Neuromyelitis optica patients 
41 F 39 NMO NMO 5 9.00 
g- m-  IFN, 
MTZ, Cy, 
RTX 
42 F 50 NMO NMO 4 7.00 
g- m- p IFN, NTZ, 
RTX 
43 M 15 NMO NMO 17 4.00 g+ m+ n IFN, IvIg 
44 M 42 NMO NMO 5 3.50 Na na p IvIg 
45 F 22 NMO NMO 5 2.50 
g+ m+ p IvIg, IFN, 
CPX 
46 F 27 NMO NMO 5 2.00 g+ m- n IFN, AZA
47 M 9 NMO NMO 14 1.00 
g- m- n IvIg, IFN, 
CPX 
48 F 8 NMO NMO 32 4.00 g+ m+ n IFN, IvIg 
49 M 19 NMO NMO 20 8.50 
g- m- n IFN, 
MTZ, Cy, 
RTX 
  Non-inflammatory neurological diseases (control) 
50 M 23 C C n.a. n.a. g- m- n.a. Nt 
51 F 77 C C n.a. n.a. g- m- n.a. Nt 
52 F 33 C C n.a. n.a. g- m- n.a. Nt 
53 F 32 C C n.a. n.a. g- m- n.a. Nt 
54 M 59 C  n.a. n.a. g- m- n.a. Nt 
55 F 36 C C n.a. n.a. g- m- n.a. Nt 
56 F 57 C C n.a. n.a. g- m- n.a. Nt 
57 M 37 C C n.a. n.a. g- m- n.a. Nt 
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58 F 21 C C n.a. n.a. g- m- n.a. Nt 
59 M 13 C C n.a. n.a. g- m- n.a. Nt 
 
 
Case = Patient number; Age = patient age in years; W.C.F = Working clinical form; C.F. 
= Clinical form; E.T. = evolution time in years; A.E. = Actual EDSS; EDSS = Expanded 
disability status scale (method of quantifying disability in MS); Gender =  patient 
gender; T = treatment; F = Female; M = male; C = Control; OCGB=oligoclonal IgG 
bands in CSF; OCMB=oligoclonal IgM bands in CSF; Ac-AQ4 = Antiaquaporin 4 
antibodies; RRMS = Relapsing-remitting multiple sclerosis; SPMS=Secondary 
progressive multiple sclerosis; CIS = Clinically isolated syndrome; MedMS = 
Medullary MS; PPMS = Primary progressive multiple sclerosis; NMO = Neuromyelitis 
optica patients; +/- = presense of IgG but no IgM antibodies in the CSF; +/+ = presense 
of both IgG and IgM antibodies in the CSF; OCGB=oligoclonal IgG bands in CSF; 
OCMB=oligoclonal IgM bands in CSF; n.a. = not applicable; n.t. = no treatment at the 
time of collection of the samples; IFN = interferon; FGM = fingolimod; MTZ = 
mitozantrone;  u. = unavailable ; CPX = copaxone®; NTZ = natalizumab; IvIg = bi-
monthly pulsed intravenous immunoglobulin; PE = plasma-exchange 2 months before 
lumbar puncture; ASCT = autologous stem cell transplant one year before LP; Cy = 
























Long! extensive! transverse! myelitis! (>3! vestibule! bodies);! 2)! Antibodies! against!
Aquaporin!4;!3)!Normal!brain!at!the!first!event.!!
1.2.5.! Controls! (NonKinflammatory! neurological!
diseases!(NIND))!
Individuals!who!were!suspected!to!have!MS!but!were!not!diagnosed!with!MS!were!
classified! as! controls! or! nonKdisease! individuals! with! no! inflammation! and! no!
neurological!disease.!
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CSF! samples!were! given!a!numerical! code! to!perform!all! procedures! in! a!blinded!
fashion! related! to! the! clinical! characteristics!of! patients.!No!patient!had! received!
treatment! with! immunosuppressive! drugs,! immunomodulators! or! corticosteroids!
for! at! least! one! month! prior! to! the! extraction! of! CSF.! Informed! consent! was!
obtained! from! all! the! patients! and! controls! for! this! study! and! authorized! by! the!
Ethical! Commitee! for! the! project! entitled! “Identification' of' neural' autoantigens'
recognized'by' immunoglobulin'M' found' in' cerebrospinal' fluid'of'multiple' sclerosis'






Paired! CSF! and! serum! samples! were! analysed! to! detect! OCGB! and! OCMB! by!








Western! blot.! Finally,! immunodetection! was! performed! by! biotinKconjugateKgoat!
antiKhuman!IgM!and!streptavidinKalkaline!phosphatase!(SigmaKAldrich).!!!
1.4.2.!Serum!studies!
AntiKAQP4! antibody! in! NMO! has! a! high! specificity! so! as! to! contribute! to! early!
diagnosis!and!optimized!treatment!of!Devic!disease.!
Serum!sample!diluted!1:10!in!PBSKTween!was!used!to!detect!the!presense!of!NMO!




were! raised! under! controlled! conditions! with! cycles! of! light/dark! (12/12h),!
temperature! of! 23°C! and! humidity! of! 60%.! Access! to! water! and! food! (standard!
rodent! feed! supplied! by! Harlan,! Teklad! 2014! Global! 14%! Protein! Rodent!
Maintenance! Diet)! was! provided.! To! obtain! offspring,! pregnant! females! were!
separated! and! kept! in! isolated! cages! during! gestation.! The! maintenance! of! the!
animals! was! performed! in! the! lower! animal! facilities! of! Prince! Felipe! Research!
Center,!Valencia,!Spain.!
3.!Determination!of!cell!viability!
In!order! to!determine!whether! factors! in!CSF!of!MS!and!NMO!patients!cause!cell!
death! in! astrocytes! or! neurons! or! both! we! first! incubated! cerebellar! granule!
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neurons! with! half! concentration! of! cytosine! arabinoside! (0.5! µM)! to! allow! the!
growth! of! astrocytes.! To! determine! cell! viability! we! used! propidium! iodide! (PI)!
which! is! excluded! by! living! cells.! The!membrane! of! these! cells! forms! a! selective!
permeability! barrier! between! the! intracellular! content! and! the! extracellular!




PBS! and! incubated! for! 30!minutes! at! room! temperature! in! darkness.! Living! cells!
were! incubated! with! rhodamineK123! cationic! dye! that! accumulates! within! the!
mitochondria! of! living! cells! due! to! the! negative! potential! difference! inside.!
Rhodamine!was!used!at!a!concentration!of!10!mg/ml!in!PBS!for!30!minutes!at!room!
temperature!in!darkness.!!
4.! Primary! culture! of! cerebellar! granule! neurons!
(CGNs)!!
All! operations! were! performed! under! sterile! conditions! in! vertical! laminar! flow!
chamber! (Telstar! AVK100! and! BioKIIKA).! All! reagents! and! culture! media! were!
obtained! from! Gibco.! The! plastic! material! used! was! sterile,! the! petri! dishes! for!
culture!from!Nunc!and!Corning,!the!Corning!tubes,!syringes!from!BD!and!Millipore!
filters,! the!glass!material! used!was! sterile.!All!materials!used!were! free!of! toxins.!
The!cells!were!kept!in!an!incubator!at!37º!C!in!a!humidified!atmosphere!composed!
of!95%!air!and!5%!CO2!(CO2!incubator!Thermo!Form,!model!371).!
Primary! cultures! of! cerebellar! granule! neurons! (CGNs)! were! obtained!
according! to! previously! described! modified! protocol! [Minana! et' al.,! 1998].!
Cerebellum!!were!collected!from!eight!day!old!Wistar!rats,!mechanically!dissociated!
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and! cerebellum! was! dissected.! Isolated! cerebella! were! stripped! of! meninges,!
minced!by!mild!trituration!with!a!Pasteur!pipette!and!treated!with!3mg/ml!dispase!
(grade! II)! for! 30!min! at! 37º! C! in! a! 5%! CO2! humidified! atmosphere.! After! half! an!
hour,! dispase! was! inactivated! with! 1mM! EDTA.! Granule! cells! were! then!
resuspended! in! basal! Eagle´s! medium! (BME,! Gibco,! ref.! 41010)! with! 40µg/ml! of!
DNaseI.!The!cell!suspension!was!filtered!through!a!mesh!with!a!pore!size!of!90µm!
and!centrifuged!at!1500!rpm!for!5!min!and!thereafter,!cell!suspension!was!washed!
three! times! with! BME.! Finally,! the! cells! were! resuspended! in! complete! BME!
medium!with!Earle´s!salts!containing!10%!heat!inactivated!FBS!(fetal!bovine!serum,!
Gibco),!2!mM!glutamine,!0.1!mg/ml!gentamycin!and!25mM!KCl.!The!neuronal!cells!
were! counted! (see! below)! and! then! the! cell! suspension! was! plated! onto! polyKLK
lysine!coated!6Kwell!(35Kmm)!culture!dishes!(Fisher)!at!a!density!of!3x105!cells/well!
and!incubated!at!37º!C!in!a!5%!CO2/95%!humidity!atmosphere.!After!20!min!at!37º!
C,! the! medium! was! removed! and! fresh! complete! medium! was! added.! 20µl! of!
cytosine!arabinoside!(1!mM)!was!added!to!each!culture!plate!after!18!to!24!hours!
to! inhibit! replication!of!nonKneuronal!cells.!The!cells!were!kept! in!an! incubator!at!
37ºC!in!a!humidified!atmosphere!composed!of!95%!air!and!5%!CO2!(CO2!incubator!
Thermo!Form,!model!371).!Cells!were! fed!every!3K4!days! in! culture!with!5.6!mM!
glucose.!!
5.!Treatment!of!cultured!cells!with!CSF!
Neuronal! cell! cultures! from! 14th! day!were! incubated!with! 10%! v/v! CSF! from!MS!





The! living! cells!were! always! kept! at! 37°! C! and! 5%!CO2.! Cells!were! analyzed! on! a!
Leica! TCS! SP2! confocal! microscope! AOBS! (Leica! Microsystems)! inverted! laser!
scanning! confocal! microscope! using! a! 63°—! PlanKApochromatKLambda! Blue! 1.4!
N.A.! oil! objective! lens.! All! confocal! images! were! obtained! under! identical! scan!
settings.! Images! of! 1,024! °—! 1,024! pixels,! 8Kbits! were! collected! for! each!
preparation.! Best! focus! was! based! on! highest! pixel! intensity.! Imaging! conditions!
were! identical! for! all! the! images,! and!no! images!were! saturated.!Metamorph!7.0!
(Molecular! Devices,! Downingtown,! PA,! USA)! was! used! for! image! analysis! on! the!
images!collected.!!
7.! Total! RNA! isolation! and! Reverse! Transcription!
(cDNA!synthesis)!
We!isolated!total!RNA!from!neurons!at!different!time!points!(day1,!day4,!day8!and!
day14)! using! Quick! RNA! MicroPrep! Kit! (Zymo! Research! Corp.)! according! to! the!
manufacturer’s! instructions! to!study! the!development!of!unmyelinated!cerebellar!
granule!neurons.!Secondly!total!RNA!from!14th!day!cell!cultures!exposed!to!the!CSF!
of! different! experimental! conditions! (IgM+/K,! IgM+/+,! medullary,! NMO,! PPMS,!
Control)!was! isolated! using! the! similar! kit! in! order! to! study! the! primary! damage!
caused! by! CSF! exposure! to! CGNs.! The! RNA! concentration! was! determined!
spectrophotometrically! at! 260! nm! using! the! Nanodrop! 1000! spectrophotometer!
(V3.7!software)!and!RNA!purity!was!checked!by!means!of!the!absorbance!ratio!at!
260/280nm.!Isolated!RNA!was!stored!at!K80°!and!later!reverse!transcribed!to!cDNA.!












V,! stained! with! ethidium! bromide,! photographed! and! evaluated! with! ImageJ!
software.! A! DNA! ladder! control! (100bp,! Invitrogen)! was! also! used! in! the!
electrophoresis!to!evaluate!DNA!fragment!size.!
9.!Gene!microarray!and!data!normalization!!
Firstly! we! performed! gene! expression! profiling! of! granule! neurons! development!
and!later!the!profiling!of!these!cells!exposed!to!the!CSF!from!MS!and!NMO!patients!
(experimental! conditions).! By! doing! this! we! could! distinguish! between! neuronal!
cells!that!are!developing!and!show!how!these!cells!react!to!a!particular!treatment.!!
We! isolated!total!RNA!during!different!developmental!stages!of!CGNs!(day1,!4,!8,!
14)! and! handed! over! to! genomics! laboratory! to! perform! one! color! microarrayK





laboratory! to! further! subject! the! total! RNA! to! one! color! microarrayKbased! gene!
expression!analysis!(Agilent!Technologies)!by!its!respective!staff.!!
The! labeled! cRNA! was! hybridized! to! the! Agilent! SurePrint! G3! Rat! GE! 8x60K!




cRNA! was! hybridized! to! the! Agilent! SurePrint! G3! Rat! GE! 8x60K! Microarray!
according!to!the!manufacturer's!protocol.!The!arrays!were!washed,!and!scanned!on!
an! Agilent! G2565CA!microarray! scanner! at! 100%! PMT! and! 3!μm! resolution.! The!
intensity!data!was!extracted!using!the!Feature!Extraction!Software!(Agilent).!
In! order! to! account! for! technical! variation! between! microarrays! (i.e.! amount! of!
starting!RNA,! and!differences! in! efficiencies!of! reverse! transcription,! labeling! and!
hybridization),!raw!signal!intensities!were!first!normalized!using!the!Percentile!shift!
method! available! in! GeneSpring! 9.0! for! one! color! microarray! (Agilent,! CA,! USA).!
Since!the!75th!percentile!is!a!more!robust!and!representative!intensity!value!of!the!
overall!microarray!signal!as!compared!to!the!median!or!the!50th!percentile!signal,!
the!default!was! set! at! 75th! percentile.! Therefore,! 75th! percentile! signal! value!was!
used!to!normalize!Agilent!oneKcolor!microarray!signals!for!interKarray!comparisons.!
After! normalization! the! data!was! filtered! in! order! to! exclude! probesets!with! low!
expression!and/or!affected!by!differences!between!the! laboratories.!Differentially!
expressed!genes!were! identified!by!comparing!average!expression! levels! in! terms!
of!fold!change!in!cases!and!controls.!All!filtering!steps!and!statistical!analyses!were!
conducted!using!GeneSpring!9.0.!
During! the! maturation! of! cerebellar! granule! neurons! (day1,! 4,! 8,! 14),! mRNA!
expression!(in!terms!of!fold!change)!from!cultured!neurons!on!day!4,!8!and!14!were!
! 93!
compared! with! day1.! mRNA! expression! (in! terms! of! absolute! fold! change)! in!
neurons! treated!with! CSF! of!MS,! NMO,! PPMS! and! NIND! patients! was! compared!
with!gene!expression!in!neurons!exposed!only!to!culture!medium.!Fold!change!(FC)!
is!a!number!describing!how!much!a!quantity!changes!from!an!initial!to!a!final!value.!




10.! Analysis! of! geneKgene! interaction! networks!
using!String!v10!software!
Next,! we! wanted! to! elucidate! whether! interaction! of! different! metabolic! genes!
related!with!a!metabolic!network!(i.e.!glycolysis,!TCA!cycle,!and!electron!transport!
chain)!affected!the!whole!network!included!those!genes!we!did!not!find!too!many!
changes! in! the! whole! carbohydrate! network.! As! we! discussed! earlier! the!
importance!of!glycolytic!enzymes!in!forming!localized!complexes,!which!may!play!a!




different! disease! subtypes! in! neurons.! Although! not! every!gene! related! with! a!
specific!network! is! affected! in!a! kind!of!MS!disease,! if!we!do!a! string!analysis!we!
may!find!that!the!physical!interaction!of!enzymes!related!with!a!metabolic!network!
(i.e.!glycolysis,!TCA!cycle,!and!electron!transport!chain)!exist!and!closely!regulated!




















network! to! compare!our!experimental!MS! conditions.! The!values!means! that! the!
reducing! on! local! flux! due! to! the! inhibition! of! an! enzymatic! activity! in! a! specific!
gene! affects! synergicaly! to! the! whole! metabolic! flux! network.! It! means! that! as!
more! genes! are! down! regulated,! the! total! flux! are! reducing! as! a! multiplicative!
factor! that!we! integrate! as! the! CFI! of! the! network.! In! the! Discussion! section!we!
integrate! in!a!draw!the!relative!changes! in!the!different!MS!and!NMO!patients!by!
calculating!the!CFI!of!the!carbohydrate!metabolic!networks!in!those!patients.!




dye! or! SYBR®!Green! detector,!which! is! a! cyanine! dye! unselectively! binding! to! all!
doubleKstranded!DNA.!The!method!differs!from!standard!PCR!in!that!the!amplified!
product! can! be! detected! and! quantified! by! measuring! fluorescence! at! each!
















We! used! realKtime! PCR! for! measuring! transcript! levels! of! commonly! used!
housekeeping!genes!in!which!detection!was!based!on!SYBR!green!chemistry.!Since!
recent! evidence! shows! that! some! house! keeping! genes! are! not! as! refractory! to!
experimental!manipulations!as!previously!thought,!we!validated!7!commonly!used!
house!keeping!genes!and!have!checked!whether!these!genes!remain!stable!during!
maturation! (day1,! day4,! day8,! day14)! and! experimental! conditions.! Candidate!
housekeeping!genes!were! selected! from! those!most! commonly!used! in! literature!
including! betaKactin! (ActB),! hypoxanthine! guanine! phosphoribosylKtransferase!
(Hprt),! ribosomal! protein! L19! (Rpl19),! lactate! dehydrogenaseA! (Ldha),! transferrin!
receptor! (Tfrc),! microglobulin! betaK2! (B2m),! and! glyceraldehydeK3KphosphateK
dehydrogenase! (Gapdh).! The! function! and! references! of! the! genes! are! listed! in!
Table!4.!
The! primer! sequences,! annealing! temperature! and! the! product! size! is! listed! in!
Table! 5.! Real! time! PCR! was! performed! in! a! 96Kwell! plate! (Roche)! incubated! in!
thermocycler! (LC480,!Roche)!with!cycling!conditions! (94°! for!15s,!45!cycles!at!60°!
for!30s!and!72°!for!30s).!Each!10ml!reaction!contained!5!ml!SYBR!Green!Master!Mix!
(Applied!Biosystems),!1!μl!geneKspecific!forward!and!reverse!primers!(0.5!μM),!1!μl!
undiluted! cDNA! and! 3!ml! DEPC! (nuclease! free)! treated! water.! Negative! controls!
with!no! template! contained!nucleaseKfree!water! instead.!All! samples!were! run! in!
duplicate! and! average! values! were! calculated.! Data! was! analyzed! using! 7300!






reference! gene.! A! oneKway! analysis! of! variance! (ANOVA)! was! conducted! to!
determine! the! significantly! variable! genes.! A! p! value! <! 0.05! was! considered!
statistically!significant.!
12.1.! Determination! of! reference! gene! expression!
stability!
To! determine! the! stability! of! these! genes! on! the! basis! of! their! Cp! values,! we!
employed!comparative!ΔCT!method.!Data!are!plotted!as!fold!change!values!which!
were!calculated!by!2Δ(Ct!expK!Ct!control).!Cp!value!is!defined!as!the!PCR!cycle!at!which!the!
fluorescent! signal!of! the! reporter!dye!crosses!an!arbitrarily!placed! threshold.!The!
numerical! value! of! the! Cp! is! inversely! related! to! the! amount! of! amplicon! in! the!
reaction.! Invariable!genes!were! later!assessed!by!publicly!available!software!tools!
named! GeNorm! and! NormFinder.! GeNorm! ranks! the! genes! according! to! their!
average! expression! stability! measure! (highest! M! value)! from! the! most! stable!
(lowest! M! value)! to! the! least! stable! (highest! M! value).! An! alternative! program,!































































































































Hprt' F:!CCTCTCGAAGTGTTGGATACAG!R:!TCAAATCCCTGAAGTGCTCAT! 60°! 105!
Rpl19' F:!ACCTGGATGCGAAGGATGAG!R:!CCATGAGAATCCGCTTGTTT! 60°! 139!
Ldha' F:!AGGAGCAGTGGAAGGATGTG!R:!AGGATACATGGGACGCTGAG! 60°! 214!
Tfrc' F:!GTTGTTGAGGCAGACCTTCA!R:!ATGACTGAGATGGCGGAAAC! 60°! 112!
B2m' F:!GTCGTGCTTGCCATTCAGA!R:!ATTTGAGGTGGGTGGAACTG! 60°! 116!





diagnoses.!We! selected! patients!with! definitive!MS! from! our! database! according!
the!2010!McDonald!criteria.!For!our!study!we!selected!two!clinical!forms!of!MS:!1)!
a!set!of!PPMS!patients,!defined!by!a!progressive!onset!for!more!than!one!year!of!
neurological! dysfunction! with! magnetic! resonance! Swanton! criteria! of!
dissemination! in! space! (McDonald! criteria)! in! which! IgG! oligoclonal! bands! were!
present!in!both!the!serum!and!the!CSF,!with!more!bands!present!only!in!the!CSF,!an!
OCB! pattern! that! have! been! recognized! as! more! specific! of! PPMS! and! 2)! RRMS!
patient!cohort!defined!by!two!or!more!relapses!separated!by!one!month;!Swanton!
! 100!
criteria! for! dissemination! in! time! and! space,! and! also! the! OCB! of! the! IgG! type!




cells! were! grown! in! NM10! (high! glucose! DMEM! supplemented! with! 10%! fetal!
bovine!serum),!and!cultured!for!one!week!at!37°C,!5%!CO2.!After!one!week,!loosely!
attached!microglia!were!removed!by!a!lowKspeed!shaking!(210!rpm)!for!20!min!on!
a! rotary! platform! shaker.! Media! was! removed! and! discarded! and! replaced! with!




defined!media! (ODM)! containing! 100! μg/mL! bovine! transferrin,! 5.0! μg/mL! yeast!
recombinant!insulin,!100!μg/mL!bovine!serum!albumin!fraction!V,!1!mg/mL!biotin,!
0.628!mg/mL!progesterone,!0.3804!mg/mL!sodium!selenite,!16.1!μg/mL!putrescine.!
For! cell! expansion,! chemicallyKdefined! media! was! supplemented! with! 20! ng/mL!
basic!fibroblast!growth!factor!(bFGF)!and!10!ng/mL!plateletKderived!growth!factor!
AA!(PDGFKAA)!and!cells!were!allowed!to!proliferate!for!48!hours!prior!to!treatment.!
OPC! cultures! were! 99%+! pure! cultures,! with! less! than! 1%! detectable! GFAP+!
astrocytes,!or!Iba1+!microglia,!as!detected!by!immunocytochemistry.!
14.! Treatment! of! cultured! OPCs! with! CSF! and! RNA!
extraction!!
OPCs!were! treated!with!CSF!diluted!at! a! 1:1!dilution! in!ODM!supplemented!with!
bFGF! (20! ng/mL)! and! PDGFKAA! (10! ng/mL).! Cells! were! treated! for! 24! h!with! the!
! 101!
diluted! CSF! and! RNA! was! extracted! using! the! Qiagen! RNeasy! RNA! extraction! kit!




The! labeled! cRNA! was! hybridized! to! the! Agilent! SurePrint! G3! Rat! GE! 8x60K!




cRNA! was! hybridized! to! the! Agilent! SurePrint! G3! Rat! GE! 8x60K! Microarray!
according!to!the!manufacturer's!protocol.!The!arrays!were!washed,!and!scanned!on!









































or!worse!prognosis!based!on! the!presense!of!oligoclonal!bands! in!CSF.! The!NMO!
patients!were!identified!on!the!presense!of!antiKAQP!4!antibodies!in!the!sera!(see!
Material!and!Methods!for!the!final!classified!list!of!patients).!!
1.1.!! Detection! of! oligoclonal! bands! (OCGB! and!
OCMB)!in!CSF!of!MS!patients!
The! detection! of! oligoclonal! bands! in! MS! patients! was! performed! by! isoelectric!
focussing,! followed!by! immunodetection! to! identify!oligoclonal! IgG!bands! (OCGB)!






Figure! 12:! Immunodetection! of! oligoclonal! bands! (OCBs)! in!
serum! (S)! and! CSF! (L).! Pattern! 1:! No! OCBs! seen! (negative,!
polyclonal):!No!oligoclonal!bands!in!CSF!or!Serum.!No!intrathecal!
Ig! synthesis;! Pattern! 2:!OCBs! in! CSF! only! (positive):!Oligoclonal!
bands! present! in! CSF! only.! Intrathecal! IgG! synthesis! as! seen! in!
MS;! Pattern!3:! Identical!OCBs! in!both! (mirror):! Bands! in! serum!
mirror!those!in!CSF.!This!suggests!systemic!Ig!synthesis;!Pattern!
4:!Identical!OCBs!in!both!with!extra!in!CSF!(more!than):!Identical!




The! figure! 12! shows! oligoclonal! bands! in! CSF! and! in! serum! in! some!




shows! the!presense!of! identical!OCBs! in!both!CSF!and!serum!suggesting! systemic!
IgG! synthesis.! The! pattern! 4! shows! identical! OCBs! in! both! CSF! and! serum,! with!
extra!bands!in!CSF.!This!demonstrates!both!intrathecal!and!systemic!Ig!synthesis.!
!1.2.! Detection! of! anti;aquaporin! 4! antibodies!
(Anti;AQP4,! Anti;NMO,! NMO;IgG)! in! sera! of! NMO!
patients!
To!diagnose!NMO,!we!performed!indirect!immunofluorescence!in!cells!transfected!
by! aquaporin! 4! (Euroimmun! Medizinische! Labordiagnostika! AG)! to! detect! the!
presense!of!NMO!specific!IgG!antibodies!in!serum!samples!of!the!patients.!Panel!I!
of!figure!13!shows!as!example!a!positive!sample.!NMO!specific!IgG!antibodies!were!
also! observed! in! the! serum.! The! panel! II! shows! the! case! of! an! absense! of! IgG!
antibodies!specific!for!NMO!(NMO!negative).!
! Therefore,! the!clinical! form!of!MS!we!will!use! in! this!work!are:!1)!RRMS!
patients! “IgM+/M' subtype”! had! IgG! antibodies! (+)! but! no! IgM! (K)! oligoclonal!
antibodies!detected! in! the!CSF.!2)!RRMS!patients!“IgM+/+'subtype”!had!both! IgG!







Figure!13:! Indirect! immunofluorescence! in!cells! transfected!by!
aquaporin! 4! (EUROIMMUN! Aquaporin;4! IIFT).! Panel! I:! AntiK
AQP4! antibodies! observed! in! the! serum! of! NMO! patients!
















serum.! 4)! PPMS!patients! are! characterized! by! progressive! decline! in! neurological!
disability! with! IgG! (+)! antibodies! but! no! IgM! (K)! antibodies! in! CSF.! 5)! NMO! are!
positive! with! antibodies! against! Aquaporin! 4,! with! long! extensive! transverse!







10! were! controls! (NIND! patients).! The! baseline! characteristics! of! the! patients!
population!are!described!in!Table!6.!!
The!prevalence!of!MS,!as!known!in!the!literature,!was!found!more!in!women!than!
in! men! (75%! in! women).! The! mean! age! of! MS! patients! was! 30.7±9.7! years! old,!




and! the! other! two! MS! forms! (p=0.003),! between! the! EDSS! (Expanded! Disability!
Status!Scale)!of!RRMS!and!the!two!other!MS!forms!(<0.001),!and!the!evolution!time!
between!PPMS!and!RRMS!(p=0.043),!after!Bonferroni!correction.!The!table!8!shows!
the! characteristics! of! MS! patients! according! to! new! proposal! and! working!












%!females!(n)! 60.0!(6)! 75.0!(30)! 55.6!(5)! 0.40!(χ2)!
Age!(mean,!SD)! 40.3!(19.5)! 30.7!(9.7)! 25.6!(15.0)! 0.04!(Anova!
test)!
EDSS!! n.a.! 4.5!(2.3)! 4.6!(2.8)! 0.94!(tKtest)!







%!females!(n)! 83.3!(15)! 72.7!(8)! 63.6!(7)! 0.48!(χ2)!
Age!(mean,!SD)! 27.3!(7.2)! 27.9!(7.3)! 38.9!(11.2)! 0.003!(Anova!
test)!
EDSS!! 2.4!(1.2)! 6.2!(1.5)! 6.3!(1.1)! <0.000!
(Anova!test)!






Our! findings! suggests! that! RRMS! and! SPMS! cases! shared! similar! age! at! disease!
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onset! (mean=27.3! versus! 27.9! years! old;! p=0.003)! (Table! 7),! whereas! significant!










PPMS! subtype,! and! the! symptoms! continually!worsen! from! the! time!of!diagnosis!
rather!than!having!wellKdefined!attacks!and!recovery.!The!PPMS!usually!results! in!
disability!earlier!than!RRMS.!!
Significant! differences! (p=0.043)! were! also! found! in! the! evolution! time!
from! the! first! to! the! second! episode! between! RRMS! and! PPMS.! In! patients!
experiencing! a! progressive! course,! the! evolution! time!was! similar! in! SPMS! cases!
and! in! cases! that! were! progressive! from! onset! (13.5! versus' 13.8)! (Table! 7).!!
According! to! the! new! proposal! and! working! classification,! the! inflammatory! MS!
subtypes! shared! similar! age! at! disease! onset! (mean=26.7! versus! 26.3! years! old;!
p=0.005).! Significant!differences!were! found!between! the!age!at!disease!onset! in!
medullary! MS! and! PPMS! with! the! inflammatory! MS! (p=0.005).! The! degree! of!
disability,!as!measured!by!EDSS,!was!similar! in!MedMS!and!PPMS!(6.2!versus!6.3)!
whereas! significant! differences! were! found! between! disability! extent! in! MedMS!
and!PPMS!with! the! inflammatory!MS! (p<0.001).!The! IgM+/K!group! represents! the!
less!aggressive!inflammatory!subtype!with!OCGB!in!CSF!with!poor!prognosis!
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90!(9)! 81.8!(9)! 62.5!(5)! 63.6!(7)! 0.40!(χ2)!
Age!(mean,!
SD)!
26.7!(4.8)! 26.3!(8.7)! 31.4!(7.0)! 38.9!
(11.2)!
0.005!
EDSS! 2.5!(1.5)! 3.4!(2.2)! 6.2!(1.4)! 6.3!(1.1)! 0.000!
Evolution!
time!





to! inflammatory! subtypes.! The! disability! in! patients! experiencing! PPMS! worsens!
over!time!with!no!relapses!and!remission.!
3.! CSF! of! MS! patients! causes! cerebellar! granule!
neuronal!cell!death!
Since! axonal! damage! has! now! been! widely! accepted! as! the! major! cause! of!









of! MS! clinical! subtypes.! The! cerebellar! cortex! is! a! well! described! structure! that!
provides!unique!opportunities! for! studying!neuronal!properties! and!development!
[Altman! and! Bayer,! 1997;! Hatten! and! Heintz,! 1995].! Of! the! cerebellar! neuronal!
types! (granule! cells,! Purkinje! cells! and! inhibitory! interneurons),! the! granule!
neurons!are!by!far!the!most!numerous!and!most!abundant!type!of!neurons!in!the!
mammalian!brain.!In!rodents,!cerebellar!granule!neurons!are!generated!during!the!
first! two! postKnatal! weeks! from! progenitor! cells! in! the! outermost! layer! of! the!
cerebellar! cortex,! the! external! granule! layer! (EGL).! Due! to! their! postnatal!
generation! and! the! feasibility! of! wellKcharacterized! primary! in' vitro! cultures,!
cerebellar! granule! cells! are! a! model! of! election! for! the! study! of! cellular! and!





Since! all! the! cells! of! the! brain,! namely! neuronal! and! nonKneuronal! cells,! are!
affected! in!this!disease,!we!first!wanted!to!know!if!CSF!causes!any!effect!on!nonK
neuronal! cells.! We! determined! the! viability! of! cerebellar! cultures! by! adding!
propidium! iodide! and! rhodamineK123! to! the! primary! cell! cultures.! The! dead!
neuronal!cells!incorporated!the!dye!propidium!iodide!(red!fluorescence),!however,!
living! cells! (astrocytes)! retained! their! mitochondrial! membrane! potential! by!
incorporating! rhodamineK123! dye! (green! fluorescence).! The! healthy! neurons! and!
astrocytes! were! observed! in! control! whereas! dead! neuronal! cells! were! found! in!




MS!patients!may!have!caused!cell!death! in! cerebellar!granule!neurons!but!not! in!
astrocytes.!
4.! Confocal! images! of! cerebellar! granule! neuronal!
cell!cultures!
To!exclude!nonKneuronal!cells! that!might!cause! interference! in!the!study,!we!first!
obtained! pure! cultures! of! CGNs! to! study! primary! neuronal! damage.! For! this!
purpose,!it!was!necessary!to!add!a!chemical!to!prevent!the!growth!of!nonKneuronal!
cells.!The!presence!of!cytosine!arabinoside! (1!mM)! in! the!culture!during!18! to!24!
hours,! inhibit! the! replication! of! nonKneuronal! cells.! To! quantify! the! CGNs! in! the!
primary!cultures!of!granule!neurons!isolated!from!cerebellum,!we!stained!the!cells!
with! texas! red! and! FITC! dyes,! and! nuclei! were! stained! with! DAPI.! The! figure! 15!
showed! the! stained! neurofilaments! characteristic! of! neurons,! indicating! that! the!
culture!contains!a!pure!population!of!CGNs!devoid!of!any!nonKneuronal!cells.!
5.! Treatment! of! primary! cultures! with! CSF! of! MS,!
NMO!patients!and!controls!
The!next!chapter!of!our!work!was!developed!with!the!hypothesis!that!CSF,!which!!
may! contain! cellular! damage! products,! including! lipids! [Vidaurre!et' al.,! 2014],! or!
cytokines! [Rossi! et' al.,! 2014;! Rossi! et' al.,! 2012],! may! influence! the! cellular!
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Figure! 14:! Viability! and! cell! death! in! CGN! (white! arrow)! and!
astrocytes!(red!arrow).!6!days!culture!of!CGNs!treated!with!CSF!
of! MS! patients.! PI! =! red! fluorescence! and! RhodamineK123! =!







mediate! nervous! system!damage! and! inhibit! repair! in! distinct! types! of!
MS.! ! For!example,! ceramides!present! in!MS!CSF!promote!axonal! injury!





















Therefore,! in! order! to! determine! the! effect! of! CSF! in! CGN! culture,! we! perform!
experiments! to! identify! global! transcriptional! changes!by!microarray! analysis.! For!
this! purpose,! we! treated! the! neuronal! cell! cultures!with! 10%! (v/v)! CSF! from!MS!
! 115!
(IgM+/K,! IgM+/+,! medullary,! PPMS)! patients,! NMO! patients! and! controls! for! 24!
hours!in!the!next!part!of!our!experiments.!
In! some! previous! work! from! our! laboratory! [Beltran! et' al.,! 2012]! it! was!
revealed! that! IgMKAb! from! CSF! of!MS! patients! showed! a! pattern! of! reactivity! to!
neuronal! surface! antigens!when! CGNs!were! treated!with! the! CSF! of!MS! patients!
We!checked!that! in!our!conditions!of!work,!with!neuronal!cell!cultures! from!14th!
days!of!growing! in!presence!of!5.6!mM!glucose,! the!same!pattern!of! reactivity! to!
neuronal! surface!antigens!when!CGNs!were! treated!with! the!CSF!of!different!MS!
subtype! and! NMO! patients! in! comparison! with! control! patients! [Beltran! et' al.,!
2012]! (Figure! 16).! The! investigators! also! found! that! the! level! of! binding! of! antiK
neuronal! surface! IgMKAb! to! neurons! in! culture,! measured! as! a! percentage! of!
average! fluorescence! intensity,!was! significantly! higher! for! CSF! from!MS! patients!
than!for!CSF!from!either!the!NIND!group!(p=0.0004)!or!NMO!patients!(p=0.0003),!in!
which! neuronal! binding! was! detected! at! low! levels,! as! also! happened! in! our!
experiments!(Figure!17).!
6.! Identification! of! stably! expressed! housekeeping!
genes!for!microarrays!data!normalization!!
One!of! the!main!problems! in!any!microarray!analysis,! in!order! to!obtain!accurate!
gene! expression! data,! is! the! correct! normalization! of! the! changes! obtained! of!
target!mRNA!transcripts!using!in!most!cases!housekeeping!genes!as!controls.!
However,! previous! data! from! our! laboratory! experienced! variation! in! sodium!
channel! gene(s)! expression! while! normalizing! them! with! commonly! used!











unstable!and! fluctuated!expression!of!βMactin! and!Gapdh' in!neurons! treated!with!




intensity! of! ßMActin! gene! was! highest! in! neurons! treated! with! CSF! of! medullar!
patients!as!compared!to!control.! IgM+/+!treated!neurons!exhibit! the! lowest!band!
intensity! as! compared! to! control! (Table! 9).! Similarly! for! Gapdh! gene! the! band!
intensity!was!highest!in!neurons!treated!with!CSF!of!medullar!patients!and!lowest!
in!IgM+/+!treated!neurons!as!compared!to!control.!Overall,!it!can!be!seen!that!the!











Figure! 16:! Immunofluorescent! detection! of!
neuroaxonal! surface! antigens! recognized! by!
IgMs! present! in! the! CSF! of! MS,! NMO! and!
NIND! patients.! Confocal! images! of! rat!
cerebellar! granule! neurons,! in! primary!
culture,! that!have!been!exposed!to!10%!CSF!
for!2!h.!IgM!molecules!in!green!(FITC)!and!βK



























The! data! provided! in! the! previous! chapter! compiled! to! identify! stably! expressed!
reference! genes! suitable! to! be! used! in! global! gene! expression! analysis! by!
microarrays.!!
With! this! aim,! we! performed! real! time! PCR! for! a! set! of! seven! commonly! used!
housekeeping! genes! (HKGs)! chosen! from! literature! as! genes! with! invariable!









































al.,! 1999;! Hamalainen! et' al.,! 2001;! Vandesompele! et' al.,! 2002].! ! The! candidate!
HKGs! selected! were! βKActin! (ActB),! hypoxanthine! guanine! phosphoribosylK
transferase!(Hprt),!ribosomal!protein!L19!(Rpl19),! lactate!dehydrogenase!A!(Ldha),!
transferrin! receptor! (Tfrc),! microglobulin! betaK2! (B2m),! and! glyceraldehyde! 3K
phosphate!dehydrogenase!(Gapdh).!
The! cerebellar! granule! neurons! were! cultured! for! a! period! of! 2! weeks! and! we!
determined! expression! of! the! HKGs! selected! during! different! time! points! of!
neuronal! development! (day! 1,! 5! 8,! 14).! The! ΔCT! method! and! GeNorm! and!
NormFinder! algorithms! were! used! to! assess! the! expression! stability! of! these!
reference!genes.! ! The!GeNorm! program!defines! the!gene! stability! as! the!average!
pairwise! variation!of! a!particular! gene!with!all! other! control! genes!and! ranks! the!
genes!according!to!their!average!expression!stability!denoted!by!M![Vandesompele!
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et' al.,! 2002].! The! gene!with!minimum!M! value! is! considered! to! be! highly! stable!
whereas! the! gene!with! highest!M! value! is! least! stable! and! can! be! excluded.! The!
NormFinder!algoritm!ranks!the!candidate!reference!genes!based!on!the!combined!
estimates!of!both!intraK!and!interKgroup!variations![Andersen!et'al.,!2004].!!
The! GeNorm! algorithm! revealed! that! Hprt,' Gapdh! were! the! most! stable! genes!
followed! by! Tfrc! during! the! maturation! of! CGNs! (day! 1,! 5,! 8,! 14).! For! instance,!
average!M!value! for!Hprt! and!Gapdh! genes!was!0.06!and!0.08! for!Tfrc'gene.!The!
NormFinder! algoritm!depicted! that!Gapdh! and!Hprt! showed!most! invariable!gene!
expression!followed!by!Tfrc'(average!M!value:!0.03!for!Gapdh!and!Hprt'genes!and!
0.036! for' Tfrc' gene).! Therefore,! both! algoritms! showed! similar! pattern! of! stably!
expressed! genes! hence! they! should! be! used! as! reference! genes! during! the!
maturation! of! cerebellar! granule! neurons! to! accurately! normalize! the! gene!
expression!data.!!
On!the!contrary,!βMActin,!a!commonly!used!HKGs!in!most!laboratories,!showed!the!





higher! expression! observed! on! day! 14! as! compared! to! day! 1! during! CGNs!
development.!This! is!a!marked!fluctuation! in!ActB!gene!expression!when!neurons!
develop! from!day!1! to!day!14.!Both!GeNorm! and!NormFinder! algorithms! identify!
ActB' the! highly! variable! gene! during! CGNs! development.! We! conclude! that! this!
gene!is!not!suitable!to!normalize!gene!transcripts!during!CGNs!maturation.!
The! expression! of! hypoxanthine! phosphoribosyltransferase! (Hprt)! gene! was! 0.2!
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folds! on! day! 5! which! was! slightly! lower! as! compared! to! day! 1.! Similary! the!
expression!was!0.13!folds!lower!on!day!8!and!0.4!folds!on!day!14!as!compared!to!
day! 1.! The! data! suggests! that! there! was! slightest! difference! in! gene! expression!
during! different! time! points! of! granule! cell! development.! Additionally,! GeNorm!
identifies! Hprt! as! the! most! stable! gene! hence! this! gene! may! be! used! for!
normalization!purpose!in!treated!CGNs.!
There!was! no!difference! in! the! expression!of! ribosomal! protein! L19! (Rpl19)! gene!
during!granule!neuron!development!from!day!1!to!day!5.!On!day!8!and!day!14,!the!
expression! level! of! this! gene! reduced! to! 0.6! folds! as! compared! to! control.! The!






there! is! a!huge!variation! in!Ldha! gene!expression!during!different!developmental!
time!points!of!granule!neurons.!To!corroborate!this!data!GeNorm!and!NormFinder!
softwares! identifies! this! gene! as! one! of! the! least! stable! genes! during! CGN!
development! (Average! expression! stability! value:! 1.6! by! GeNorm! and! 5.1! by!
NormFinder).!!
The!expression!of!transferrin!receptor!(Tfrc)'gene!was!reduced!to!0.16!folds!on!day!
5! as! compared! to! day! 1.! Similarly! when! granule! neurons! reached! day! 8! of! its!
development!the!expression!remained!same.!The!expression!was! further!reduced!
to! 0.36! folds! when! neurons! reached! day! 14.! This! data! indicates! very! slight!








The! data! indicates! the! expression! of! glyceraldehyde! 3Kphosphate! dehydrogenase!
(Gapdh)! gene! reduced! to! 0.34! folds! from! day! 1! to! day! 5.! There! was! negligible!
difference! in! its! expression! when! the! cells! reached! day! 8! of! the! development.!
Furthermore! the!expression!dropped! to!0.4! folds!when! the!neurons! reached!day!
14th! of! its! development.! We! can! see! that! there! was! slightest! difference! in! the!
expression!of!Gapdh!gene!during!neuronal!development.!To!corroborate!this!data,!
we!used!GeNorm!and!NormFinder!softwares!which!further!demonstrates!Gapdh'as!
the! second!most! stable!gene! to!be!used! in!neuronal!development! (Average!gene!
expression!stability:!0.06!using!GeNorm!and!0.03!using!NormFinder).!
The! figure!19!depicts! the! fold! change! values!obtained! from!qPCR!experiment! for!!
each!reference!gene!tested!during!the!development!of!cerebellar!granule!neurons!
(day!1,!5,!8,!14)!normalized!to!the!expression!of!day!1.!!




Tfrc' during! CGNs! development.! On! the! other! hand,! β−actin' showed! highest!
fluctuation! and! therefore! its! use! is! strictly! discouraged! while! normalizing! gene!
expression!data!in!studies!related!with!global!gene!expression.!
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Once! establish! that! we! may! used! some! HKGs! to! normalize! data! as! constantly!
expressed,! independently! of! changes! in! the! time! of! growth! for! CGNs,! we! asked!
ourself! if! treatment! of! the! cells! with! CSF! of! MS! patients! may! induce! additional!
changes! in! the! expression.! Changes! in! the! HKGs! depending! on! the! type! of! MS!







1.78! folds! in! NMO! patients! compared! to! control.! Although! the! variation! in! the!
expression!level!of!this!gene!in!all!the!different!experimental!conditions!is!not!large,!
we! employed! GeNorm! software! to! compare! the! expression! stability! of! all! the!
reference!genes!with!each!other!(Table!11).!The!software!GeNorm!ranked!ActB!gene!



























Figure! 19:! Fold! change! for! each!
reference! gene! tested! during! the!










Table! 10.! Candidate! housekeeping! genes! ranked! during! the! development! of!
cerebellar!granule!neurons!according! to! their!expression!stability!by!GeNorm!and!
NormFinder! methods.! Average! expression! stability! measure! (M)! of! reference!















1! Hprt+ 0.060! 1! Gapdh+ 0.030!
1! Gapdh+ 0.060! 1! Hprt+ 0.030!
2! Tfrc+ 0.088! 2! Tfrc+ 0.036!
3! B2m' 0.137! 3! B2m' 0.060!
4! Rpl19' 0.214! 4! Rpl19' 0.141!
5! Ldha' 1.689! 5! Ldha' 5.147!







In! relation! with' ribosomal! protein! L19! (Rpl19)' gene,! its! expression! was! down!
regulated!by!0.2!and!0.5!folds!in!IgM+/K!and!IgM+/+!treated!neurons!respectively!as!
compared! to! control.! There! was! only! 0.1! folds! decrease! when! neurons! were!
treated!with!medullary,!PPMS!and!NMO!CSF!patients!as!compared!to!control.!We!
can! see! that! ! there! is! a! negligible! variation! in! all! the! experimental! conditions,! as!








in!PPMS!and!NMO!patients.! The!data! signifies! that! the!expression!of! this! gene! is!
not! constant! in! all! the! experimental! conditions.! The! average! expression! stability!
(M)! value! of! this! gene! was! 1.25! and! thus! was! ranked! as! the! 4th! stable! gene!
according!to!GeNorm!software.!!
In! the' transferrin! receptor' (Tfrc)'study,! the!gene!was!up!regulated!by!1.2! folds! in!
neurons! treated!with! IgM+/K!CSF! treated!neurons! as! compared! to! control.! In! the!
IgM+/+! CSF! treated! neurons,! the! expression! level! almost! remained! the! same! as!
compared!to!control.!In!medullary!patients!the!expression!was!reduced!by!0.2!folds!
and! in!PPMS!CSF!treated!neurons!the! level!was! increased!by!only!1.1! folds!which!
was! almost! similar! as! compared! to! control.! There! was! a! downregulation! of! this!
gene!by!0.4!folds!in!neurons!treated!with!the!CSF!of!MS!patients.!Overall,!we!found!
that! there! was! a! negligible! variation! in! the! gene! expression! in! different!
experimental! conditions.!Moreover,! and! according! to! the!GeNorm!algorithm,! the!
average!expression!stability!value!was!1.092!and!it!was!ranked!the!best!reference!
gene!with!respect!to!others.!
The! data!with! betaK2!microglobulin! (B2m)! indicates! that! there!was! 1.2! folds! upK
regulation! of! gene! in! IgM+/K! CSF! treated! neurons! as! compared! to! control.! The!
expression!was!down!regulated!by!0.9!folds! in! IgM+/+!CSF!treated!neurons!which!
was! not! a! large! variation! as! compared! to! control.! It! dropped! to! 0.2! folds! in!
medullary! CSF! treated! neurons! and! 0.4! folds! in! PPMS! CSF! treated! neurons.! The!
expression!decreased!by!0.8!folds!in!NMO!treated!neurons!as!compared!to!control.!
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According! to! the! GeNorm! algorithm! the! average! expression! stability! value! was!
similar! to!Tfrc! average! expression! stability! (M:! 1.092)! and! it!was! also! ranked! the!
best!reference!gene!with!respect!to!others.!
The!expression! level!of!glyceraldehyde!3Kphosphate!dehydrogenase! (Gapdh)!gene!
was! 0.89! folds! lower! in! IgM+/K! treated! neurons! as! compared! to! control.! The!
expression! level! increased! by! 2! folds! in! IgM+/+! treated! neuons! as! compared! to!
control.! In! neurons! treated! with! the! CSF! of! medullary! MS! patients! the! gene!
downregulated! by! 0.02! folds! and! by! 0.1! fold! in! neurons! treated!with! the! CSF! of!
PPMS!patients.!Similarly!the!expression!level!declined!by!0.38!folds!in!NMO!treated!
patients.! As! we! ! can! see! from! the! qPCR! data! that! there! is! a! huge! fluctuation! in!
Gapdh!gene!expression!in!our!experimental!conditions.!Normally,!Gapdh!is!used!as!
a! housekeeping! gene! but! we! find! that! it! is! not! a! housekeeping! gene! in! our!
experimental! conditions.! GeNorm! ranked! this! gene! as! the! least! stable! gene!with!
4.2!as!the!average!expression!stability!value.!!
The! results! of! Figure! 20! illustrates! candidate! HKGs! genes! in! cerebellar! granule!
neurons! treated!with! CSF! of!MS/NMO! patients! according! to! their! gene! expression!
measured! by! qPCR.! The! gene! expression! values! of! all! the! experimental! conditions!!
were!normalized!to!control.!
Table! 11! shows! the! candidate! HKGs! genes! ranked! according! to! their! expression!
stability!analyzed!by!GeNorm!and!NormFinder!methods.!
The!data!of!this!chapter!allow!us!to!conclude!that!both!Tfrc'and!B2m!with!similar!




















Figure! 20:! Fold! change! for! each! reference! gene! tested! in!
distinct! disease! courses! of! multiple! sclerosis.! IgM+/+! and!
IgM+/K:! Inflammatory! forms! of! relapsing! remitting! multiple!





Table! 11.! Candidate! housekeeping! genes! ranked! in! cerebellar! granule! neurons!
treated! with! CSF! of! MS/NMO! patients! according! to! their! expression! stability! by!
GeNorm!and!NormFinder!methods.!Lower!M!value!of!average!expression!stability!















1! Tfrc+ 1.092! 1! Tfrc+ 0.546!
1! B2m+ 1.092! 2! Ldha+ 0.589!
2! Rpl19+ 1.198! 3! Rpl19+ 0.972!
3! Ldha' 1.253! 4! B2m' 1.102!
4! Hprt' 1.318! 5! Hprt' 1.379!
5! ActB' 2.929! 6! ActB' 6.099!




CSF! of! IgM+/;,! IgM+/+,!medullary,! PPMS! and! NMO!
patients!using!microarray!
The!next!step!of!our!work!was!the!study!of!the!effect!of!CSF!of!different!MS!type!




analysis.! Similarly! we! isolated! total! RNA! from! CGNs! exposed! to! the! CSF! of!




respective! staff! at! centralized! service! of! our! center.! The! hybridization! data! was!
extracted!using!Agilent! Feature! Extraction! software! and,! to! normalize!microarray!
signals,! we! used! the! 75th! percentile! as! it! is! a!more! robust! value! in! Gene! Spring!
software!(9.0!version).!!!
From!the!different!functional!group!of!genes!obtained,!we!found!that!genes!related!
with! carbohydrate!metabolism!and! further!pathways! involved! in!ATP!production,!
namely! TCA! cycle! and! electron! transport! chain,! are! overrepresented! in! our!
experimental!conditions.! !We!also!we!also!found! in!the!previous!chapter!that!the!
widely! used! HKGs! ActB! did! not! express! constitutively! during! CGNs! cells!
development! and! therefore! it! was! not! regarded! as! a! good! reference! gene! to!
normalize!gene!expression!in!microarray!data.!On!the!contrary,!other!of!the!most!
widely! used,! HKG!Gapdh,! showed! a! constitutive! expression! during! different! time!
points! of! CGNs!development! (day! 1,! 5,! 8,! 14)! but! its! expression! fluctuated!when!
CGNs!were!treated!with!the!CSF!of!distinct!clinical!types!of!MS!and!NMO!patients.!!
Having! this!data! in!mind,!we! redirect!our! research!under! the!proposal! that! there!
should! be! some! specific! factors! in! the! CSF! of! MS! patients! that! should! alter!
expression! of! genes! specifically! involved! in! carbohydrate! metabolism! and! ATP!
production,! and! that! these! transcriptional! changes! may! be! related! with! the!
differential! repairing! capacity! of! neurons! damage! of! the! MS! subtypes.! These!









The! microarray! data! from! the! first! step! of! glycolysis,! the! hexokinase! (Hk)! gene,!
show!that!its!expression!was!downregulated!showing!around!30%!of!expression!in!
neurons! treated! with! RRMS! IgM! +/+! and! medullary! clinical! forms! of! MS,! as!
compared! to! neurons! exposed! to! the! CSF! of! nonKinflammatory! neurological!
controls.! The! other! three! conditions! we! analyze! (RRMS! IgM+/K,! PPMS)! have! just!
negligible!Hk!gene!expression!differences! in!relation!with!the!control,!and!a!slight!
increasing!of!gene!expression!in!NMO!patients!(Figure!21!A).!
The! data! obtained! of! glyceraldehyde! 3Kphosphate! dehydrogenase! (Gapdh)!
indicates!that!gene!expression!was!downregulated!to!33!%,!34!%!and!35%!of!gene!
expression! respectively! in!neurons! treated!with!CSF!of!RRMS! IgM+/+,! IgM+/K!and!
medullary!form!of!MS!as!compared!to!neurological!control.!By!contrary,!PPMS!and!
NMO!show!similar!values!of!gene!expression!than!the!control!(Figure!21!B).!!!
The! results! obtained! for! the! phosphogycerate! kinase! (Pgk)! indicate! that! the!




The! data! indicates! that! phosphoglycerate! mutase! (Pgm)' gene! expression! was!
downregulated!up!to!around!30!%!of!gene!expression!in!neurons!treated!with!CSF!
of!IgM+/K,!IgM+/+,!and!PPMS!clinical!forms!of!MS!clinical!form!of!MS!as!compared!
to! control.! By! contrary,! CSF! of! medullary! patients! do! not! affect! Pgm! gene!
! 135!
expression,! and!produce! a! slight! increasing!of! gene!expression! in! treatment!with!
CSF!of!NMO!patients!(Figure!21!D).!!!
The! data! obtained! with! enolase! (Eno)! gene! indicates! that! Eno' gene! was! also!
downregulated!up!to!29!%,!20!%!and!23!%!of!expression! in!neurons! treated!with!
IgM+/K,!IgM+/+,!and!medullary!clinical!forms!of!MS!clinical!form!of!MS!respectively!
as! compared! to! neurons! exposed! to! the! CSF! of! neurological! controls.! Treatment!
with!CSF!of!PPMS!patients!do!not!mainly!affect!Eno!gene!expression,!and!produce!a!
slight! increasing! of! gene! expression,! up! to! 150!%! in! treatment!with! CSF! of!NMO!
patients!(Figure!21!E).!!!
Finally,! the! expression! of! the! pyruvate! kinase! isozyme! 2! gene! (Pkm2)! was! also!
downregulated!up!to!33%!!and!31%!of!the!gene!expression!realted!with!controls!in!
neurons! treated! with! the! CSF! of! IgM+/+! and! medullary! MS! patients,! with! no!
significant!changes!in!the!other!experimental!conditions!(Figure!21!F).!!
Figure! 21! shows! gene! expression! involved! in! carbohydrate! metabolism! in! CGNs!
treated!with!CSF!of!MS!and!NMO!patients!related!to!neurons!exposed!to!the!CSF!of!
neurological! controls.! We! have! plotted! the! percentage! variation! of! genes! in!
experimental!conditions!with!respect! to!control!calculated! from!the!absolute! fold!
change!values!from!microarray!data.!!
7.2!Krebs!cycle!pathway!
The! oxidative! phosphorylation! is! the! metabolic! process! that! oxidizes! several!
substrates!through!the!Krebs!(or!tricarboxylic!acid,!TCA)!cycle!to!produce!reducing!




The! first! part! of! the! oxidative! phosphorylation,! the! TCA! cycle,! is! connected!with!
glycolysis!by!the!reaction!catalyzed!by!pyruvate!decarboxylase!(PDH).!The!Pdh!gene!
was! also! downregulates! to! similar! gene! expression! values,! around! 30! %! of! the!
expression!of!controls,!during!treatment!of!neurons!with!CSF!of!all!clinical!forms!of!
MS,!with!the!exception!of!CSF!of!NMO!patients!(Figure!22!A).!
The!unique! gene!of! TCA! cycle! that! is! affected! in! neurons! by! CSF! treatments!was!
malate! dehydrogenase! (Mdh).! The! data! indicates! that! Mdh! gene! was!
downregulated! up! to! 23! %! of! gene! expression! in! neurons! treated! with! IgM+/+!
clinical!form!of!MS!as!compared!to!controls.!Similarly,!the!expression!was!reduced!
to!27!%!and!29!%!in!neurons!treated!with!medullary!and!PPMS!clinical!forms!of!MS,!
and! to!32!%!and!35!%! in!neurons!exposed! to! the!CSF!of!RRMS! IgM+/K! and!NMO!
patients,! respectively! in! comparison!with! nonKinflammatory! neurological! controls!
(Figure!22!B).!!!
7.3.! Mitochondrial! genes! involved! in! electron!
transport!chain!(ETC)!
In!the!last!part!of!the!oxidative!phosphorylation,!the!electron!transport!chain,!two!
subunits!of! the!ATP! synthase! complex!are!affected!by!CSF! treatment!of!neurons,!
the!α!and!β!subunit.!!
The!expression!of'ATP!synthase!subunit!alpha!(Atp5A)!gene!was!downregulated!up!
to! around! 35%! of! gene! expression! in! neurons! treated!with! CSF! of!Medullar! and!
PPMS!clinical!form!of!MS!as!compared!to!controls,!whereas!just!slight!changes!are!
observed!in!the!other!experimental!conditions!(Figure!23!A).!















Figure! 21:! Normalized! gene! expression! involved! in! glycolytic!
pathway! in! CGNs! treated! with! CSF! of! MS! and! NMO! patients!
normalized! to! gene! expression! in! CGNs! treated! with! CSF! of!
non;inflammatory! neurological! controls.! CGNs:! cerebellar!
granule! neurons;! Blank:! Neurons! exposed! only! to! culture!




conditions! treatment! with! the! exception! of! NMO! that! show! a! slight! increase! of!
gene!expression!up!to!129%!in!comparison!with!the!neurological!control!(Figure!23!
B).!!
Overall,! the! microarray! findings! demonstrate! that! the! genes! involved! in!
carbohydrate! metabolism! were! differentially! expressed! in! cerebellar! granule!





Figure! 22:! Normalized! gene! expression! involved! in! TCA! cycle!
pathway! in! CGNs! treated! with! CSF! of! MS! and! NMO! patients!
normalized! to! gene! expression! in! CGNs! treated! with! CSF! of!
non;inflammatory!neurological!controls.!
!
CGNs! altered! the! carbohydrate! metabolism! in! these! neurons! and! may! alter! the!
capacity! of! these! cells! to! repair! axonal! damage.! In! the! discussion! section! we!
interprete! the! data! for! the! different! CSF! MS! type! treatment! with! this! reducing!
capacity!of!neuronal!repairing.!
8.! Identification! of! stably! expressed! housekeeping!




of! the! CNS! and! the!myelin! sheath! is! crucial! to! neuronal! function,! enabling! rapid!
propagation!of!nerve!impulses!and!providing!trophic!support!to!the!axon.!Its!loss!in!
demyelinating! diseases! like! MS! has! profound! pathological! consequences.! The!
strategies! to! repair! CNS! myelin! during! the! disease! course! of! MS! have! gained!
significant!momentum!in!order!to!find!strategies!for!central!nervous!system!repair.!
Many! studies! have! been! doing! to! identified! molecular! players! involved! in! the!
blockade! of! oligodendrocyte! progenitor! cell! (OPCs)! differentiation,! cells! that! are!
considered! as! the! source! for! remyelination! in! the! MS! demyelinating! disease.! In!
addition!to!intrinsic!factors,!the!characterization!of!extracellular!molecules!and!the!
environmental! milieu! that! OPCs! experience! in! plaques! is! necessary! in! order! to!
better! understand! repair! strategies! for! MS.! Since! the! CSF! is! in! contact! with! the!
OPCs! in! the! brain! parenchyma! and! ventricles,! some! patientKdependent! factors!
present! in! MS! type! disease! can! influence! the! cellular! physiology! of! OPCs! and!
neurons!(Armati,!2010).!!
There!are!many! research! in! the! literature! indicating! that! the! type!and!amount!of!
inflammation,! the! capacity! of! remyelination,! and! of! tissue! damage! vary! between!
different! forms! of! MS! and! between! different! stages! of! the! disease.! These!
differences! possibly! reflecting! different! pathogenic! mechanisms! in! the! disease!
spectrum!of!MS!types.!In!our!work!we!are!trying!to!identify!aberrant!transcriptional!
changes! in! carbohydrate! metabolism! genes! that! occur! during! brain! repair! by!
performing! gene!microarray! profile,! studiying! the! effect! of! CSF! of!MS! and! NMO!
patients!to!proliferating!OPCs.!







Figure! 23:! Normalized! gene! expression! involved! in! oxidative!
phosphorylation! in!CGNs! treated!with!CSF!of!MS!and!NMO!patients!
related! to! gene! expression! in! CGNs! treated! with! CSF! of! non;
inflammatory! neurological! controls.! CGNs:! cerebellar! granule!
neurons;!Blank:!Neurons!exposed!only!to!culture!medium;!IgM+/K!and!
IgM+/+:! types! of! inflammatory!MS;!Med:!Medullary!MS;! PP:! Primary!
progressive!multiple!sclerosis;!NMO:!Neuromyelitis!Optica!
!
We! selected! the! panel! of! reference! genes! studied!with! neurons! analysis! and!we!
determine! from! the! microarray! data! the! changes! of! gene! expression! in! the!
different!MS! and! NMO! patients,! and! determined! their! expression! stability! using!
GeNorm'and!NormFinder!algorithms.!According! to!GeNorm'algorithm!Mrpl19!and!
Hprt1!were!identified!as!the!best!housekeeping!genes!followed!by!B2m!(average!M!
value:! 0.102! for!Mrpl19! and!Hprt1' genes! and' 0.147! for' B2m! gene).! Surprisingly,!
ActB! and!Gapdh! showed! the! most! unstable! gene! expression! in! OPCs! that! were!
exposed! to! the! CSF! of! our! experimental! conditions.! NormFinder! found! an!
altogether! different! ranking! of! housekeeping! genes.! According! to! this! software,!
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IgM+/+! and! medullary! MS! as! compared! to! control.! The! expression! was!
downregulated!by!37%!in!OPCs!exposed!to!the!CSF!of!NMO!patients!as!compared!
to!control!(Figure!24A).!We!can!see!a!marked!fluctuation!in!ActB!gene!expression!in!
OPCs! exposed! to! the! CSF! of! various! experimental! conditions.!GeNorm' identified!
ActB'a!highly!variable!gene!in!these!experimental!conditions.!We!conclude!that!this!
gene!is!not!suitable!to!normalize!gene!transcripts!in!treated!OPCs.!
The! expression! of! betaK2! microglobulin! (B2m)' gene! was! downregulated!





The! expression! of! hypoxanthine! phosphoribosyltransferase' (Hprt1)' gene! was!
downregulated!significantly!by!49%,!38%,!and!49!%!in!OPCs!exposed!to!the!CSF!of!
IgM+/K,!IgM+/+!and!medullary!MS!as!compared!to!control.!Similarly!the!expression!













The! data! indicates! that! the! expression! of! glyceraldehyde! 3Kphosphate!
dehydrogenase! (Gapdh)! gene!was! downregulated! by! 44%,! 54%! and! 49%! in!OPCs!
treated! with! IgM+/K,! IgM+/+! and! medullary! clinical! form! of! MS! as! compared! to!
OPCs! exposed! to! the! CSF! of! neurological! controls.! Similarly,! the! expression! was!
reduced!by!55%!and!44%!in!OPCs!treated!with!the!CSF!of!PPMS!and!NMO!patients!
as! compared! to! OPCs! exposed! to! the! CSF! of! nonKinflammatory! neurological!
controls! (NIND)! (Figure! 24F).! According! to! GeNorm' and! NormFinder! algorithms,!
Gapdh!was!ranked!as!an!unstable!gene!for!normalizing!mRNA!transcripts.!
9.! Whole! genome! profiling! in! oligodendrocytes!
(OPCs)! treated! with! the! CSF! of! IgM+/;,! IgM+/+,!
medullary,! PPMS! and! NMO! patients! using!
microarray!
In! the! next! group! of! experiments,! we! performed! gene! expression! profiling! in!
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oligodendrocytes! treated! with! the! CSF! of! IgM+/K,! IgM+/+,! medullary,! PPMS! and!
NMO! patients! using! microarray! technology.! Oligodendrocytes! (OPCs)! are! the!
myelinating! glial! cells! of! the! CNS! and! the! myelin! sheath,! generated! by!




to! find! strategies! for! central!nervous! system! repair.!Many! studies!have! identified!
molecular!players!involved!in!the!blockade!of!oligodendrocyte!progenitor!cell!(OPC)!
differentiation.! In!addition!to!intrinsic!factors,!the!characterization!of!extracellular!
molecules! and! the! environmental! milieu! that! OPCs! experience! in! plaques! is!
necessary! in! order! to! better! understand! repair! strategies! for! MS.! Cerebrospinal!
fluid!(CSF)! is! in!contact!with!the!brain!parenchyma!and!ventricles,!which!can!be!a!
site! for! deposition! of! cellular! damage! products,! including! lipids! [Vidaurre! et' al.,!
2014],! cytokines! [Rossi! et' al.,! 2014;! Rossi! et' al.,! 2012]! which! can! influence! the!
cellular!physiology!of!OPCs,!myelinating!oligodendrocytes!and!neurons.!Numerous!
studies!have!attempted! to! identify! soluble! factors! in! the!CSF!of!MS!patients! that!
account! for! the! observed! cellular! effects.! For! example,! ceramides! present! in!MS!
CSF! promote! axonal! injury! and! neuronal! damage! through! oxidative! stress!
mechanisms! and! mitochondrial! bioenergetic! failure! [Vidaurre! et' al.,! 2014].! In!
addition,!microarray!profiling!of!MS!cortical!gray!matter!revealed!gene!changes!in!
oxidative!stress,!and!remyelination/repair![Fischer!et'al.,!2013].!Therefore,!in!order!
to! identify! the! transcriptional! changes! that! occur! to! proliferating! OPCs,! we!


















tested! in! distinct! disease! courses! of! multiple! sclerosis.! IgM+/+! and!
IgM+/K:!Inflammatory!forms!of!relapsing!remitting!multiple!sclerosis;!Med:!
Medullary! form;! NMO:! Neuromyelitis! Optica;! Control:! Other! nonK
inflammatory!neurological!diseases!(NIND).!
!
progenitor! cells! (OPLs)! using! the! Qiagen! RNeasy! RNA! extraction! kit.! ! Therafter,!
mRNA!was! reverse! transcribed! in! the!presence!of!T7K!oligoKdT!primer! to!produce!
cDNA.!cDNA!was!then!in'vitro!transcribed!with!T7!RNA!polymerase!in!the!presence!
of! Cy3KCTP! to! produce! labeled! cRNA.! The! labeled! cRNA! was! hybridized! to! the!




In! the! graphs! shown! below! we! have! plotted! the! expression! of! genes! in!
experimental!conditions!with!respect!to!neurological!control!calculated!from!the!
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Table! 12.! Candidate! housekeeping! genes! ranked! in! oligodendrocytes!
exposed! to! the! CSF! of! RRMS! and! PPMS! patients! according! to! their!












1! Mrpl19+ 0.102! 1! Tfrc++ 0.033!
1! Hprt1+ 0.102! 1! B2m+ 0.033!
2! B2m+ 0.147! 2! ActB+ 0.087!
3! Tfrc' 0.160! 3! Hprt1' 0.222!
4! ActB' 0.192! 4! Mrpl19' 0.260!
5! Gapdh' !!!!!0.272! 5! Gapdh' 0.426!
!
!
raw! Log2! values! obtained! from! microarray! data.! Figure! 25! shows! normalized!
expression!of!genes!involved!in!carbohydrate!metabolism!in!OPLs!treated!with!CSF!
of!MS! and! NMO! patients! related! to! neurons! exposed! to! the! CSF! of! neurological!
controls.!!






52%! in! OPCs! treated! with! IgM+/K! and! IgM+/+! MS! patients.! The! gene! was! 56%!
reduced! in!OPCs!treated!with!medullary!clinical! form!of!MS!as!compared!to!OPCs!
exposed!to!the!CSF!of!neurological!controls.!Similarly,!the!expression!was!reduced!
by! 38%! in! OPCs! treated! with! the! CSF! of! PPMS! patients! as! compared! to! OPCs!
exposed!to!the!CSF!of!nonKinflammatory!neurological!controls!(NIND)!(Figure!25!A).!!!
The! expression! of! glucoseK6Kphosphate! isomerase! (Gpi)! gene! was! found! to! be!
downregulated! by! 56%! and! 40%! in! OPCs! treated! with! IgM+/K! and! IgM+/+! MS!
patients.! There!was!46%!down! regulation! in!OPCs! treated!with!medullary! clinical!
form! of! MS! as! compared! to! OPCs! exposed! to! the! CSF! of! neurological! controls.!
Similarly,!the!expression!was!reduced!by!54%!and!42%!in!OPCs!treated!with!the!CSF!
of! PPMS! and! NMO! patients! as! compared! to! OPCs! exposed! to! the! CSF! of! nonK
inflammatory! neurological! controls! (NIND).! In! addition,! the! gene! expression! in!
OPCs!treated!with!the!CSF!of!IgM+/K!MS!patients!was!significantly!reduced!by!15%!
as!compared!to!OPCs!treated!with!the!CSF!of!IgM+/+!MS!patients!(Figure!25!B).!!!
The! data! indicates! that! the! expression! of! aldolase! C! (Aldoc)! gene! was!
downregulated! showing! 28%! in! OPCs! treated! with! NMO! as! compared! to! OPCs!
exposed! to! the!CSF!of!neurological! controls.! Furthermore,! there!was!a! significant!
difference! found! in! neurons! exposed! to! CSF! from! medullary! MS! with! 64%!
expression! and! neurons! exposed! to! CSF! from! NMO! patients! showing! 28! %!
expression!(Figure!25!C).!!!
The! data! indicates! that! the! expression! of! glyceraldehyde! 3Kphosphate!
dehydrogenase! (Gapdh)! gene!was!downregulated! showing!53%!and!44%! in!OPCs!







downregulated! by! 33%! in! OPCs! treated!with! IgM+/+!MS! patients.! The! gene!was!
reduced!by!40!%!in!OPCs!treated!with!medullary!clinical!form!of!MS!as!compared!to!
OPCs! exposed! to! the! CSF! of! neurological! controls.! Similarly,! the! expression! was!
reduced!with!37%! in!OPCs!treated!with!the!CSF!of!NMO!patients!as!compared!to!
OPCs! exposed! to! the! CSF! of! nonKinflammatory! neurological! controls! (NIND).! ! In!
addition,! we! found! significant! differences! in! the! gene! expression! between! OPCs!
treated!with!the!CSF!of! IgM+/K!MS!patients!with!33!%!and!the!OPCs!treated!with!
the!CSF!of!IgM+/+!MS!patients!with!60!%!gene!expression!(Figure!25!E).!!!
The!expression!of! phosphoglycerate! kinase! (Pgk1)! gene!was! significantly! reduced!
by!57%!and!39%! in!OPCs!treated!with! IgM+/K!and! IgM+/+!patients.!The!gene!was!
reduced!by!45%!in!OPCs!treated!with!medullary!clinical!form!of!MS!as!compared!to!
OPCs! exposed! to! the! CSF! of! neurological! controls.! Similarly,! the! expression! was!
reduced!showing!46%!in!OPCs!treated!with!the!CSF!of!NMO!patients!as!compared!
to! OPCs! exposed! to! the! CSF! of! nonKinflammatory! neurological! controls! (NIND).!
Furthermore,! we! found! significant! differences! in! the! gene! expression! between!
OPCs!treated!with!the!CSF!of!IgM+/K!MS!patients!and!the!OPCs!treated!with!the!CSF!
of!IgM+/+!MS!patients!(Figure!25!F).!!!






and! 43%! in! OPCs! treated! with! IgM+/K! and! IgM+/+! MS! patients.! There! was! 51%!
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down!regulation!in!OPCs!treated!with!medullary!clinical!form!of!MS!as!compared!to!
OPCs! exposed! to! the! CSF! of! neurological! controls.! Similarly,! the! expression! was!




was!downregulated!by!41%!and!44%! in!OPCs! treated!with! IgM+/+!and!medullary!
clinical! form! of! MS! as! compared! to! OPCs! exposed! to! the! CSF! of! neurological!
controls.! Similarly,! the! expression! was! reduced! showing! 5%! and! 44%! in! OPCs!
treated!with!the!CSF!of!PPMS!and!NMO!patients!as!compared!to!OPCs!exposed!to!
the!CSF!of!nonKinflammatory!neurological! controls! (NIND).! ! In!addition,!we! found!
significant!differences! in! the!gene!expression!between!OPCs!treated!with! the!CSF!
of! IgM+/K!MS!patients! and! the!OPCs! treated!with! the!CSF!of! IgM+/+!MS!patients!
(Figure!25!I).!!!
The! data! indicates! that! the! expression! of! pyruvate! kinase! (Pk)! gene! was!




NMO! patients! as! compared! to! OPCs! exposed! to! the! CSF! of! nonKinflammatory!
neurological!controls!(NIND)!(Figure!25!J).!!!
The!data! indicates! that! the!expression!of!Pkm2! gene!was!downregulated!by!44%!
and! 47%! in! OPCs! treated! with! IgM+/+! and! medullary! clinical! form! of! MS! as!
compared! to! OPCs! exposed! to! the! CSF! of! neurological! controls.! Similarly,! the!
expression!was!reduced!by!57%!and!44%!in!OPCs!treated!with!the!CSF!of!PPMS!and!
NMO! patients! as! compared! to! OPCs! exposed! to! the! CSF! of! nonKinflammatory!
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by! 56%,! 28%! and! 41%! in! OPCs! treated! with! the! CSF! of! IgM+/K,! IgM+/+! and!
medullary! clinical! form! of! MS! as! compared! to! OPCs! exposed! to! the! CSF! of!
neurological!controls.!Similarly,!the!expression!was!reduced!by!31%!in!OPCs!treated!
with! the! CSF! of!NMO!patients! as! compared! to!OPCs! exposed! to! the! CSF! of! nonK
inflammatory!neurological!controls!(NIND)!(Figure!26!A).!!!
The!data!indicates!that!the!expression!of!mitochondrial'aconitase'(Aco2)!gene!was!
downregulated! by! 52%! and! 46%! in! OPCs! treated! with! IgM+/K! and! IgM+/+! MS!
patients.! The! gene! expression! lowered! by! 50%! in! OPCs! treated! with! medullary!
clinical! form! of! MS! as! compared! to! OPCs! exposed! to! the! CSF! of! neurological!
controls.!Similarly,!the!gene!was!down!regulated!with!54%!and!38%!expression! in!


































in! OPCs! treated! with! CSF! of! MS! and! NMO! patients! related! to! gene!
expression!in!OPCs!treated!with!CSF!of!non;inflammatory!neurological!
controls.!!OPCs:!oligodendrocytes;!Control:!Neurons!treated!with!CSF!of!






dehydrogenase! (Ogdh)! gene! was! downregulated! showing! 53%,! 36%! and! 29%!
expression!in!OPCs!treated!with!IgM+/K,!IgM+/+!and!medullary!clinical!form!of!MS!
as! compared! to! OPCs! exposed! to! the! CSF! of! neurological! controls.! Similarly,! the!
expression! was! reduced! showing! 38%! in! OPCs! treated! with! the! CSF! of! NMO!
patients! as! compared! to! OPCs! exposed! to! the! CSF! of! nonKinflammatory!
neurological!controls!(NIND)!(Figure!26!D).!!!
The! expression! of! succinate! dehydrogenase! (Sdh)! gene! was! found! to! be!
downregulated! with! 36%! and! 49%! in! OPCs! treated! with! IgM+/+! and! medullary!
clinical! form! of! MS! as! compared! to! OPCs! exposed! to! the! CSF! of! neurological!
controls.!Similarly,!the!expression!was!reduced!showing!47%!in!OPCs!treated!with!
the! CSF! of! NMO! patients! as! compared! to! OPCs! exposed! to! the! CSF! of! nonK
inflammatory! neurological! controls! (NIND).! ! In! addition,! we! found! significant!
differences! in! the!gene!expression!between!OPCs! treated!with! the!CSF!of! IgM+/K!
MS!patients!and!the!OPCs!treated!with!the!CSF!of!IgM+/+!MS!patients!(Figure!26!E).!!!
The! expression! of! mitochondrial! malate! dehydrogenase! (Mdh2)! gene! was!
significantly!reduced!with!30%!and!26%!in!OPCs!treated!with!the!CSF!of!IgM+/+!and!
NMO! patients! as! compared! to! to! OPCs! exposed! to! the! CSF! from! neurological!
controls!(Figure!26!F).!
9.3.! Mitochondrial! genes! involved! in! electron!
transport!chain!(ETC)!
We! also! analysed,! as!we! did!with! neurons,! the! changes! in! the! expression! of! the!
genes! related! with! ATP! production! by! the! mitocondrial! electronic! chain! and!
oxidative!phosphorylation!by!treatment!of!OPC!with!CSF!of!MS!patients.!
The! expression! of! ATP! synthase! gene! alpha! subunit! (ATP5a1)! was! found! to! be!
! 156!
downregulated! by! 46%! and! 41%! in! OPCs! treated! with! IgM+/K! and! IgM+/+! MS!
patients.! There! was! 48%! reduction! of! gene! expression! in! OPCs! treated! with!
medullary! clinical! form! of! MS! as! compared! to! OPCs! exposed! to! the! CSF! of!
neurological! controls.! Similarly,! the! expression! was! reduced! by! 50%! and! 52%! in!
OPCs! treated! with! the! CSF! of! PPMS! and! NMO! patients! as! compared! to! OPCs!
exposed!to!the!CSF!of!nonKinflammatory!neurological!controls!(NIND)!(Figure!27!A).!
The! expression! of! another! gene! that! form! the! mitochondrial! H+/ATPase! (the! ß!
subunit,! ATP5b)! was! found! to! be! also! downregulated! by! around! 50%! in! OPCs!
treated!with!IgM+/+,!and!medullary!clinical!form!of!MS!and!around!54!%!in!IgM+/K!
as! compared! to! OPCs! exposed! to! the! CSF! of! neurological! controls.! Similarly,! the!
expression!was!reduced!by!36%!in!OPCs!treated!with!the!CSF!of!NMO!patients!as!




and! medullary! clinical! form! of! MS! as! compared! to! OPCs! exposed! to! the! CSF! of!
neurological! controls.! Similarly,! the! expression! was! reduced! by! 28%! and! 42%! in!
OPCs! treated! with! the! CSF! of! PPMS! and! NMO! patients! as! compared! to! OPCs!
exposed!to!the!CSF!of!nonKinflammatory!neurological!controls!(NIND)!(Figure!27!C).!!
The! expression! of! NADHKubiquinone! oxidoredutase! chain! 2! (MTMND2)' gene! was!
downregulated! by! 52%! and! 48%! in! OPCs! treated! with! IgM+/K! and! IgM+/+! MS!
patients.! The! gene! expression! reduced! by! 52%! in! OPCs! treated! with! medullary!
clinical! form! of! MS! as! compared! to! OPCs! exposed! to! the! CSF! of! neurological!



















expression! in! OPCs! treated! with! CSF! of! non;inflammatory!
neurological! controls.! ! OPCs:! oligodendrocytes;! Control:!
Neurons! treated! with! CSF! of! nonKinflammatory! neurological!




The!expression!of! cytochrome!c1! (Cyc1)'gene!was! found! to!be!downregulated!by!
50%,! 39%! and! 47%! in! OPCs! treated! with! IgM+/K,! IgM+/+,! and! medullary! clinical!
form! of! MS! as! compared! to! OPCs! exposed! to! the! CSF! of! neurological! controls.!
Similarly,!the!expression!was!reduced!by!40%!in!OPCs!treated!with!the!CSF!of!NMO!
patients! as! compared! to! OPCs! exposed! to! the! CSF! of! nonKinflammatory!
neurological!controls!(NIND)!(Figure!27!E).!!!
In! our! work! we! found! that! the! genes! involved! in! glucose! metabolism! (including!
glycolysis,! TCA! cycle! and!oxidative!phosphorylation)!were!differentially! expressed!
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in! OPC! treated! with! the! CSF! of! MS! patients.! This! data! demonstrates! that! the!
carbohydrate!metabolism!is!altered!in!treated!oligodendrocytes.!!In!conclusion,!MS!




In! the! next! section! of! the! thesis,! we! were! interested! to! know! whether! the!
interaction! of! different! metabolic! genes! related! with! a! metabolic! network! (i.e.!
glycolysis,! TCA! cycle,! and! electron! transport! chain)! affected! the! whole! network,!
included!those!genes!we!did!not!find!too!many!changes!in!the!whole!carbohydrate!
network.! As! discussed! in! chapter! 1! (Introduction)! the! importance! of! glycolytic!
enzymes!in!forming!localized!complexes!may!play!a!crucial!role!in!allowing!intricate!
regulatory! control! of! glycolytic! pathway.! The! formation! of! glycolytic! complex! is!
involved! in! increasing! the! solvation! capacity! with! the! cytosol! and! channeling! of!
substrates.!The!channeling!promoted! in!a!complex!would!allow!kinetic!advantage!
of! the!reaction.!The!attraction!of! the!enzyme!molecule! for! the!activated!complex!
would! lead! to! a! decrease! in! its! energy! and!hence! to! a! decrease! in! the!energy!of!
activation!of!the!reaction!and!to!an!increase!in!the!rate!of!reaction.!The!fact!that!an!
enzymeKcatalyzed! reaction! has! a! maximal! velocity! suggests! the! formation! of!
enzyme!substrate!complex.!Genes!purely! involved! in!glycolysis! interact!with!each!
other! or! with! other! pathways! and! form! complexes.! Therefore,! we! wanted! to!


















Figure! 27:! Normalized! gene! expression! involved! in! oxidative!
phosphorylation! in!OPCs! treated!with!CSF!of!MS!and!NMO!patients!
related! to! gene! expression! in! OPCs! treated! with! CSF! of! non;
inflammatory!neurological!controls.!!OPCs:!oligodendrocytes;!Control:!
Neurons! treated!with! CSF! of! nonKinflammatory! neurological! controls;!
IgM+/K! and! IgM+/+:! types! of! inflammatory!MS;!Med:!Medullary!MS;!
PP:!Primary!progressive!multiple!sclerosis;!NMO:!Neuromyelitis!Optica.!!
!




Although! not! every!gene! related! with! a! specific! network! is! affected! in! a! kind! of!
MS!disease,! if!we!do!a!string!analysis!we!may!find!that!the!physical! interaction!of!
enzymes!related!with!a!metabolic!network!(i.e.!glycolysis,!TCA!cycle,!and!electron!
transport! chain)! exist! and! closely! regulated! in! a! complex! ensures! that! the!whole!
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network! is! affected! (increasing! general! intermediate! metabolic! flux! within! the!





that! as! more! genes! are! down! regulated,! the! total! flux! are! reducing! as! a!
multiplicative!factor!that!we!integrate!as!the!CFI!of!the!network.!In!the!Discussion!
section!we! integrate! in!a!draw!the!relative!changes! in!the!different!MS!and!NMO!
patients! by! calculating! the! CFI! of! the! carbohydrate!metabolic! networks! in! those!
patients.!!
With! this! calculation! of! CFI! parameters,! we! may! say! that! whole! glycolytic! flux!
decreased! in! neurons! (CFI! 0.0296)! and! OPCs! (CFI! 0.0192)! when! exposed! to! CSF!
derived! from! IgM+/K! patients.! The! flux! related! to! TCA! cycle! is! also! decreased! in!
neurons! (CFI! 0.0960)! and! OPCs! (CFI! 0.0602)! whereas! it! is! down! regulated! in!
oxidative!phosphorylation! in!neurons! (CFI!0.3300)!and!OPCs! (CFI!0.0119).!Overall,!
carbohydrate! flux! is!decreased! in!neurons!and!OPCs!exposed! to!CSF! from! IgM+/K!
MS! patients! (Figure! 28).! Since! the! genes! involved! in! glucose! metabolism! form!
complexes!and!interact!among!themselves!and!with!others!from!related!pathways,!












The!CFI! results! in! neurons! treated!with!CSF! from!MS!medullar! patients! indicated!
that!glycolytic!flux!is!strongly!decreased!both!in!neurons!(CFI!0.0075)!and!OPCs!(CFI!
0.0019).!The!flux!related!to!TCA!cycle!is!also!decreased!in!neurons!(CFI!0.0810)!and!
in! OPCs! (CFI! 0.0124)! as! compared! to! control,! and! it! is! also! decreased! in! the!
oxidative!phosphorylation!network! in!neurons! (CFI!0.1050)!and!slightly!decreased!
in!OPCs!(CFI!0.0328).!Overall,!carbohydrate!flux!and!ATP!synthesis!are!decreased!in!
neurons! and! OPCs! exposed! to! CSF! from! medullary! MS! patients! to! the! similar!
magnitude! to! the! IgM+/+! MS! patients,! and! both! are! stronger! reduced! in!
comparison!with!IgM!+/K!MS!(Figure!30).! !Those!data!are! in!close!correlation!with!
the! severity! and! prognosis! of!medullary!MS! and! IgM+/+!MS! in! contrast!with! the!
IgM+/K!type!of!MS.!
The! results! obtained! with! the! neurons! treated! with! CSF! from! PPMS! patients!
indicated! that! glycolytic! flux! is! slightly! decreased! in! neurons! (CFI! 0.3000)! and!
stronger!decreased!in!OPCs!(CFI!0.0033).!The!flux!related!to!TCA!cycle!is!decreased!
in! both! neurons! (CFI! 0.0870)! and! OPCs! (CFI! 0.5400),! as! well! as! decreased! the!
oxidative! phosphorylation! in! neurons! (CFI! 0.1050)! and! in! OPCs! (CFI! 0.0728).!
Overall,!we!may! say! that! the! carbohydrate!metablic! flux! and!ATP!production! are!
















































Figure! 28:! Visualization! of! gene! interaction! network! generated! by!
String! v10! in! neurons! and! oligodendrocytes! exposed! to! CSF! from!
IgM+/;!MS.! Different! line! colors! represent! the! types! of! evidence! for!




oligodendrocytes;! Red! color! signifies! upregulated! expression,! blue!
color!signifies!down!regulated!expression!and!grey!color!signifies!genes!
that!we!do!not! find!variations! in!their!expression! in!our!experimental!
conditions.! LOC689343! signifies! Pk! gene! and! ENSRNOG00000015290!
signifies!Tpi!gene!
!
0.0013)! in! comparison!with! the! controls.! The! flux! related! to! TCA! cycle! is! slightly!
decreased!in!neurons!(CFI!0.2174)!and!decreased!in!OPCs!(CFI!0.0055)!!whereas!it!is!




The! variation! of! the! metabolic! flux,! estimated! with! their! values! of! CFI,! in! the!
different! treatments! with! CSF! of! MS! and! NMO! patients! were! integrated! by!
designing! a! draw! of! the! carbohydrate! metabolism! and! ATP! production.! These!
figures!will!allow!us!to!compare!how!CFI!changes!may!give!some!explanation!on!the!





















































from! IgM+/+! MS.! Different! line! colors! represent! the! types! of!
evidence!for!the!association!between!the!proteins.!A,!C,!E)!genes!
involved!in!glycolysis,!TCA!cycle!and!oxidative!phosphorylation!in!
neurons;! B,! D,! F)! genes! involved! in! glycolysis,! TCA! cycle! and!
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oxidative! phosphorylation! in! oligodendrocytes;! Red! color!
signifies! upregulated! expression,! blue! color! signifies! down!
regulated! expression! and! grey! color! signifies! genes! that!we! do!
not! find! variations! in! their! expression! in! our! experimental!


































































neurons;! B,! D,! F)! genes! involved! in! glycolysis,! TCA! cycle! and!
oxidative! phosphorylation! in! oligodendrocytes;! Red! color!
signifies! upregulated! expression,! blue! color! signifies! down!
regulated! expression! and! grey! color! signifies! genes! that!we! do!
not! find! variations! in! their! expression! in! our! experimental!





























































in! glycolysis,! TCA! cycle! and! oxidative! phosphorylation! in!
neurons;! B,! D,! F)! genes! involved! in! glycolysis,! TCA! cycle! and!
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oxidative! phosphorylation! in! oligodendrocytes;! Red! color!
signifies! upregulated! expression,! blue! color! signifies! down!
regulated! expression! and! grey! color! signifies! genes! that!we! do!
not! find! variations! in! their! expression! in! our! experimental!































































in! glycolysis,! TCA! cycle! and! oxidative! phosphorylation! in!
neurons;! B,! D,! F)! genes! involved! in! glycolysis,! TCA! cycle! and!
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oxidative! phosphorylation! in! oligodendrocytes;! Red! color!
signifies! upregulated! expression! and! blue! color! signifies! down!







































the! central! nervous! system! that! mainly! affects! young! people.! The! disease! often!




its! classification! into! into! relapsing–remitting! (RRMS),! secondary! progressive!
(SPMS)!or!primary!progressive!MS!(PPMS).!The!majority!of!patients!commence!with!
a! RRMS! disease! course! characterized! by! periodic! attacks! (relapses)! followed! by!
partial! or! complete! recovery! (remissions).! Inspite! of! receiving! antiKinflammatory!
drugs! to! prevent! relapse! the! same! patients! eventually! enter! the! secondary!
progressive! phase! (SPMS)! with! irreversible! neurologic! worsening.! Patients! with!
primary! progressive! disease! course! (PPMS)! undergo! continuous! deterioration! of!
neurological! symptoms! suggesting! that! the!pathophysiology!of! progression! is! not!
solely!inflammatory!in!nature!(McDonald,!2000;!Confavreux!et'al.,!2000).!A!deeper!
understanding!and!the!identification!of!mechanisms!underpinning!the!progression!
of! the! disease! may! assist! in! the! development! of! therapeutic! strategies! for!
treatment.!!
Although! all! cells! of! the! CNS! including! oligodendrocytes,! myelin! they! form! and!
astrocytes!that!undergo!astrogliosis!can!be!regarded!as!the!cellular!“victims”!in!MS,!
neuronal! damage! is! widely! accepted! as! the!major! cause! of! persistent! functional!
disability! in! these!patients,! the!origin!of!which! is!unclear.!One!of! the!overarching!
hypotheses! is! that! axonal! damage! in! demyelinated! axons! results! from! the!
increased! energetic! demand! consequent! to! the! redistribution! of! Na+/K+! ATPase!
before! increased! intracellular! Ca2+! levels! (Waxman,! 2006b).! Axonal! damage! has!
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also! been! attributed! to! defective! metabolic! or! impaired! trophic! support,! due! to!
damaged!oligodendrocytes!(Funfschilling!et'al.,!2012;!Lee!et'al.,'2012).!However,!it!
is!believable!that!diffusible!factors!present!in!the!CSF!could!also!impact!the!ability!
of! neurons! to! respond! with! adequate! energy! production,! especially! in! the!





Furthermore,! during! the! RRMS! disease! course! the! patient’s! bodies! alone! are!
capable! of! repairing! the! damage,! remyelinating! the! axon! and! recovering! the!
neurological! function.!Cerebrospinal! fluid! (CSF)!which! is! in! contact!with! the!brain!
parenchyma! and! ventricles,! is! a! site! of! tissue! damage! products! and! hence! a!
promising! biofluid! in! the! search! for! biomarkers! in! MS,! both! with! respect! to!














cytokines! in! the! CSF,! leading! to! cytokine! induced! synaptic! hyperexcitability! and!
consequent! glutamate! dependent! neurotoxicity! (Rossi! et' al.,! 2012,! 2013).! This!
interpretation! was! supported! by! elevated! glutamate! levels! detected! in! acute!




added!cytosine!arabinoside!to! the!cell! cultures! to!allow!the!growth!of!astrocytes.!
Specific! amount! of! cytosine! arabinoside! (1!mM)! prevents! the! replication! of! glial!
cells!whereas!a!little!lower!with!half!concentration!allows!the!growth!of!astrocytes.!
The! results! demonstrate! that! neurons! underwent! cell! death! whereas! astrocytes!
were!found!to!remain!viable!with!CSF!exposure!as!measured!by!propidium!iodide!
and!RhodiumK123!dyes!(Refer!Figure!10).!!




Therefore! we! first! identified! the! most! stably! expressed! reference! genes! in! our!
experimental! set! up! using! quantitative! PCR! in! order! to! obtain! accurate! gene!
expression!data.!
Quantitative! RTKPCR! has! recently! become! the! most! widely! accepted! method! of!
quantification! for! its! sensitive,! accurate! and! reliable! determination! of! gene!
expression! levels! in! cells! and! tissues.! To! avoid! sampleKtoKsample! variation,!
normalization! of! gene! transcripts! is! required.! The! conventional! way! to! perform!
normalization! is! to! select! a! housekeeping! gene! whose! expression! is! believed! to!
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remain! stable! in! all! cell! types/tissues,! during! cellular! development! and! under!
various!experimental! conditions! then! relate! the!expression!of! gene!of! interest! to!








lines! of! evidence! show! that! their! rate! of! transcription! is! influenced! by! a! variety! of!
factors!such!as!EGF!factor,!TGFKβ!and!PDG!factor!while!constitutively!expressed![Leof!
et'al.,!1986;!KeskiKOja!et'al.,!1988;!Elder!et'al.,!1984].!Therefore,!their!expression!may!
not! necessarily! be! constant! in! all! conditions.! Furthermore,! GAPDH! is! implicated! in!
nonKmetabolic!processes!independent!of!its!metabolic!function!such!as!transcription!
activation,! vesicle! transport! from! endoplasmic! reticulum! to! Golgi! apparatus! and!
polymerization!of!tubulin! into!microtubules![Zheng!et'al.,!2003;!Tisdale!et'al.,!2007;!
Kumagai!et'al.,!1983;!Durrieu!et'al.,!1987;!Muronetz!et'al.,!1994].!Previous!literature!
reveals! that! neuronal! apoptosis! is! associated! with! suppressed! glycolytic! activity! of!
GAPDH! [Dastoor!et'al.,! 2001;!Burke!et'al.,! 1983;!Makhina!et'al.,! 2009].! It!has!been!
observed! that! GAPDH! interacts! with! other! proteins! which! results! in! reduced!
glycolytic! activity! [Hara,! 2005].! This! process! may! lead! to! neuroaxonal! damage! in!
neurodegenerative! diseases! such! as! Huntington’s,! Parkinson’s! and! Alzheimer’s!
disease![Ve´csei!et'al.,!1993;!Senatorov!et'al.,!2003;!Tsuchiya!et'al.,!2005;!Mazzola!et'
al.,! 2003;! Li! et' al.,! 2004].! The! realization! that! these! reference! genes! may! not!
necessarily! express! in! stable! manner! in! cellular! development! or! under! all!
experimental!conditions!has! led!to!their!preKvalidation!for!their!expression!stability.!
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Their! evaluation! prior! to! normalization! is! a! critical! step! to! obtain! unbiased! gene!
expression!data.!'
Our! findings! indicate!Hprt! and!Gapdh! (M:! 0.06)! the!most! stable! genes! followed!by!






(M:! 1.19)! as! indicated!by!geNorm! algorithm!whereas!Gapdh' (4.2)! and!βMactin! (2.9)!
showed! highest! fluctuation.! In! another! experiment! when! OPCs! were! treated! with!
diseased!CSF,!Mrpl19!and!Hprt'(M:!0.1)!showed!most!stable!expression!followed!by!
B2m! (M:! 0.14)! whereas! βMactin! (M:! 0.19)! and! Gapdh! (M:! 0.27)! were! least! stably!
expressed!genes!as!indicated!by!geNorm!algorithm.!!
After!evaluating!best!stably!expressed!reference!genes,!the!next!step!was!to!perform!
global! gene! expression! profiling! using! microarray.! In! parallel! to! this,! we! were!
interested! to! search! for! biomarkers! in! distinct! clinical! courses! of!multiple! sclerosis!
and!another!similar!but!distinct!neurological!disease,!neuromyelitis!optica!(NMO).!In!
MS,!the!pattern!of!nerves!damaged,!severity!of!relapses,!extent!of!recovery,!and!time!
between! relapses! all! differ! extensively! from! individual! to! individual.! Our! results!




hence! their! categorization! is! important.! In! our! study,! we! found! significant!
differences!between!the!Expanded!Disability!Status!Scale!(EDSS)!of!RRMS!and!the!
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two! other! MS! forms! (RRMS! and! SPMS)! (p<0.001).! Although! nerve! injury! always!
occurs,! the! pattern! is! specific! for! each! individual! with! MS.! Disease! severity! and!
disability! increases! from!RRMS! to! SPMS! course! and! in! PPMS! subtype,! symptoms!
continually! worsen! from! the! time! of! diagnosis! rather! than! having! wellKdefined!
attacks! and! recovery.! Primary! progressive! MS! usually! results! in! disability! earlier!
than!RRMS.!Significant!differences!were!found!in!the!evolution!time!from!the!first!
to! the! second! episode! between! RRMS! and! PPMS! (p<0.043).! In! patients!
experiencing!a!progressive!course,!evolution!time!was!similar!in!SPMS!cases!and!in!
cases!who!were!progressive!from!onset!(13.5!versus!13.8).!
According! to! the! new! proposal! and! working! classification,! inflammatory! MS!
subtypes! shared! similar! age! at! disease! onset! (mean=26.7! versus' 26.3! years;!
p=0.005).! Significant!differences!were! found!between! the!age!at!disease!onset! in!
medullary! MS! and! PPMS! with! the! inflammatory! MS! (p<0.005).! The! degree! of!
disability!as!measured!by!EDSS!was!similar! in!medullary!MS!and!PPMS!(6.2!versus'
6.3)! whereas! significant! differences! were! found! between! disability! extent! in!
medullary!MS!and!PPMS!with! the! inflammatory!MS! (p<0.001).! IgM+/K! represents!
the! less! aggressive! inflammatory! subtype!with! OCGB! in! CSF!with! poor! prognosis!
whereas!IgM+/+!signifies!a!more!aggressive!category!with!OCGB!and!OCMB!in!CSF!
with! worse! prognosis.! On! the! contrary,! medullary! MS! represents! the! most!
aggressive!subtype!of!MS!with!increased!neurological!disability!and!dysfunction!as!
compared! to! inflammatory! subtypes.! Disability! in! patients! experiencing! primary!
progressive!MS!worsens!over!time!with!no!relapses!and!remission.!!
The! presence! of! lipidKspecific! oligoclonal! IgM! bands! (OCMB)! and! increased! IgM!
index! have! been! associated! with! poor! prognosis! in! MS! and! a! more! rapid!
progression! to! irreversible! disability! (Villar! et' al.,! 2005;! Thangarajh! et' al.,! 2008).!
These!OCMB!usually! persist! in!MS!patients! throughout! the! course!of! the!disease!
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(Walsh! and! Tourtellotte,! 1986),! and! their! persistence! indicates! that! they! are! not!






pathogenesis! of! MS! [see! Figure! 44].! Initial! studies! describing! the! possibility! of!
defective! pyruvate! metabolism! in! MS! were! performed! by! Jones! et' al.! in! 1950s!
[Jones! et' al.,! 1950].! The! group! observed! elevated! blood! pyruvate! level! in! both!
fasting! and! postprandial! times! in! MS! patients! with! relapse.! Similarly,! other!
investigators!also!reported!increased!fasting!pyruvate!level!in!this!disease![Ervenich!
1952;! Ervenich! 1953;! Sercl! and' Johnova! 1956].! However,! there! were! conflicting!
reports! demonstrating! normal! fasting! lactate! level,! or! increase! in! only! a! small!
number! of! patients! [Bauer! 1956;! Henneman! et' al.,! 1954;! Jeanes! and! Cumings!
1958].!On! the!other!hand,! Jeanes! and!Cumings! (1958)! found!an!abnormal! rise! in!
the! blood! pyruvate! level! after! glucose! intake.! These! reports! hint! to! a! possible!
abnormality!of!pyruvate!metabolism!in!MS!patients.!!
A!report!from!Regenold´s!group!describe!the!role!of!CNS!energy!metabolism!in!MS!
disease! progression.! The! group! measured! the! levels! of! lactate,! sorbitol! and!
fructose,!all!metabolites!of!extraKmitochondrial!glucose!metabolism,! in! the!CSF!of!
RRMS! and! SPMS! patients! [Regenold! et' al.,! 2008].! Sorbitol! and! fructose! are! the!
metabolites! of! polyol! pathway! that! run! parallel! to! glycolysis! and! lactate! is! the!
metabolite!of!anaerobic!pathway.!The! finding!demonstrated!elevated! levels!of!all!
three! metabolites! in! the! CSF! of! SPMS! patients! and! to! a! lesser! extent! to! RRMS!
patients.! There! are! two! assumptions! set! forth! as! an! explanation! for! increased!
lactate!in!MS!patients.!First!ascribes!to!the!accumulation!of!leukocytes!in!inflamed!
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active! MS! lesions! in! which! glycolytic! pathway! is! activated.! In! addition,! a! strong!
correlation!of!the!number!of!inflammatory!plaques!with!lactate!deposition!further!
strengthened! the! hypothesis! [Lutz! et' al.,! 2007].! Second! explanation! is! deduced!
from! the! relationship! between! the! extraKmitochondrial! pathways! and!
mitochondrial!dysfunction.!Under!anaerobic!conditions,!pyruvate!is!converted!into!
lactate! by! neurons! and! astrocytes! to! meet! the! energy! requirements.! In!
mitochondrial! disorders,! oxidative! phosphorylation! is! impaired! leading! to! lactate!
accumulation.! Taken! together,! the! finding! supports! a! link! between! increased!
activity! of! extraKmitochondrial! pathways! of! glucose! metabolism! and! MS! disease!
progression.!Neuroimaging!and!molecular!studies!have!shown!that!both!pathways!
are!dysregulated! in!mitochondrial!disorders![Frackowiak!et'al.,!1998;!Danielson!et'
al.,! 2005;! Rango! et' al.,! 2001].! These! alterations! in! energy! metabolism! may!
contribute!to!mitochondrial!dysfunction!and!neuroaxonal!degeneration!underlying!
MS!progression.!!
Furthermore,! mitochondrial! dysfunction! is! implicated! in! various! pathological!
conditions! like! diabetes,! cardiovascular! disease,! anxiety! disorders;!
neurodegenerative!diseases!like!Alzheimer’s,!Huntington’s!and!Parkinson’s!disease;!
cancer! and! fatigue.! It! is! only! recently! that! mitochondrial! aberrations! have! been!
studied!in!MS.!Unlike!nuclear!DNA,!mitochondrial!DNA!(mtDNA)!is!not!surrounded!
by! histones,! proteins! that! shield! nuclear! DNA! from! free! radicals.! Therefore! it! is!
quite!prone!to!damage.!The!number!of!mitochondria!in!a!cell! is!determined!by!its!
energy! requirement.! For! instance,! there!may!be!up! to!200! to!2000!mitochondria!
present!in!a!single!somatic!cell!whereas!the!number!is!fixed!to!16!in!spermatozoa!
germ! cells! and!100,000! in! oocytes.!Metabolically! active! cells! like! skeletal!muscle,!
cardiac!muscle!and!brain!contain!largest!number!of!mitochondria.!It!has!been!seen!





increases!with! concomitant! impairment! of! Krebs! cycle! and/or! neuronal! oxidative!
phosphorylation!within!the!CNS.!!
A!body!of!evidence!indicates!a!link!between!disturbed!metabolic!function!and!the!
progression! of! neurodegenerative! diseases! like! Alzheimer’s! disease,! Huntington’s!
disease! and! Parkinson’s! disease.! A! short! comparison! between! disturbed! glucose!
metabolism!in!MS!and!other!neurodegenerative!diseases!is!illustrated!in!Table!13.!
A! report! documented! that! GAPDH! glycolytic! function! is! impaired! in! subcellular!
fractions!of!fibroblasts!from!Alzheimer!and!Huntington!patients!whereas!the!gene!
expression! remained! unchanged! [Mazzola! and! Sirover! 2001].! This! might! have!
occured! due! to! postKtranslational! modification! of! the! GAPDH! protein.! In! a!
transgenic!model!of!Huntington’s!disease,!Gapdh!is!seen!to!overexpress!in!specific!
neuronal!populations!of!several!brain!regions,!such!as!the!neocortex!and!caudate!
putamen! neurons.! This! study! also! revealed! translocation! of! GAPDH! into! the!
nucleus!and!the!subsequent!cell!loss!in!the!neocortex!and!caudate!putamen!region!
of!the!brain![Senatorov!et'al.,!2003].!Similar!finding!was!observed!by!ByoungKIl!Bae!
et' al.! who! demonstrated! that! GAPDH! facilitates! nuclear! translocation! of! mutant!
Huntingtin! protein! (mHtt)! and! causes! neurotoxicity! [Bae! et' al.,! 2006].! In! Aβ!
(amyloid! beta)! resistant! cells! of! Alzheimer’s! brain,! glycolytic! pathway! was!
upregulated!and!hexose!monophosphate! shunt! (HMS)!was!activated.! The!activity!
of! Gapdh,! hexokinase! and! pyruvate! kinase! was! increased! in! both! glycolysis! and!
HMS![Soucek!et'al.,!2003].!
Moreover,! there! are! studies! that! have! investigated! the! metabolic! disorders! in!
alcoholic!brain.!Gapdh!protein!known!to!exhibit!diverse!functionality!is!reported!to!
increase!significantly! in! the!brains!of!human!subjects!with!alcoholism! [AlexanderK
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Kaufman! et' al.,! 2006].! This! study! used! proteomics! based! approach! and! found!
variation! in! protein! expression! in! alkoholic! brain.!Most! of! the! proteins! identified!
through! this! study! were! metabolic! enzymes! including! Gapdh,! creatine! kinase,!
NADH2,! ubiquinone,! fructose! biphosphate! aldolase! C,! transketolase! and! others.!
This! demonstrates! that!metabolic! disturbances! play! an! important! role! in! alkohol!
related!brain!cell!damage.!Another!recent!study!showed!that!nuclear!GAPDH!was!




MS! and! NMO,! we! incorporated! the! whole! data! in! a! general! metabolic! pathway!
design! in! this!work.! This! also! allowed!us! to! better! interrelate! the! changes! in! the!
neurons!and!OPCs,!with!the!aim!to!find!correlations!in!the!whole!process!of!axonal!




dehydrogenase! and! aldolase! in! the! CSF! of! patients! with! disseminated! sclerosis!
make!them!a!sensitive!indicator!of!active!demyelination![Royds!et'al.,!1981].!Kolln!
et'al.,!2006!demonstrated!that!B!cells!and!antibodies!reactive!with!Tpi!and!Gapdh!
are! produced! intrathecally! in! CSF! and! lesions! of!multiple! sclerosis.! Both! TPI! and!
GAPDH! are! essential! metabolic! enzymes! involved! in! ATP! production.! Other!
functions! of!GAPDH! include! endocytosis! [Jeffery! 1999],! polymerization! of! tubulin!





















visualized!when! antiKGAPDH! IgG!was! exhausted! from! the! CSF! demonstrating! the!
role! of! antiKGAPDH! antibodies! in! impeding! the! GAPDH! enzyme! activity! in! brain!
leading!to!neuronal!apoptosis!and!cytotoxicity.!!
In! systemic! lupus,! an! autoimmune! rheumatoid! disorder,! autoantibodies! were!
found! reactive! to!GAPDH! [Takasaki!et'al.,!2004].!Accumulating!evidence! indicates!
that! inhibition!of!GAPDH!activity! in!glycolytic!pathway!is!associated!with!neuronal!
apoptosis.! It!has!been!purported! that!GAPDH!enzyme!activity! suppresses!when! it!
reacts!with!other!proteins!in!the!CNS![Burke!1983;!Hara!et'al.,!2005].!Single!chain!
variable! fragment! antibodies! (scFvKabs)! obtained! from! clonally! expanded! B! cells!
binds! specifically! with! GAPDH! and! TPI! in! active! MS! lesions! [Zhang! et' al.,! 2005;!
Zhang!et'al.,!2005].! In!addition,! interaction!of!GAPDH!with!ßKamyloid!protein!and!




down! regulated! expression! in! neurons! exposed! to! the! CSF! derived! from! IgM+/K!
clinical!form!of!MS!(Figure!21).!The!data!indicated!that!Gapdh!gene!expression!was!
downregulated!up!to!around!34!%!of!gene!expression!in!neurons!treated!with!CSF!
of! IgM+/K! clinical! form! of! MS! as! compared! to! control.! Similarly,! Pgam! and! Eno!
genes!were!down!regulated!up!to!30!%!as!compared!to!control.!Genes!involved!in!




[Smith! and' Lassmann! 2002].! Mitochondrial! proteins! are! expressed! in! greater!
amounts! in! both! active! and! inactive! lesions.! Activity! of! complex! IV! found! on!
mitochondrial! membrane! is! increased! dramatically! in!MS! lesions! and! it! is! found!
that,! mitochondrial! heat! shock! protein! (mtHsp70)! is! highly! immuneKreactive! in!




from! ischemic! insult! [Voloboueva! et' al.,! 2008].! This! shows! that! oxidative! stress!
generated! in! response! to! defective!mitochondrial!metabolism!may! contribute! to!





Our! results! indicated! that!ATP5b,'gene! involved! in!oxidative!phosphorylation!and!
ATP! generation,! showed! 30%! decreased! expression! as! compared! to! neurological!
controls! (Figure! 23).! In! another! experiment! when! OPCs! were! exposed! to! IgM+/K!
CSF,!expression!of!many!glycolytic!genes!including!Hk,'Gpi,'Gapdh,'Tpi,'Pgk1,'Eno1,'
Eno2,'Pk,'and!Pkm2!was!decreased! (Figure!25).! Furthermore,! genes! implicated! in!







glycolytic! pathway!decreases! significantly! in!neurons! (CFI! 0.0296)! and! in! the!OPC!
(CFI! 0.0192).! The! cumulative! flux! index! associated! with! the! TCA! cycle! is! also!
reduced! in! neurons! (CFI! 0.0960)! and! OPCs! (CFI! 0.0602).! In! oxidative!





Neuronal! cells! undergoing! tissue! damage! require!more! energy! in! form!of! ATP! to!
survive,!but!in!these!patients!metabolic!genes!are!inhibited!leading!to!a!reduction!
in!the!overall!metabolic!flux.!This!causes!a!decrease!in!ATP!production!and!overall!
ability!of! these!cells! to! repair! the!damaged!healthy!cells,!which!can!be! related! to!
the!development!of!pathology!in!these!patients.!
RRMS!IgM+/+!
The! results! obtained! when! neurons! were! exposed! to! CSF! from! patients! with!
IgM+/+! RRMS! demonstrated! that! genes! catalyzing! crucial! steps! of! glucose!
metabolic!pathway!and!ATP!generation!such!as'Hk,'Gapdh,'Pgk,'Pgam,'Eno,'Pkm2,'
Pdh,'Mdh2,'and' ATP' synthase' subunit' beta! had! reduced!expression! compared! to!
control!(Figure!21K23).!There!was!around!30%!expression!showed!by!these!genes!in!
these!neurons!with!respect!to!control.!When!OPCs!were!exposed!to!CSF!of!IgM+/+!











(untreated! neurons);! thick! black! arrow! represents! elevated!









genes! in! OPCs! treated! with! the! CSF! of! IgM+/K! MS! patients;! GE:! Gene!













and! forcefully! in! OPCs! (CFI! 0.0024).! In! oxidative! phosphorylation,! flux! index! was!









repair! damaged!neurons!degenerated! in!MS! lesions! can!be!much! lower! than! the!
aggressive!IgM!+/+!RRMS.!
To! combat! oxidative! stress! generated! in! neurological! diseases,! the! cells! need! to!
produce!large!quantities!of!reducing!equivalents!for!energy!production.!However,!if!
there! is! insufficient! energy! production,! such! as! in! how! aggressive! form! severely!
impairs! the! ability! to! repair! nerve! damage.! The! same! happens! in! the!OPCs! cells,!
where! lower!energy! level!which!can!block! the!repair!process!occurs!by! the!OPCs.!





Another! important! result! we! highlight! is! that! the! CSF! treated! OPCs! reveals!
significant! differences! in! gene! expression! of! Eno2,' Gpi,' Tpi,' Pdha1,' Pgk1,' Pkm2,'
Aldoc,! and! Sdhaf2! between! IgM+/K! and! IgM+/+! RRMS! patients.! Similarly,!
differences! were! found! in! Pgam1! and! Cox6b2! gene! expression! between! OPCs!
exposed!to!CSF!from!IgM+/K!and!OPCs!exposed!to!CSF!from!medullary!patients!(see!






(35! %! expression),' Eno' (23! %! expression),' and' Pkm2! (31! %! expression),! showed!
down! regulated! expression! in! them! as! compared! to! neurons! exposed! to! the! CSF!
from!neurological!controls.! In!amyotrophic! lateral!sclerosis! (ALS),!abnormalities! in!
electron! transport! chain! have! been! reported.! The! study! found! decreased!mRNA!
expression!levels!of!electron!transport!chain!proteins,!specifically!FAD!synthetase,!
riboflavin! kinase! (RFK),! cytochrome! C1! (CYC1),! and! succinate! dehydrogenase!
complex!subunit!B!(SDHB)![Lin!et'al.,!2009].!We!found!that!genes!implicated!in!TCA!
cycle! including! Pdh' (30! %! expression)! and! Mdh2! (27! %! expression)! and! ATP'
synthase! gene! associated! with! electron! transport! chain! both! alpha! (35! %!













(untreated! neurons);! thick! black! arrow! represents! elevated!









genes! in! OPCs! treated! with! the! CSF! of! IgM+/+! MS! patients;! GE:! Gene!









that!most! of! the! glycolytic! genes! including!Hk1,' Gpi,' Gapdh,' Tpi,' Pgk1,' Eno,' and'
Pkm2' (see! figure! 25)! were! reduced! in! expression.! These! genes! may! serve! as!
biomarker!in!medullary!MS!patients.!!
Previous! reports! demonstrated! increase! in! levels! of! Krebs! cycle! acids! like! alphaK
ketoglutarate!in!fasting!and!citrate!after!glucose!intake!in!MS!patients![Henneman!
et'al.,!1954].!McArdle!et'al.! in!1960!found!elevated! levels!of!pyruvate!and!αKketo!
glutarate! in!MS! [McArdle!et' al.,! 1960].!Our! findings! revealed! down! regulation! of!
genes! implicated! in! TCA! cycle! including!Pdh,'Aco2,' Idh,'Ogdh,'and!Sdh! in! treated!
OPCs! (Figure! 26).! A! recent! finding! by! Pedro! et' al.! demonstrated! changes! in!
mitochondrial!complex!enzyme!activities!and!cytochrome!c!expression!in!platelets!
of! MS! patients.! Krebs! cycle! enzyme! aconitase! activity! was! higher! in! patients!
without!fatigue!and!all! respiratory!complex!enzyme!activities! (complex! I,! II,! III,! IV,!
V)!were!higher! in!MS!patients!compared!to!controls.!Complex!II!activity! increased!
significantly!in!MS!group!between!patients!with!and!without!fatigue![Iñarrea!et'al.,!
2013].! Safavizadeh! et' al.,! (2013)! observed! a! significant! reduction! in! the! gene!
expression! of! cytochrome! c! oxidase! 5B! subunit! (COX5B)! in! MS! patients.! This!
suggests! that! there! is! a! down! regulation! of! genes! associated!with!mitochondrial!
electron!transport!chain.!Analysis!of!a!number!of!respiratory!chain!proteins!reveals!
functionally! important! defects! of! mitochondrial! proteins! [cytochrome! c! oxidase!
(COX)!and!its!catalytic!component!COXK1]!in!complex!III!in!MS![Mahad!et'al.,!2008].!
Different! expression! of! mitochondrial! proteins! namely! cytochrome! c! oxidase!
subunit!5b!(COX5b),!hemoglobin!β,!creatine!kinase!and!myelin!basic!protein!(MBP)!
was! found! in! the! brain! of! multiple! sclerosis! [Broadwater! et' al.,! 2011].! Taken!
together,! these! studies! show! that!mitochondrial! abnormalities!and!energy! failure!
may! cause! functional! disturbance! in! the! surviving! demyelinated! axons! in! MS!
resulting! in! neurological! dysfunction.! Our! findings! suggest! that! genes! of! ETC!
! 196!
including! ComplexI/NADH:ubiquinone!oxidoreductase,! Cyc1,! Complex! IV/COX! and!
ATP' synthase! (both! alpha! &! beta! subunits)! showed! down! regulated! gene!
expression!in!these!treated!OPCs!(Figure!27).!
Our! results! revealed!a! significant!decrease! in!metabolic! flux! rates!accumulated! in!
the!glycolytic!pathway!(CFI!0.0019)!Krebs!cycle!(CFI!0.0124)!and!electron!transport!
chain!and!oxidative!phosphorylation! (CFI!0.0328)! in! the!OPCs! treated!with!CSF!of!
these! patients! (Figure! 39).! Compared! with! nonKMS! patients! (controls),! total!
cumulative! flux! index!fell! in!all! three!metabolic!pathways!to!a!very! low!value!(CFI!
7.94269EK07),!similar!to!what!occurs!in!IgM!+/+!RRMS!(Figure!39).!
The!spinal! form!of!MS! is!a!subtype!of!MS!with!damaged!neurons!found!mostly! in!
the! region! of! the! bone! and! is! one! of! the! most! aggressive! subtype! of! MS,!
comparable! to!more! aggressive! CNS! IgM+/+! RRMS! form,! showing! a! similar! gene!
expression! pattern.! The! drastic! reduction! of! metabolic! genes! expression! in! both!
types! of! MS! would! result! in! a! bioenergetic! failure,! eventually! causing!
oligodendrocytes! to! block! the! repair! of! important! axonal! damage! in! neurons!
exposed!to!energy!depletion!of!these!aggressive!types!of!MS!correlated!with!worse!
prognosis!in!contrast!to!the!IgM!type!+/K!RRMS.!
As! the! data! indicates! that! Idh2,' gene! showed! differential! expression! in! OPCs!
exposed!to!the!CSF!of!medullary!patients.!The!gene!expression!was!not!altered!in!








metabolic! genes! in! neurons! treated!with! the! CSF! of!medullary!
subtype! of! MS! patients;! GE:! Gene! expression! in! CGNs! treated!
with! medullary! CSF! related! to! CGNs! exposed! only! to!
culture(untreated! neurons);! thick! black! arrow! represents!








metabolic! genes! in! OPCs! treated! with! the! CSF! of! medullary!
subtype! of! MS! patients;! GE:! Gene! expression! in! OPCs! treated!
with! medullary! CSF! related! to! OPCs! exposed! only! to! culture!
(untreated! OPCs);! thick! black! arrow! represents! elevated!








reduction! in! gene! expression! of! Pgam! gene! of! glycolytic! pathway! (Figure! 21).!
Among! the! genes! involved! in! TCA! cycle,!Pdh! and!Mdh2! showed! down! regulated!
expression!in!these!neurons!(Figure!22).!Similarly,!both!alpha!and!beta!subunits!of!
ATP' synthase! gene! which! is! involved! in! ATP! production! showed! decreased!
expression! (Figure! 23).! Conversely,! several! of! the! genes! of! glycolytic! pathway!
including!Hk1,' Gpi,' Pfkb4,' Aldoa,' Gapdh,' Eno2,' Pk! were! down! regulated! in! OPCs!
treated!with!the!CSF!from!PPMS!(Figure!25).!These!genes!may!serve!as!biomarker!
in!PPMS!patients.!As!we!can!see!from!the!data!that!Hk3!gene!showed!differential!
expression! in! OPCs! exposed! to! the! CSF! of! PPMS! patients.! However,! the! gene!
expression!was!not! altered! in!NMO!group!of!patients!which! suggests! that! it!may!
serve! as! a! biomarker! to! distinguish! between! PPMS! and! NMO! (NMO! vs.! PPMS!
patients).!Genes! involved!in!TCA!cycle! including!Aco2,'was!also!down!regulated!in!
these! OPCs! (Figure! 26).! Similarly,! ComplexI/MTKND2,! Complex! IV/COX! and! ATP'
synthase! (alpha! subunit)! which! is! involved! in! ATP! production! showed! decreased!
expression!(Figure!27).!
The!results!obtained!with!treatment!with!CSF!of!patients!with!PPMS!indicated!that!
glycolytic! flux! slightly! decreased! in! neurons! (CFI! 0.3000)! (Figure! 40)! and! more!
heavily!on!the!OPC!(CFI!0.0033!)!(Figure!41)!.!The!flux!associated!with!the!TCA!cycle!
is! decreased! in! both! neurons! (CFI! 0.0870)! (Figure! 40)! and! the! OPC! (CFI! 0.5400)!
(Figure! 41)! and! in! oxidative! phosphorylation! decreased! in! neurons! (CFI! 0.1050)!
(Figure!40)!and!the!OPC!(CFI!0.0728!)!(Figure!41)!.!
In! general,! we! can! say! that! the! cumulative! flux! index! in! carbohydrates! and! ATP!
production!in!neurons!decreases!slightly!(CFI!0.00274)!and!stronger!in!the!OPC!(CFI!
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Another! inflammatory,! demyelinating! and! autoimmune! disease! of! the! CNS! but!
totally! distinct! from!MS! known! as! “Neuromyelitis! optica”! showed! an! altogether!




with! CSF! from! neurological! controls! (Figure! 21).! Conversely! the!Mdh2! and! Aco'
genes! of! TCA! cycle! expressed! in! significantly! lower! quantities! (Figure! 22).!
Furthermore,! chain! genes! TCA! cycle! and! electron! transport! chain! including' Pdh!
(Figure! 22)! and! the! alpha! and! beta! subunits! of! ATP! synthase! showed! increased!
expression!in!treated!neurons!(Figure!23).!!
In! general,! an! increase! in! the! values! of! CFI! on! two! metabolic! pathways,! the!
glycolytic! pathway! (CFI! 1.9656)! and! the! electron! transport! chain! and! oxidative!
phosphorylation! (CFI! 1.5867),! and! a! slight! decrease! in! Kreb! cycle! enzymes! was!
observed!(CFI!0.2174)!(Figure!42).!This!causes!the!cumulative!flux!index!in!all!three!
metabolic!pathways!be!virtually!unchanged!(0.67787!IFC).!
Unlike!MS!NMO! it! is!not!progressive.! In! fact! less! than!2%!of!patients!NMO!has!a!
progression! to! disability! relapsing.! So! this! clinical! difference!may! be! because! the!







primary! progressive!MS! (PPMS);! GE:! Gene! expression! in! CGNs!
treated!with!the!CSF!of!PPMS!patients!related!to!CGNs!exposed!
only! to! culture! (untreated! neurons);! thick! black! arrow!
represents!elevated!expression!whereas!a!thin!arrow!represents!










CSF! related! to! OPCs! exposed! only! to! culture! (untreated!







Furthermore,! in!OPCs!exposed! to!CSF!of!patients!with!NMO,!expression!of! genes!
that!catalyze!reactions!via!glycolysis! including!Gpi,'Aldo,'Gapdh,'Tpi,'Pgk,'Eno'and!
Pk,! showed! reduced! expression! of! the! genes! compared! to! controls! (Figure! 25).!
Furthermore,!the!TCA!cycle!genes,!including!Pdh,'Aco2,'Igdh'Ogdh,'Sdh'and'Mdh2'
showed!decreased!expression! in! treated!OPCs! (Figure!26).! Similarly,! the!genes!of!
the!electron!transport!chain!and!oxidative!phosphorylation,!such!as!CI,!Cyc1,!CIV!/!
Cox!and!the!alpha!and!beta!subunits!of!ATP!synthase!also!showed!the!reduction!in!
gene!expression! (Figure!27).! SInce! IgG!antiKNMO!do!not!have!a!direct!effect!over!
OPCs,! and! it! has!high! affinity! for! the! astroglial! receptors! [Marignier!et'al.,! 2010].!
Despite!purified!cultures!of!OPCs!were!used,!the!1%!presence!of!astrocytes!could!
explain!the!downregulation!of!metabolic!genes.!Another!possible!explanation!(not!
tested),! is! that!some!NMO!patients!could!presented!antiKMOG,!a! recent!antibody!
against!myelin!associated!oligodendrocyte,! that! in!cases!of!NMO!patients!cause!a!
profound! oligodendropathy! nonKassociated! to! astrocyte! damage! [Ikeda! et' al.,!
2015].!Becouse!antiKMOG!is!present!in!40%!of!seronegativeKNMO,!and!in!our!series!
we! have! four! NMO! patients! with! no! antiKNMO! antibodies,! we! can! rule! out! the!
possibility!that!some!patients!presented!antiKMOG.!
Our! results! revealed! a! decrease! in! the! cumulative! flux! index! accumulated! in!
glycolysis!(CFI!0.0013),!Krebs!cycle!(CFI!0.0055),!and!oxidative!phosphorylation!(CFI!
0.0149)! in! OPCs! treated! with! CSF! from! NMO! patient! compared! to! nonKMS!
(controls)! (Figure! 43).! The! results! indicate! that! the! flux! indexes! accumulated! in!
neurons! exposed! to! CSF! of! NMO! patients! suffer! a! very! slight! decrease! (IFC!
0.67787),!while!the!OPCs!decreased!significantly!(IFC!1.10046EK07).!
Altogether,! results! obtained! from! oligodendrocyte! data! are! consistent! with!
neuronal!data!except!for!NMO!where!we!found!upregulated!expression!in!treated!
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neurons! compared! to! downregulated! expression! in! treated! OPCs.! Moreover,!
metabolic!genes!were!downregulated!in!all!forms!of!MS!in!neurons!and!OPCs.!!
Our! findings! indicate! an! up! regulated! expression! of! enolase! gene! in! neurons!
exposed!to!the!CSF!from!NMO!patients.!However,!the!gene!was!down!regulated!in!
neurons! exposed! to! the! CSF! from! inflammatory! MS! (IgM+/K! and! IgM+/+),! and!
medullary! MS.! Enolase! may! serve! as! a! potential! biomarker! to! distinguish! NMO!
from!MS.!At!the!same!time,!we!did!not!find!any!differential!expression!of!this!gene!
in! neurons! exposed! to! CSF! from! PPMS! patients.! Therefore! enolase! differential!
expression!in!NMO!can!be!used!to!differentiate!it!from!PPMS!patients.!!The!findings!
of! our! other! experimental! conditions! reported! down! regulated! expression! of!
enolase! (Eno2)! gene! in! oligodendrocytes! (OPCs)! exposed! to! the! CSF! from!
medullary,! PPMS! and! NMO! patients! as! compared! to! neurological! controls.!










MS!and!NMO.! !Nearly!most! of! the! genes! from!all! the! three!pathways!of! glucose!
metabolism!were! down! regulated! in! CGNs! treated! with! CSF! of!MS! compared! to!





metabolic! genes! in! neurons! treated! with! the! CSF! of! NMO!
patients;!GE:!Gene! expression! in! CGNs! treated!with! the!CSF! of!
NMO! patients! related! to! CGNs! exposed! only! to! culture!
(untreated! neurons);! thick! black! arrow! represents! elevated!








GE:!Gene!expression! in!OPCs! treated!with!NMO!CSF! related! to!
OPCs! exposed! only! to! culture! (untreated! neurons);! thick! black!
arrow! represents! elevated! expression! whereas! a! thin! arrow!








MS! and! NMO! subjects.! Since! CSF! is! in! contact! with! brain! parenchyma! and!
ventricles,! any! cellular! damage! product! deposited! in! the! fluid! can! influence! the!
cellular! physiology! of! neurons,! oligodendrocyte! progenitor! cells! (OPCs)! and!
myelinating! oligodendrocytes.! Therefore,! the! exposure! of! CGNs! to! diseased! CSF!
represents! an! excellent! cellular! model! to! study! the! primary! neuronal! damage.!
Oligodendrocytes!which!repair!the!damaged!myelin!during!the!relapsing!remitting!
phase!of!MS!also!showed!an!altered!carbohydrate!metabolism!upon!CSF!exposure!
from!MS!patients.!Our! results! indicate! that! the! factors! secreted! in! the!CSF!of!MS!
and!NMO!patients!cause!a!disturbance! in! the!metabolic!pathways!by!altering! the!
expression!of!genes!catalyzing!essential!steps.!!
The! results! indicate! that! factors! present! in! the! CSF,! in! our! model,! perturb! the!
metabolism!of!neurons!and!clearly!differentiate!more!benign!forms!from!the!most!
aggressive! forms! in! MS.! The! study! also! differentiates! NMO! from! MS,! which! is!
sometimes! difficult! to! distinguish! by! the! clinicians.! However,! whether! these!
alterations!in!metabolic!gene!expression!cause!MS!and!NMO!or!are!simply!a!mere!
consequence!of!the!disease!is!still!elusive.!!
In! addition! to! identifying! a! disturbed! metabolic! function! associated! with! the!
cellular!model!of!MS,!we!found!a!fluctuated!expression!of!Gapdh!and!beta'actin!in!
our! experimental! conditions.! These! genes! are! commonly! used! as! housekeeping!




gene!may! show! stable! expression! in! one! condition!whereas! unstable! in! another.!
Invariable! expression! of! reference! genes! has! been! observed! with! cellular!
development! and! under! distinct! experimental! conditions.! Therefore! it! is!
indispensible! to! preKvalidate! the! expression! stability! of! reference! genes! to!
accurately! normalize! the! gene! expression! data.! In! this! thesis,! we! have! validated!
best! housekeeping! genes! to! be! used! in! our! experimental! set! up! and! we! found!
Gapdh!showed!the!most!fluctuated!expression.!
There!are!some!limitations!of!the!study.!First,!we!did!not!perform!kinematic!assays!
to!measure! the! activity! of! proteins.! There! is! a! lot! of! processing! and!modification!




metabolism! pathway! in! CGNs! and! OPCs! treated! with! the! CSF! of! distinct! clinical!
forms!of!MS!and!NMO!open!new!avenues!of!study!and!allow!the!development!of!
therapeutic! agents! targeted! to! restore! the! metabolic! function! and! hence! repair!
and/or!prevent!axonal!damage!responsible!for!functional!disability!in!the!patient.!A!
greater! understanding! of! these! impaired! metabolic! pathways! may! offer! new!
insights! into!more! efficacious! treatments! for!MS! and!NMO.! In! addition! our! data!
suggests! that! it! is!desirable!to!determine!the!suitability!of!any!common!HK!genes!


















MS! brain.! Glucose! enters! cells! through! glucose! transporters!
(GLUTs)!and!is!phosphorylated!by!hexokinase!to!produce!glucose!
6Kphosphate.!Glucose!6Kphosphate!can!be!processed! into! three!
main! coordinated! metabolic! pathways.! First,! it! can! be!
metabolized! through! glycolysis! giving! rise! to! two!molecules! of!
pyruvate!and!producing!ATP!and!NADH.!Pyruvate!can!then!enter!
mitochondria,!where! it! is!metabolized! through! the! tricarboxylic!
acid! (TCA)! cycle! and! oxidative! phosphorylation,! producing! ATP!
and! CO2.! Alternatively,! pyruvate! can! be! reduced! to! lactate! by!
lactate! dehydrogenase! (Ldh).! This! lactate! can! be! released! into!
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the! extracellular! space! through! monocarboxylate! transporters!
(MCTs).!The!complete!oxidation!of!glucose!produces!30K34!ATP!
molecules! in! the! mitochondria.! Alternatively,! glucose! 6K
phosphate! can! be! processed! through! the! pentose! phosphate!
pathway!(PPP)!leading!to!the!production!of!reducing!equivalent!
in! the! form! of! NADPH.! Note! that! the! PPP! and! glycolysis! are!
linked! at! the! level! of! glyceraldehydeK3Kphosphate! (GLAP)! and!
fructose! 6Kphosphate.! Finally,! glucose! 6Kphosphate! can! be!
converted! to! glycogen! through! the! process! of! glycogenesis! in!
astrocytes.! Abbreviations! are! as! follows:! Hk:! Hexokinase;! Gpi:!
glucoseK6Kphosphate! isomerase;! Pfk:! phosphofructokinaseK1;!
DHAP:! dihydroxyacetone! phosphate;! Tpi:! triose! phosphate!
isomerase;! GAPDH:! glucoseK6Kphosphate! dehydrogenase;! Pgk:!
phosphoglycerate!kinase;!Pgam:!phosphoglycerate!mutase;!Eno:!
enolase;!Pk:!pyruvate!kinase;!Ldh:!lactate!dehydrogenase;!6KPGL:!





























observed! in! both! fasting!
and!postprandial! times! in!
MS! patients! with! relapse!
(Jones!HH!et'al.,!1950)!
• Pyruvate! levels!
were! found! to! be!
increased! in!MS!(McArdle!
et'al.,!1960)!




found! to! be! increased! in!




















The! activity! of! GAPDH,!
hexokinase! and!pyruvate!
kinase! was! increased! in!
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isomerase! (TPI)! and!
GAPDH,! bind! with! them!
and! inhibit! the! glycolytic!
activity! of! GAPDH! in! MS!
patients! (Kölln! et' al.,!
2010)!
















fasting! and! citrate! levels!
after! glucose! intake!were!






























moderate! and! severe! AD!









• A! reduction! in!
the! expression! of! ATP!
synthase! gene! was!



















C1! (CYC1),! and! succinate!
dehydrogenase! complex!














and! a! decrease! in! gene!
expression! of! complex! I,!
complex! III,! complex! IV,!
and! ATP! synthase! has!
been! observed! in!
nonlesional! motor! cortex!
(Dutta! et' al.,! 2006).! In!
contrast,! enzyme!
activities! of! complex! I,! II,!
III,! IV! and! V! were! found!









reduction! in! the! gene!
expression!of!cytochrome!
c! oxidase! 5B! subunit!
of! AD! patients! (Brooks!et'
al.,!2007,!Chandrasekaran!
















(COX5B)! was! observed! in!
MS! patients! (Safavizadeh!
et'al.,!2013)!













































MS! still! remains! elusive.! Perturbed! glucose! metabolism! is! implicated! in!
neurodegenerative! disorders! like! Alzheimer’s,! Parkinson’s! and! Huntington’s.!
However,! little! is! known!about! its! role! in!MS!pathology.! The! findings! reported! in!
this!thesis! indicate!that!factors!present! in!the!CSF,! in!our!model,!are!affecting!the!
metabolism!of!neurons!and!oligodendrocytes!and!clearly!differentiate!more!benign!
forms! from! the!most! aggressive! forms! in!MS.! The! study! also! differentiates!NMO!
from!MS,!which!is!sometimes!difficult!to!distinguish!by!the!clinicians.!






4. CSF! factors! altered! glucose!metabolism! in! oligodendrocytes! exposed! to!
the!CSF!from!MS!and!NMO!patients.!
5. The!housekeeping!gene!Gapdh!variates!in!treated!oligodendrocytes.!
6. The!CSF!effect! is!different! in!MS!aggressivity!of!RRMS!and!PPMS!clinical!
form!(IgM+/K,!IgM+/+,!Med,!PP).!
7. IgM+/+! and! medullary! derived! CSF! treated! neurons! and! OPCs! are!
strongest! affected!by! reducing! carbohydrate!metabolism!as!evidenced!by!
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down! regulation! of! most! of! the! genes! which! is! suggestive! of! least! ATP!
synthesis.!This! indicates!more!damage!to!neurons!and!blockage!of!myelin!
repair!by!OPCs!and!correlated!with!worst!prognosis.!
8. NMO! derived! CSF! exposed! neurons! reveals! increased! carbohydrate!
metabolism! as! indicated! by! increased! expression! of! genes! whereas!
neurons!and!OPCs!treated!with!CSF!from!IgM+/K!MS!patients!demonstrates!
slightly! reduced! carbohydrate! metabolism! with! less! neuronal! damage!
correlated!with!poor!prognosis.!!




monitor! the! effects! of! future! therapies! aimed! at! preventing! MS! disease!
progression.! These! observations! open!new!perspectives! for! the! understanding! of!
metabolic! dynamics! in! multiple! sclerosis! yet! many! puzzling! aspects! and! critical!
questions! need! to! be! addressed.! For! instance,! how! does! defect! in! metabolic!
pathway!contributes!to!demyelination?!Does!metabolic!pathway!alters!in!other!cell!
types! in! MS?! The! changes! in! a! cell! type,! may! affect! directly,! through! some!
unknown! factor,! or! indirectly,! through! global! changes! in!metabolic! intermediates!
levels!in!CSF,!to!other!cell!types?!Is!disturbance!in!metabolic!pathway!a!mere!cause!
or!a!consequence!of!MS?!Can!those!genes!be!used!as!a!pharmacological!target!to!
alleviate! MS! pathology?! Much! more! research! is! required! to! fully! unravel! the!


























La! esclerosis!múltiple! (EM)! es! una! enfermedad! crónica! del! sistema! nervioso!
central! (SNC)! en! el! que! episodios! repetidos! de! inflamación! (bortes),! dan! lugar! a!
inflamación! que! conduce! a! la! interrupción! de! la! vaina! de! mielina! por! daños!
producidos! en! la! misma.! Junto! a! este! fenómeno! de! inflación! focal,! existe! una!
inflamación!difusa!en!el!SNC,!que!unida!a!la!anterior,!dará!lugar!a!que!aparezca!un!
proceso! de! neurodegeneración,! que! será! el! responsable! último! de! la! afectación!
axonal! y! neuronal! difusa! que! es! la! que! va! a! condicionar! la! discapacidad! en! los!
pacientes!afectos!de!EM.!La!enfermedad!es!una!causa!importante!de!discapacidad!
neurológica! y! de! disfunción! neurológica! en! adultos! jóvenes! que! afecta! a!más! de!
dos! millones! de! personas! en! todo! el! mundo.! En! España,! la! prevalencia! de! la!






curso! evolutivo,! la! anatomía! patológica! (donde! se! han! descrito! hasta! 4! patrones!
distintos! de! afectación! patológica)! y! la! respuesta! a! los! tratamientos.! Estas!
diferencias! llevaron! a! la! clasificación! de! los! tipos! de! EM!en! remitenteKrecurrente!
(EMRR),! EM! secundaria! progresiva! (EMSP)! o! EM! primaria! progresiva! (EMPP).! La!
mayoría!de!los!pacientes!comienzan!con!un!curso!de!la!enfermedad!del!tipo!EMRR!
que! se! caracteriza! por! ataques! periódicos! (brotes),! seguidos! de! su! recuperación!
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parcial!o!completa!(remisiones).!A!pesar!de!recibir!medicamentos!para!prevenir!la!
recaída! de! los! pacientes,! que! tienen! un! efecto! antiinflamatorio! pero! sobre! todo!
inmunomodulador,! los! pacientes! entran! finalmente! en! la! fase! secundaria!
progresiva! (EMSP)! con!un! empeoramiento!neurológico! irreversible.! Los! pacientes!
que! cursan! con! una! enfermedad! progresiva! primaria! (PPMS)! sufren! un! deterioro!
continuo!de!los!síntomas!neurológicos,!! lo!que!sugieren!que!la!fisiopatología!de!la!
progresión!no!es!únicamente!de!naturaleza!inflamatoria.!!
El! desarrollo! de! tratamientos! eficaces! se! ha! visto! obstaculizado! por! nuestro!
aún! limitado! entendimiento! de! la! patogénesis! de! la! EM.! Es! evidente! que! una!
comprensión!más!profunda!de! los!mecanismos!que!sustentan! la!progresión!de! la!
enfermedad! pueden! ayudar! en! el! desarrollo! de! estrategias! terapéuticas! para! el!
tratamiento!de!esta!patología.!
Aunque! todas! las! células! del! SNC,! incluyendo! oligodendrocitos! y! astrocitos,!
pueden!considerarse! como!"víctimas"! celulares!en! la!EM,! se!acepta!ampliamente!
que!es!el!daño!neuronal!la!causa!principal!de!la!discapacidad!funcional!persistente!
en! estos! pacientes,! aunque! su! origen! no! está! aún! del! todo! aclarado.! Una! de! las!
hipótesis! generales! es! que! el! daño! axonal! en! los! axones! desmielinizados! es! el!
resultado!del!aumento!de!la!demanda!energética!consecuente!con!la!redistribución!
de! la! bomba! Na+/K+! ATPasa! anterior! al! aumento! de! los! niveles! intracelulares! de!
Ca2+.!El!daño!axonal!también!se!ha!atribuido!a!defectos!metabólicos!defectuosa!o!a!
un! soporte! trófico! deteriorado! a! causa! de! daños! en! los! oligodendrocitos.! Sin!
embargo,! también! se! cree! que! ciertos! factores! difusibles! presentes! en! el! líquido!
cefalorraquídeo!(LCR)!podrían!también!afectar!a!la!capacidad!de!las!neuronas!para!
responder!al!daño!axonal!con!una!producción!de!energía!adecuada,!especialmente!
en! la! patogénesis! de! las! lesiones! corticales.! La! disminución! de! la! capacidad! para!
satisfacer! la! demanda! energética! se! ha! observado! durante! el! deterioro!
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mitocondrial! en! estudios! con! neuronas! cultivadas,!modelos! preclínicos! de! EM!en!
animales,!y!en!muestras!de!EM!humana.!




es! por! tanto! un! biofluido! prometedor! para! la! búsqueda! de! biomarcadores! y! de!
proteínas! asociadas! al! desarrollo! de! la! EM,! tanto! con! respecto! al! proceso!
inflamatorio! como! al! neurodegenerativo.! Los! factores! liberados! en! el! LCR! de!
pacientes!con!EM!incluyen!factores!apoptóticos,!citoquinas,!enzimas!proteolíticas,!
productos!oxidativos!y!radicales! libres!que!son!producidos!por! las!células!gliales!y!





explicar! ese! daño! neuronal.! Por! otra! parte,! el! estudio! de! los! posibles! patrones!
genéticos! diferenciales! sobre! las! OPCs! incubados! con! el! LCR,! el! cual! podría!
contener!factores!que!dañan!éstas!células!durante!los!intentos!de!reparación!de!las!
neuronas,! podría! facilitar! la! progresión! de! la! EM.! La! identificación! de! los!







En! base! a! esta! hipótesis,! el! objetivo! principal! fue! intentar! determinar! los!
mecanismos! que! están! implicados! en! la! degeneración! axonalKregeneración! en! la!
EM.!Para!ello!se!centró!el!estudio!en!el!daño!neuronal!primario,!independiente!del!
daño! secundario! como! resultado! de! la! desmielinización,! utilizando! cultivos!
primarios! de! neuronas! granulares! del! cerebelo! (CGCs)! como! modelo! celular.! Es!
verosímil!que!factores!hasta!ahora!desconocidos!presentes!en!el!LCR!de!pacientes!
con!EM!son!capaces!de!regular! la!destrucción!a! la!reparación!axonal,!y!hacer!una!
remielinización! estable! o! no! y! que! la! recuperación! funcional! pueda! ser! posible! o!
permanecer! en! el! curso! de! la! enfermedad.! Además,! durante! las! fases! de! la!
enfermedad! remitenteKrecurrente!el! cerebro!del!paciente!por! sí! solo!es! capaz!de!
reparar! el! daño,! remielinizar! el! axón! y! recuperar! la! función! neurológica.! Por! lo!
tanto,! decidimos! tratar! a! las! CGC! y!OPCs! con! LCR! derivado! de! diferentes! formas!
clínicas!de!la!EM!y!llevar!a!cabo!estudios!de!expresión!génica!global.!Por!otro!lado!
nos! planteamos! también! como! objetivo! identificar! los! genes! de! referencia! más!
estables!expresadas!en!CGC!y!OPCs! tratados!para!poder!normalizar!con!precisión!
las! niveles! de! mRNA! en! los! perfiles! de! expresión.! ! Por! último,! nos! planteamos!
intentar! identificar! posibles!biomarcadores!que!ayuden!a!distinguir! las! diferentes!
formas! clínicas! de! la! EM! y! permitan! explorar! las! diferencias! y! similitudes! con! la!
neuromielitis!óptica!(NMO).!






2.! Determinar! el! efecto! de! la! LCR! en! la! viabilidad! y! el! daño! celular! de! las!
neuronas!granulares!del!cerebelo!y!en!oligodendrocitos.!
3.! Establecer! una! relación! entre! la! afectación! neuronal! y! la! agresividad! en!
diferentes!formas!clínicas!de!EM!y!NMO.!
4.! Identificar! genes! constitutivos! durante! la! maduración! de! CGCs! y! en!!
neuronas!y!OPC!expuestos!a!la!LCR!de!pacientes!con!EM!y!NMO.!
!5.! Analizar!mediante! ensayos! con!micromatrices! de!DNA! la! afectación! en! la!
expresión!génica!del!tratamiento!con!el!LCR!de!los!cultivos!primarios!de!CGCs!y!en!
OPC.!
6.! Analizar! las! variaciones! en! los! genes! implicados! en! el!metabolismo!de! los!






Se! han! estudiado! un! total! de! 59! pacientes! en! los! diferentes! experimentos!







de! acuerdo! con! los! criterios! de! Lublin.! Adicionalmente,! los! pacientes! con! EMRR!
fueron! reclasificamos! en! función! de! la! presencia! de! bandas! oligoclonales! de! tipo!
IgM,! manteniendo! un! subgrupo! con! predominio! de! afectación! medular,! que! se!
clasificó! como! tal.! Los! pacientes! con! EM! incluidos! en! este! estudio! fueron!
diagnosticados! según! los! criterios! de!McDonald! 2010,! y! todos! ellos! cumplen! las!
siguientes!características:!bandas!IgG!oligoclonales!presentes,!habiéndose!realizado!
la!punción!lumbar!fuera!de!un!brote!y!que!hayan!pasado!al!menos!un!mes!después!
de! la! última! dosis! de! corticoides.! Se! utilizaron! los! criterios! Wingerchuk! para!
diagnosticar!pacientes!con!enfermedad!NMO.!Los!pacientes!sufrieron!recaídas!de!
neuritis!óptica!y!mielitis,!y!2!de!los!tres!criterios,! la!RM!normal!o!que!no!cumplen!




59! pacientes,! 21! tenían! EM!de! tipo! inflamatoria! (11! EMRR! subtipo! IgM! +/+! y! 10!
EMRR!subtipo! IgM!+/K),!8! tenían!EM!de!subtipo!medular! (EMMed),!11! tenían!EM!
primaria! progresiva! (EMPP),! 9! tenían! neuromielitis! óptica! (NMO),! y! 10! eran!
controles! (pacientes! NIMD).! La! tabla! 3! muestra! la! clasificación! final! y! las!
características!clínicas!de!los!pacientes!usados!en!este!estudio.!
Estos!pacientes!fueron!analizados!mediante!electroforesis!para!determinar! la!




3.2.! Análisis! de! LCR! y! suero! en! pacientes! con! EM!y!
NMO!
Para! determinar! los! subtipos! de! EM! y! NMO! señalados! arriba,! se! analizaron!
muestras!de!LCR!y!suero!pareadas!para!detectar!las!bandas!oligoclonales!de!IgG!y!
IgM! mediante! isoelectroenfoque! (IEF)! e! inmunodetección.! La! técnica! consiste,!
usando!un!kit!comercial!(Helena!BioScience!IgGKIEF)!y!el!método!descrito!por!!Villar!
et! al.! (2001),! consiste! en! la! dilución! de! las! de! las! muestras! de! LCR! hasta!
concentraciones!similares!de!proteínas,!y!la!incubación!con!ditiotreitol!para!reducir!
IgM.! El! electroenfoque! enfoque! se! realizó! en! un! sistema! de! electroforesis!
Multiphor!II! (GE!Healthcare)!a!un!pH!entre!de!5!a!8.!Las!proteínas!se!transfirien!a!
una! membrana! de! PVDF! y! se! analizan! mediante! Western! blot! usando! en! la!
inmunodetección! anticuerpo! antiKIgM! humano! conjugado! con! biotina! y!
estreptavidinaKfosfatasa! alcalina! para! la! detección.! En! los! estudios! con! suero! de!
pacientes! con!NMO!se!usó!el!anticuerpo!antiKAQP4!para! la! inmunodetección.! ! Se!
usó!además! la! !para!detectar! la!presense!de!NMO!anticuerpos! IgG!específicos.!La!
inmunofluorescencia! indirecta! (IFI)! se! realizó! además! en! las! células! transfectadas!




Para! los! diversos! experimentos! con! cultivos! celulares! primarios! se! utilizaron!
ratas!Wistar! (Harlan! Iberica)! con! peso! entre! 200K250! g.! El!mantenimiento! de! los!





Los! cultivos! primarios! de! neuronas! granulares! del! cerebelo! (CGCs)! se!
obtuvieron!de!acuerdo!con!el!protocolo!modificado!descrito!previamente![Minana!
et!al.,!1998].!Los!extrajeron!los!cerebelos!de!ratas!Wistar!de!8!días!y,!tras!eliminar!
las! meninges,! se! disgregaron! con! pipeta! ! Pasteur,! se! trataron! con! 3! mg/ml! de!
dispasa!(grado!II)!durante!30!min!a!37ºC!en!atmósfera!humidificada!de!CO2!5%!y!se!
inactivó! la! enzima! con! 1!mM! EDTA.! Las! células! granulares! se! resuspendieron! en!
medio!basal!de!Eagle!(BME,!Gibco)!con!40μg/ml!de!DNAasa!I.!La!suspensión!celular!




contaron! las! células! neuronales,! se! sembró! la! suspensión! en! placas! de! cultivo!
revestidas!de!poliKLKlisina!a!una!densidad!de!3x105!células/pocillo!y!se!incubaron!a!
37º! C.! Para! la! obtención! de! cultivos! enriquecidos! en! neuronas,! se! incubaron! las!
células!con!arabinósido!de!citosina!1!mM!entre!de!18!a!24!horas,! lo!que!inhibe!la!
replicación!de!células!no!neuronales.!!
3.3.3.! Cultivos! primarios! de! células! precursoras! de!
oligodendrocitos!(OPCs)!
Las!OPCs! se! aislaron! a!partir! de! la! corteza!de! ratas!postnatales! el! día! 1! y! se!






en! un! agitador! de! plataforma! rotatoria.! El! medio! se! retira! y! se! desecha! y! se!
reemplaza! con! medio! fresco! NM10.! Los! matraces! se! agitaron! durante! la! noche!
durante! 18K20! horas! a! 220! rpm! y! las! células! se! inmunoseleccionaron! en! una!
columna! de! purificación! magnética! Miltenyi! MACS! usando! anticuerpo! de! ratón!
antiKA2B5.! Las!OPCs! primarias! se! sembraron! en!placas! revestidas! de! poliKlysine! a!
una! densidad! de! 2.000! células! por! cm2! y! se! cultivaron! en! medio! de! definición!
química! de! oligodendrocitos! (ODM)! que! contiene! 100! mg/ml! de! transferrina!




factor!de!crecimiento!de! fibroblastos! (bFGF)!y!10!ng/ml!del! factor!de!crecimiento!
AA!derivado!de!plaquetas!(PDGFKAA),!y!las!células!se!dejaron!proliferar!durante!48!
horas!antes!del!tratamiento!con!los!LCR!.!Los!cultivos!de!OPCs,!tal!como!se!detectó!
por! inmunocitoquímica,! eran! 99%+! cultivos! OPCs! puros,! con! <1%! de! astrocitos!
detectables!GFAP+!y!<1%!de!microglia!detectables!Iba1!+.!
3.3.4.! Tratamiento! de! CGCs! y! OPCs! con! LCR! de!
pacientes!con!MS!y!NMO!
Los! cultivos! de! CGCs! de! día! 14º! se! incubaron! con! 10%! (v/v)! de! los! LCF! de!
pacientes!con!MS!(IgM!+/K,!IgM!+/+,!medular,!PPMS!y!controles)!y!NMO!durante!24!







que! se!acumula!dentro!de! la!mitocondria!de! las! células!debido!a! la!diferencia!de!
potencial! negativa! interna,! a! una! concentración! de! 10!mg/ml! en! PBS! durante! 30!
min! a! temperatura! ambiente! en! oscuridad.! Las! células! se! visualizaron! mediante!
microscopía!confocal!en!microscopio!Leica!TCS!SP2!AOB!de!escaneo!láser!confocal!
invertido.! El! análisis! de! las! imágenes! obtenidas! se! realizó! usando! el! programa!
Metamorph'7.0!(Molecular!Devices).!
3.4.! Análisis! de! expresión! global! con!micromatrices!
de!DNA!y!normalización!de!datos.!
Los!análisis!de!expresión!de!genes!de!células!de!CGCs!y!OPCs!en! las!diversas!
condiciones! experimentales! señaladas! en! resultados! se! llevaron! a! cabo! tras! la!





verificó! por! electroforesis! capilar! utilizando! un! Bioanalyzer! 2.100! (Agilent)! y! se!
retroKtrascribieron!a!cDNA.!!
Estos! RNA! se! usaron! tanto! en! los! ensayos! con!micromatrices! de! DNA! como!




Por! otra! parte,! los! genes! constitutivos! de! referencia! invariables! fueron!
evaluados! por! herramientas! de! software! GeNorm! y! NormFinder! disponibles!
públicamente.! El! programa! GeNorm! clasifica! los! genes! de! acuerdo! a! su! medida!
promedio!de!estabilidad!de! la!expresión,!desde! los!más!estables! (valor!de!M!más!
bajo)! a! los! menos! estables! (el! más! alto! valor! de! M).! Un! programa! alternativo,!
NormFinder,! que! se! introdujo! posteriormente! clasifica! los! genes! candidatos! de!
referencia! en! base! a! las! estimaciones! combinadas! de! ! variaciones! intra! e!
intergrupales.!
Los!RNA!purificados!se!usaron!para!el!análisis!de!expresión!génica!basado!en!
micromatrices! de! DNA! de! un! color! (Agilent! Technologies),! mediante! hibridación!
con!micromatrices!Agilent'SurePrint'G3'Rata'GE'8x60K'Microarray!(GEOKGPL13521)!
de!acuerdo!con!el!protocolo!del!fabricante.!Con!el!fin!de!dar!cuenta!de!la!variación!
técnica! entre! micromatrices! (es! decir,! la! cantidad! de! RNA! de! partida,! y! las!
diferencias! en! la! eficiencia! de! la! transcripción! inversa,! el! etiquetado! y! la!
hibridación,! etc.),! la! intensidad! de! la! señal! en! bruto! se! normalizó! utilizando! el!
método!de!“desplazamiento!de!percentil”,!fijado!en!la!intensidad!más!robusta!del!
percentil! 75,! disponible! en! GeneSpring' 9.0! para! micromatrices! de! un! color!
(Agilent).!Después!de!la!normalización,!los!datos!se!filtraron!con!el!fin!de!excluir!los!
“probesets”! con! baja! expresión! y/o! los! afectados! por! las! diferencias! entre! los!
laboratorios.! Los! genes! expresados! diferencialmente! se! identificaron!mediante! la!
comparación! de! los! niveles! de! expresión! promedio! en! término! de! veces! de!
inducción! en! las!muestras! de!MS! y! NMO! respecto! a! los! controles.! ! La! figura! 11!








de! transporte! de! electrones)! puede! condicionar! la! respuesta! de! toda! la! ruta! a!
cambios! locales! en! la! concentración! de! las! enzimas! hemos! utilizado! el! software!
STRINGv10.!!
Aunque! no! todos! los! genes! relacionados! con! una! red! específica! puedan! ser!
localmente!afectados!en!algún!tipo!de!EM!o!NMO,!el!análisis!STRING!mostraría! la!
interacción! física! de! enzimas! relacionadas! en! una! ruta! ! y! existir! un! complejo!




el! parámetro! “índice! del! flujo!metabólico! acumulado”! (CFI)! que! indica! el! cambio!
sinérgico!en!el!flujo!global!como!resultado!de!la!disminución!de!la!actividad!de!uno!
o! varios! enzimas! de! la! ruta! analizada.! Estos! valores! nos! permitirán! hacer!





se! expresan! como! el! valor!medio! +! su! error! estándar.! Una! prueba! estadística! se!
aplicó! para! buscar! diferencias! significativas! entre! las! condiciones! experimentales!
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para! cada! gen! candidato.! Se! realizó! un! análisis! unidireccional! de! la! varianza!
(ANOVA)! para! determinar! los! genes! ! con! variaciones! significativas.! Un! valor! de!
p<0.05!fue!considerado!estadísticamente!significativo.!
4.!RESULTADOS!Y!DISCUSION!
4.1.! Diagnóstico! clínico! y! clasificación! de! pacientes!
con!EM!y!NMO!
El! primer! paso! para! el! estudio! de! los! cambios! inducidos! en! las! células!
cerebrales! por! el! tratamiento! con! LCR! de! pacientes! con! EM! y! NMO! es! la!
clasificación! correcta! del! subtipo! y! del! nivel! de! la! enfermedad.! El! curso! clínico!
preciso! de! los! pacientes! con! EM! (fenotipos)! es! importante! para! el! pronóstico,! el!




Por! ellos,! se! realizó! la! clasificación! de! los! pacientes! en! base! a! la! clínica! y! la!
imagen! MRI! en! grupos! EMRR,! EMPP! y! MedMS.! En! el! primer! grupo! EMRR! se!
clasificó! en! subgrupos! con! pacientes! con!menor! o! peor! pronóstico! en! base! a! la!
presencia!de!bandas!oligoclonales! ! IgG!e! IgM!en!el! LCR! (Figura!12).! Los!pacientes!
con! NMO! se! identificaron! ! mediante! inmunofluorescencia! indirecta! en! células!









negativo!para!bandas!oligoclonales!de! IgM! (K)! en!el! LCR,! así! como,! son!negativos!
para!anticuerpos!antiKNMO!en!el!suero.!4)!Pacientes!EMPP!que!se!caracterizan!por!
disminución!progresiva!de! la! capacidad!neurológica,! con!anticuerpos! IgG! (+)!pero!
no! anticuerpos! IgM! (K)! en! el! LCR.! 5)! Pacientes! con! NMO! que! son! positivos! con!
anticuerpos! contra! acuaporina! 4,! con! una!mielitis! transversa! con! gran! extensión!
y/o!cerebro!normal!en!el!primer!evento.!6)!Controles!con!pacientes!sin!inflamación!
y!sin!enfermedad!neurológica!diagnosticada!(NIND).!
La! prevalencia! de! EM! observada! en! estos! pacientes,! como! se! conoce! en! la!
literatura,!es!mayor!en!las!mujeres!que!en!los!hombres!(75%!en!mujeres).!La!edad!
media!de!los!pacientes!con!EM!fue!de!30,7!±!9,7!años,!mientras!que!fue!de!25,6!±!
15! años! para! los! pacientes! NMO.! De! acuerdo! con! la! clasificación! clínica,! las!
características!generales!de!cada!MS!pacientes!se!describen!en!la!Tabla!7.!
Se!encontraron!diferencias!significativas!entre!la!edad!al!inicio!de!la!EMPP!y!las!
otras! dos! formas!de! EM! (p<0.003),! entre! la! EDSS! (Escala!Ampliada!del! Estado!de!
Discapacidad)!de!la!EMRR!y!las!otras!dos!formas!de!EM!(p!<0.001),!y!el!tiempo!de!
evolución!entre!la!EMPP!y!EMRR!(p<0.043),!después!de!la!corrección!de!Bonferroni.!
La! tabla! 8!muestra! las! características! de! los! pacientes! con! EM!de! acuerdo! con! la!
nueva! propuesta! y! la! clasificación! de! trabajo.! Después! de! la! corrección! de!
Bonferroni! se! encontraron! diferencias! significativas! importantes! entre! la! edad! al!
inicio!de! la!enfermedad!y! la!EDSS!entre! las!formas!EMMed!y!EMPP!respecto!a! las!
formas!inflamatorias!de!MS.!





se! produce! siempre,! el! patrón! es! específico! para! cada! individuo! con! EM.! La!
gravedad!y!discapacidad!de!la!enfermedad!aumenta!en!el!curso!de!la!EMRR!a!EMSP!
y! en! el! subtipo! PPMS! subtipo,! dado! que! los! síntomas! empeoran! continuamente!
desde!el!momento!del!diagnóstico!en! lugar!de!tener!ataques!y!recuperación!bien!
definidos.! En! nuestros! estudios! se! encontraron! diferencias! significativas! en! el!
tiempo!de!evolución!entre!la!EMRR!y!las!formas!progresivas!(p=0.043),!así!como!en!





Como! el! daño! axonal! ahora! ha! sido! ampliamente! aceptado! como! la! causa!
principal! de! discapacidad! funcional! persistente! en! pacientes! con! EM,! nos!
centramos!en! la! primera!parte!de!nuestro! estudio! en!el! daño!neuronal! primario,!
independientemente! del! daño! secundario! resultante! de! la! desmielinización.! Los!
individuos!con!MS!poseen!la!capacidad,!y! los!factores!necesarios!adecuados,!para!
reparar! la! mielina! dañada! durante! el! curso! remitenteKrecidivante! de! la!
enfermedad.!
Debido!a!su!generación!posnatal!y! la!viabilidad!de! los!cultivos!primarios!bien!
caracterizados! in' vitro,! las! células! granulares! del! cerebelo! son! un! modelo! de!
elección! idóneo!para!el!estudio!de! los!eventos!celulares!y!moleculares! implicados!
en! los! mecanismos! de! supervivencia/apoptosis! y! la!
neurodegeneración/neuroprotección!durante!la!EM.!
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Puesto! que! potencialmente! todas! las! células! del! cerebro,! neuronales! y! no!
neuronales,!pueden!verse!afectadas!por!esta!enfermedad,!se!determinó!el!efecto!
de! los!LCR!de!pacientes!en! la!viabilidad!celular!mediante! la!adición!de!yoduro!de!
propidio! y! rodaminaK123! a! los! cultivos! celulares! primarios! de! cerebro! de! rata!
(Figura! 14).! Los! resultados! muestran! que! los! astrocitos! se! encontraron! viables!
mientras!que! las!neuronas!granulares!sufrían!muerte!celular! !al! tratar! los!cultivos!
primarios! con! LCR! de! pacientes! con! EM! (paneles! B,! C! y! D! de! la! Figura! 14).! Los!
resultados!indican!que!algunos!de!los!factores!presentes!en!el!LCR!de!pacientes!con!
EM! pueden! causar! la! muerte! celular! por! apoptosis! específica! en! las! neuronas!
granulares!del!cerebelo!pero!no!en!astrocitos.!
Dado! que! no! se! puede! excluir! que! las! células! no! neuronales! pueden! causar!
interferencias!en!los!estudios!del!daño!neuronal!primario,!se!debe!obtener!cultivos!
puros! de!CGCs.! Para! este!propósito,! fue!necesario! añadir! arabinósido!de! citosina!
para!inhibir!la!replicación!y!crecimiento!de!las!células!no!neuronales.!Para!estimar!




cultivo! contiene!una!población!pura!de!CGCs,! y! que! se! encuentra!desprovisto!de!
cualquier!célula!no!neuronal.!
4.3.! Identificación! de! genes! constitutivos! estables!
para! normalización! de! datos! de! micromatrices! de!
DNA!
Uno! de! los! principales! problemas! en! cualquier! análisis! de!micromatrices! de!
DNA,! con! el! fin! de! obtener! datos! de! expresión! génica! precisos! (objetivo! del!
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siguiente!apartado),!es! la!normalización!correcta!de! los!cambios!obtenidos!de! las!




que! los! genes!ActB' y!Gadph! usados! habitualmente! para! normalizar! los! datos! se!
alteraban! en! los! tratamientos! usados! (2010,! Tesis! Doctoral! del! Dr.! Beltrán,!
Universitat!de!Valencia).!En!base!a!estos!datos!el!apartado!siguiente!de!esta!tesis!
fue! el! encontrar! genes! constitutivos! adecuados! para! normalizar! los! datos! de!
micromatrices!de!expresión.!
Los!datos!iniciales!con!los!genes!ActB!y!Gadph,!mediante!la!realización!de!PCR!
convencional! en!muestras! neuronales! tratadas! con! LCR! de! pacientes! con! EM! (de!
IgM+/+,! IgM+/K! (MS! inflamatoria),! EMMed,! EMPP,! NMO! y! NIND),! mostraban!
diferencias!significativas!en!su!valores!relativos!de!expresión!génica!(Figura!18).!Se!




elegidos! de! la! literatura! como! genes! con! expresión! invariable! observadas! en!
condiciones! experimentales! distintas.! Los! HKGs! candidatos! seleccionados! fueron!
baKactina! (ActB),! hipoxantina! guanina! fosforribosil! transferasa! (Hprt),! proteína!
ribosomal! L19! (Rpl19),! lactato! deshidrogenasa! A! (LdhA),! receptor! de! transferrina!
(Tfrc),! microglobulina! betaK2! (B2m),! y! gliceraldehído! 3Kfosfato! deshidrogenasa!
(Gapdh).!
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Por! otra! parte,! los! datos! de! qPCR! y! de! las! micromatrices! de! DNA! fueron!
evaluados! con! los! softwares! GeNormy! NormFinder! de! acuerdo! a! su! medida!
promedio!de!estabilidad!de!la!expresión.!!
Los! resultados! de! la! Figura! 20! ilustra! los! resultados! de! los! HKGs! genes!
candidatos!en!las!neuronas!granulares!del!cerebelo!tratados!con!CSF!de!pacientes!
de! MS! /! NMO! en! función! de! su! expresión! génica.! ! Los! datos! de! este! apartado!
(Figuras!19!y!Tabla!10)!nos!permiten!concluir!que!Hprt!y!Gadph!son!los!genes!más!





En! condiciones! experimentales! cuando! las! neuronas! granulares! de! cerebelo!
fueron!expuestos!a!los!LCR!de!los!diferentes!subtipos!de!EM!(Figura!20!y!Tabla!11)!
se!observó!que! !Tfcr! y!B2m!eran!expresados!de! forma!estable!constitutivamente,!
seguido!de!Rpl19'mientras!Gapdh!y!bActB!!mostraron!la!más!alta!fluctuación.!!
En!los!experimentos!en!lo!que!las!OPCs!fueron!tratados!con!LCR!de!pacientes!
con! EM!y!NMO! (Figura! 24! y! Tabla! 12),! se! encontró! que! los! genes!Mrpl19! y!Hprt!
mostraron! la!expresión!más!estable! seguida!de!B2m,!mientras!que!ActB! y!Gadph!
fueron!los!genes!menos!estables!en!su!expresión!en!las!condiciones!experimentales!
usadas.!
4.4.! Perfiles! de! expresión! génica! global! de! CGCs! y!
OLPs!tratadas!con!LCR!de!pacientes!con!EM!y!NMO.!




posibilidad! de! alteraciones! del! metabolismo! del! piruvato! en! la! EM! [Jones! et! al.,!
1.950].!
Un! informe! del! grupo! Regenold! (2008)! describe! un! posible! papel! del!
metabolismo! energético! del! SNC! en! la! progresión! de! la! EM.! Estos! investigadores!
midieron! los! niveles! de! lactato,! sorbitol! y! fructosa,! y! todos! los! metabolitos! del!





de! oligodendrocitos! (Figuras! 25K27)! tratadas! con! el! LCR! de! pacientes! con! EMRR!
IgM+/K,! EMRR! IgM! +/+,! EM! medular,! ! EMPP! y! NMO! utilizando! la! tecnología! de!
micromatrices! de! expresión.! Nuestros! estudios! se! centraron! en! la! red! del!
metabolismo! de! carbohidratos,! que! incluye! la! vía! glicolítica! y! el! ! ciclo! del! ácido!











Para! poder! "integrar"! nuestros! datos! en! las! rutas! del! metabolismo,! hemos!!
definido!un!parámetro!denominado!"ÍNDICE!DEL!FLUJO!METABÓLICO!ACUMULADO!
o!CFI"!dentro!de!la!red!para!comparar! las!diversas!condiciones!experimentales!de!
EM!y!NMO.!Los!valores!de!CFI!quieren!significar!que! la!reducción!en!el! flujo! local!
debido! a! la! inhibición! de! una! o! varias! actividades! enzimáticas! ! afectan!







Nuestros! resultados! revelaron! que! los! genes! glicolíticos! incluyendo! Gapdh,!
Pgam!y!Eno!mostraron!una!menor!expresión!en!las!neuronas!expuestas!al!LCR!de!la!
CSF! derivado! de! IgM! +/K! forma! clínica! de! la! EM! (Figura! 21).! Los! genes! que!
participan! en! el! ciclo! TCA! incluyendo!Pdh! y!Mdh2! and! gene! que! participan! en! la!
fosforilación! oxidativa! incluyendo! ATP5b! también! fueron! inhibidos! en! estas!
neuronas! (Figura! 22! y! Figura! 23).! En! los! experimentos! en! los! que! las! ! OPCs! se!
expusieron!al!LCR!de!pacientes!con!EMRR!tipo!IgM!+/K!se!observó!! la!disminución!
en!la!expresión!de!muchos!genes!glicolíticos!incluyendo!Hk,'Gpi,'Gadph,'Tpi,'Pgk1,'
Eno1,' Eno2,'Pk,! y!Pkm2' (Figura!25).!Por!otra!parte,! se! reduce! la!expresión!de! los!
genes! implicados! en! el! ciclo! TCA! incluyendo!Pdha1,' Aco2,' Idh,'and!Ogdh.! (Figura!
26).! Del! mismo!modo! los! genes! implicados! en! la! fosforilación! oxidativa,! a! saber!




EMRR! IgM+/K! (Figuras! 34! y! 35)! mostraron! que! el! flujo! glicolítico! disminuye!
significativamente!en!las!neuronas!(CFI!0,0296),!así!como!en!los!OPC!(CFI!0,0192).!
El! flujo! relacionado! con! el! ciclo! del! TCA! también! se! reduce! en! las! neuronas! (CFI!
0,0960)! y! en! OPCs! (CFI! 0,0602).! En! la! fosforilación! oxidativa,! el! flujo! se! reduce!
asimismo! en! las! neuronas! (CFI! 0,3300)! y! en! los! OPC! (CFI! 0,0119).! En! general!
podemos!señalar!que!el!flujo!metabólico!de!carbohidratos!y!de!la!síntesis!de!ATP!se!




en! forma! de! ATP! para! sobrevivir,! pero! en! estos! pacientes! los! genes!metabólicos!





Los! resultados! obtenidos! cuando! las! neuronas! se! expusieron! al! LCR! de!
pacientes! con! EMRR! IgM! +/+! demostraron! que! los! genes! que! catalizan! pasos!
cruciales!de!la!vía!metabólica!de!la!glucosa!y!la!generación!de!ATP,!tales!como!Hk,'
Gadph,' Pgk,' Pgam,' Eno,' Pkm2,' Pdh,' Mdh2,' y' ATP' sintasa! tenían! una! expresión!
reducida!en!comparación!con!el!control!(Figura!21K23).!!
En!el!tratamiento!de!las!OPCs!al!LCR!de!estos!pacientes!se!encontró!que!casi!
todas! las! enzimas! implicadas! en! la! glicolisis! (Hk1,' Gpi,' Tpi,' Gadph,' Pgk1,' Pgam5,'
Eno'y'Pk),!las!relacionadas!con!el!ciclo!de!Krebs!(Pdh,'Aco2,'Idh,'Ogdh,'Sdh,'y'Mdh2)!
así! como! las! de! la! cadena! electrónica! mitocondrial! y! fosforilación! oxidativa!
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(complejos! CI,! Cyc1,! CIV/Cox,! ATPasaA! y! ATPasaB)! se! encuentran! fuertemente!
reducidas!en!su!expresión!génica.!
Los!resultados!globales!muestran!que!cuando!las!neuronas!se!tratan!con!LCR!
de! pacientes! EMRR! IgM! +/+! pacientes! el! flujo! glucolítico! disminuye! fuertemente!
(CFI! 0,0007)! así! como!en! los!OPCs! (CFI! 0,0047).! El! flujo! global! relacionado! con!el!
ciclo!del!TCA!también!se!reduce!en!las!neuronas!(CFI!0,0690)!y!con!fuerza!en!OPCs!
(CFI!0,0024).!En! la!fosforilación!oxidativa,!el! flujo!se!reduce!tanto!en! las!neuronas!
(CFI! 0,3000)! como!en! los!OPC! (CFI! 0,0173).! En! general,! el! flujo!metabólico!de! las!
rutas! de!metabolismo! de! los! carbohidratos! y! de! la! síntesis! de! ATP! se! redujeron!
profundamente! tanto! en! las! neuronas! (CFI! 1.4201EK05),! como! en! los! OPCs! (CFI!
1.9596EK07)!cuando!se!exponen!a!los!LCR!de!pacientes!EMRR!IgM!+/+.!!
Si! comparamos! los! resultados! obtenidos! con! los! subtipos! de! EMRR! IgM+/K! y!!
IgM+/+,! se! puede! indicar! que! los! genes! implicados! en! el! metabolismo! de! los!
hidratos!de! carbono! y! la! síntesis! de!ATP!están!más! afectados!en!el! segundo! tipo!
que!el!primero! tanto!en!neuronas!como!en!OPC.!La!EMRR! IgM!+/K! !es!una! forma!
clínica!inflamatoria!más!benigna!y!menos!agresiva!de!MS,!!con!abundante!IgG!pero!
sin!anticuerpos!IgM!en!el!LCR.!Por!lo!tanto!la!energía!en!forma!de!ATP!se!requiere!




para! la! producción! de! energía.! Sin! embargo,! si! no! hay! suficiente! producción! de!
energía,!como!ocurre!en! la! forma!agresiva!se!perjudica!severamente! la!capacidad!
de!reparación!del!daño!neuronal.!Del!mismo!modo!ocurre!en!las!células!OPCs,!en!
donde! se! produce!menor! nivel! de! energía! lo! cual! puede! bloquear! el! proceso! de!
reparación!por! las!OPCs.!Llegamos!a! la!conclusión!de!que! la!expresión!diferencial!
de! genes!metabólicos! influye! en! el! perfil! de! la! bioenergética! de! las! neuronas! y,!
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Tpi,'PDHA1,'Pgk1,'Pkm2,'AldoC,'y' Sdhaf2!entre! ! los!pacientes!de!EMRR! ! IgM+/K!e!
IgM! +/+.! Del!mismo!modo,! no! se! encontraron! diferencias! en! la! expresión! de! los!
genes! Pgam1! y! Cox6b2! entre! los! OPC! expuestas! al! LCR! de! IgM! +/K! y! las! OPC!
expuestas! a! LCR! de! pacientes! medulares! (ver! más! abajo).! Estos! genes! podrían!!
servir! como!potenciales! biomarcadores! para! distinguir! entre! las! diferentes! clases!





genes! glicolíticos,! incluyendo!Hk1,' Gapdh,' Eno' y' Pkm2,! disminuyen! su! expresión!
génica!en!comparación!con!los!controles!no!neurológicos.!Por!otra!parte,!los!genes!
implicados! en! el! ciclo! de! Krebs,! incluyendo! Pdh! y!Mdh2,! y! los! genes! de! la! ATP'
sintasa!alfa!y!beta!muestran!asimismo!una!importante!disminución!en!su!expresión!
génica.!Los!valores!de!los!índices!de!flujo!acumulativo!fueron!de!0,0075,!de!0,0810!
en! las! enzimas! del! ciclo! del! Krebs,! y! de! 0,1050! en! las! enzimas! de! la! cadena! de!
transporte! y! de! fosforilación! oxidativa! al! exponer! a! las! neuronas! al! LCR! de!
pacientes!medulares! (Figura! 38).! En! total,! el! índice! de! flujo! total! acumulada! del!
metabolismo! de! la! glucosa! y! de! la! síntesis! de! ATP! se! encontró! que! era! tan! bajo!
como!6.36727EK05!en!estas!neuronas.!!
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En! los! experimentos! con! OPCs! tratados! con! el! LCR! de! estos! pacientes! se!
encontró!que!muchos!de!los!genes!de!la!ruta!glicolítica,!como!Hk1,'Gpi,'Gapdh,'Tpi,'
Pgk1,'Eno'y'Pkm2!(Figura!25),!!del!ciclo!de!Krebs,!como!Pdh,'Aco2,'Idh,'Ogdh'y'Sdh'
(Figura! 26),! y! de! los! complejos! de! la! cadena! de! transporte! electrónica! y! la!
fosforilación!oxidativa,!como!CI,'CycC1,'CIV/Cox,'ATPasa'A'y'ATPasa'B'(Figura!27),'
se!encuentran!profundamente!reprimidos.!
Nuestros! resultados! revelaron! una! importante! disminución! de! los! índices! de!
flujo!metabólico!acumulado!en!la!ruta!glicolítica!(CFI!0,0019),!del!ciclo!de!Krebs!(CFI!
0,0124)!y!de!la!cadena!electrónica!y!de!la!fosforilación!oxidativa!(CFI!0,0328)!en!las!
OPC! tratadas! con! el! LCR! de! estos! pacientes! (Figura! 39).! En! comparación! con! los!




encuentran! sobre! todo! en! la! región! de! la! médula! y! que! constituye! uno! de! los!
subtipo!más! agresivo! de!MS,! comparable! al!más! agresivo! del! SNC! de! EMRR! IgM!
+/+,! con! el! que! muestra! un! patrón! de! expresión! génica! similar.! La! drástica!
reducción! en! ambos! tipos! de! EM!de! la! expresión! de! los! genes!metabólicos! daría!
lugar! a! un! fracaso! bioenergético! lo! que! hace! que! los! oligodendrocitos! no! sean!









mientras! que! las! subunidades! alfa! y! beta! de! la! ATP! sintasa! implicadas! en! la!
producción!de!ATP!mostraron!asimismo!disminución!de!su!expresión!(Figura!23).!!
Por!el!contrario,!varios!de!los!genes!de!la!ruta!glicolítica!se!ven!afectados!a!la!




mismo!modo,! los! complejos!CI,' CIV/Cox! y' ATP' sintasa' (subunidad' alfa)!muestran!
asimismo!reducción!en!su!expresión!(Figura!27).!
Los! resultados!obtenidos!con!el! tratamiento!con!LCR!de!pacientes!con!EMPP!







carbono! y! de! producción! de! ATP! disminuye! ligeramente! en! las! neuronas! (CFI!








La! neuromielitis! óptica! (NMO)! es! otra! enfermedad! del! SNC! de! tipo!
inflamatoria,!desmielinizante!y!autoinmune!pero! totalmente!distinta!de! la!EM.!La!




expuestas! a! la! LCR!de!pacientes!NMO!en! comparación! con! las!neuronas! tratadas!
con! LCR!de! controles!neurológicos.! Sólo! los! genes!Gadph! y!Mdh2!mostraron!una!
ligera! disminución! de! su! expresión! (Figura! 21).! Además,! los! genes! de! cadena! del!
ciclo!TCA!y!transporte!de!electrones! incluyendo!Pdh! (Figura!22)!y! las!subunidades!
alfa! y! beta! de! la! ATP' sintasa! mostraron! una! mayor! expresión! en! las! neuronas!
tratadas!(Figura!23).!Por!el!contrario!el!gen!Mdh2!del!ciclo!del!TCA!se!expresó!en!
cantidades!considerablemente!más!bajos!(Figura!22).!
En! general,! se! observó! una! aumento! de! los! valores! de! CFI! en! dos! rutas!
metabólicas,! la!vía!glicolítica!(CFI!1,9656)!y! la!cadena!de!transporte!y!fosforilación!
oxidativa! (CFI! 1,5867),! y!una! ligera!disminución!de! las! enzimas!del! ciclo!de!Krebs!
(CFI! 0,2174)! (Figura! 42).! ! Esto! hace! que! ! el! índice! de! flujo! acumulativo! en! el!
conjunto!de!las!tres!rutas!metabólicas!se!encuentre!prácticamente!inalterado!(CFI!
0,67787).!!







Tpi,' Pgk,' Eno! y' Pk,' muestran! reducción! en! la! expresión! de! los! genes! en!
comparación!con!los!controles!(Figura!25).!Por!otra!parte,! los!genes!del!ciclo!TCA,!
incluyendo!Pdh,'Sdh,'Aco,'Ogdh'y'Mdh2,!mostraron!disminución!de!la!expresión!en!
las! OPCs! tratadas! (Figura! 26).! Del! mismo! modo,! los! genes! de! la! cadena! de!








expuestas! al! LCR! de! pacientes! NMO! sufren! una! muy! ligera! disminución! (CFI!
0,67787),!mientras!que!en!las!OPC!disminuyó!sensiblemente!(CFI!1.10046EK07).!!




producto! en! el! fluido! puede! influir! en! la! fisiología! celular! de! las! neuronas,! las!
células! progenitoras! de!oligodendrocitos! y! los! oligodendrocitos!mielinizantes.! Los!
datos! aportados! en! este! último! capítulo! nos! indican! que! los! potenciales! factores!
presentes! en! el! LCR! pueden! estar! perturbando! el!metabolismo! energético! de! las!
neuronas!y!las!OPCs.!El!estudio!también!diferencia!la!NMO!de!la!EM,!lo!que!a!veces!
es! difícil! distinguir! por! los! clínicos,! por! poseer! patrones! de! expresión! génica!






A! pesar! de! la! amplia! investigación! que! se! ha! llevado! a! cabo! durante! la!
última! década,! la! causa! subyacente! de! la! EM! sigue! siendo! difícil! de! conocer.! El!
metabolismo! perturbado! de! la! glucosa! está! implicado! en! diversas! enfermedades!
neurodegenerativas!como!el!Alzheimer,!el!Parkinson!y!el!Huntington.!Sin!embargo,!





también!diferencia! la!NMO!de! la! EM!en!base! a! su!diferente!patrón!de!expresión!
génica,!que!a!veces!es!difícil!distinguir!por!los!clínicos.!
Las!conclusiones!que!se!derivan!de!esta!tesis!se!pueden!resumir!en!las!siguientes:!
1.! Se! clasificaron! los! pacientes! en! base! a! la! clínica,! la! existencia! de! ! bandas!
oligoclonales! ! IgG! e! IgM! en! el! LCR,! de! anticuerpos! antiKNMO! en! suero! y! la!
imagen! MRI! en! grupos! EMRR,! EMPP,! MedMS! y! NMO.! Se! encontraron!
diferencias! significativas! entre! la! edad! al! inicio! de! la! EMPP! y! las! otras! dos!








3.! En! condiciones! experimentales! cuando! las! neuronas! granulares! de! cerebelo!
fueron!expuestas!a! los! LCR!de! los!diferentes! subtipos!de!EM!se!observó!que!
los! genes! Tfcr! y! B2m! eran! expresados! de! forma! estable! constitutivamente,!
seguido!de!Rpl19,!mientras!Gapdh!y!bActB!!mostraron!la!más!alta!fluctuación.!
En! los! experimentos! con! las!OPCs! se! encontró! que! los! genes!Mrpl19! y! Hprt!
mostraron! la! expresión! más! estable! seguida! de! B2m,! mientras! que! ActB! y!
Gadph!fueron!los!genes!menos!estables!en!su!expresión.!!
4.! En! los! experimentos! con! micromatrices! de! expresión! se! determinaron! los!
cambios! de! expresión! de! las! enzimas! implicadas! en! el! metabolismo! de!
carbohidratos! [Glicolisis! (GLI),! Ciclo! de! Krebs! (TCA)! y! cadena! de! transporte!
electrónica! mitocondrial! y! fosforilación! oxidativa! (CTE/PO)]! cuando! CGCs! y!
OPCs!son!tratadas!con!LCR!de!pacientes!con!EM!y!NMO.!Los!datos!indican!que!
las!formas!más!agresivas!y!de!peor!pronóstico!de!EM,!EMRR!IgM+/+!y!EMMed!








6.! !En! la! forma! intermedia! de! agresividad! y! pronóstico! y! de! curso!más! lento! y!
progresivo,! la!EMPP,! los! valores!de!CFI! globales! son!asimismo!más!elevados,!
de! 0,00274! en! CGCs! y! de! 0,00013! en! OPCs,! y! posiblemente! las! enzimas!
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directamente! afectadas! directamente! pueden! influir! en! su! pronóstico! y!
agresividad.!!!
7.! La! NMO! como! un! tipo! de! enfermedad! ! inflamatoria,! desmielinizante! y!
autoinmune! del! SNC! distinta! de! la! EM! tiene! un! patrón! de! expresión! génica!
completamente!diferente.! ! Se!observó!un! aumento!de! los!CFI! en! la! ruta!GLI!
(CFI! 1,9656)! y! en! la!CTE/PO! (CFI! 1,5867),! y! una! ligera!disminución!en! la! TCA!
(CFI!0,2174),! lo!que!da!un!CFI!global!prácticamente! inalterado! (CFI!0,67787),!
en! neuronas.! Por! el! contrario,! en! las! OPC! disminuyó! sensiblemente! (CFI!
1.10046EK07).!Estas!diferencias!pueden!ayudar!!diferenciar!los!tipos!de!EM!de!
la!NMO.!
8.! Aunque! no! todas! las! enzimas! de! una! ruta! metabólica! están! afectados! por!





que!podrían!ayudar!a!diferenciar! clínicamente! los!diversos! subtipos!de!EM!y!
NMO.!
Estas! observaciones! abren! nuevas! perspectivas! para! la! comprensión! de! la!
dinámica!del!metabolismo!en!la!EM!con!todavía!muchos!aspectos!desconcertantes!
y!preguntas! críticas!que!deben!ser!abordados.!Por!ejemplo:!¿Cómo!el!defecto!en!
una! ruta! metabólica! contribuye! a! la! desmielinización?! ¿Las! vías! metabólicas! en!
otros!tipos!de!células!se!encuentran!asimismo!alteradas!en!la!EM?!¿Los!cambios!en!
un! tipo! de! célula,! pueden! afectar! directamente! a! través! de! algún! factor!
desconocido,! o! indirectamente! por! cambios! globales! en! los! niveles! de! los!
intermedios!metabólicos!en!el!LCR!a!otros!tipos!de!células?!¿Esta!perturbación!en!
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las! rutas!metabólica! es! causa! o! consecuencia! de! la! EM?! ¿Pueden! esos! genes! ser!
usados!como!una!diana!farmacológica!para!aliviar!la!patología!MS?.!
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Multiple sclerosis (MS) is a complex debilitating disease of the central nervous system
(CNS) perceived to result from the autoimmune effect ofT cells in damagingmyelin sheath.
However, the exact pathogenesis of the disease remains elusive. Initial studies describ-
ing the possibility of defective pyruvate metabolism in MS were performed in 1950s. The
group observed elevated blood pyruvate level in both fasting and postprandial times in MS
patients with relapse. Similarly, other investigators also reported increased fasting pyruvate
level in this disease.These reports hint to a possible abnormality of pyruvate metabolism in
MS patients. In addition, increase in levels of Krebs cycle acids like alpha-ketoglutarate in
fasting and citrate after glucose intake in MS patients further strengthened the connection
of disturbed pyruvatemetabolismwithMS progression.These studies led the investigators
to explore the role of disturbed glucose metabolism in pathophysiological brain function.
Under normal circumstances, complex molecules are metabolized into simpler molecules
through their respective pathways. Differential expression of genes encoding enzymes of
the glucosemetabolic pathway in CNSmay result in neurological deﬁcits. In this review arti-
cle, we discuss the studies related to disturbed carbohydrate metabolism in MS and other
neurodegenerative diseases. These observations open new perspectives for the under-
standing of metabolic dynamics in MS yet many puzzling aspects and critical questions
need to be addressed. Much more research is required to fully unravel the disease mecha-
nism, and a proper understanding of the disease could eventually lead to new treatments.
Keywords: brain glucose metabolism, cell-speciﬁc mechanisms, mitochondrial defects, multiple sclerosis,
neurodegenerative diseases
INTRODUCTION
Multiple sclerosis (MS) is a chronic inﬂammatorydisease of proba-
bly immune origin affecting more than two million people world-
wide. Demyelinated plaque, inﬂammatory inﬁltrates, accumula-
tion of antibodies, and complement proteins are the pathological
hallmarks of MS (1). It is believed that immune cells particularly T
cells penetrate the brain and mistakenly recognize myelin tissue as
foreign anddamage it. The inﬂammatory cells includingmicroglia,
macrophages; antibodies, cytokines, complement system, and oth-
ers enhance the damaging effect. The process of demyelination is
associated with axonal degeneration that underlies neurological
deﬁcits in MS (2). The lesions formed as a consequence of neu-
roaxonal injury are found in both white and gray matter of the
central nervous system (CNS) (3). Although research underscores
the role of immunological, genetic, and environmental pathologic
inﬂuences, the exact mechanisms underlying MS pathology are yet
uncertain.
Abbreviations: CNS, central nervous system; ETC, electron transport chain; FAD,
ﬂavin adenine dinucleotide; MS, multiple sclerosis; NAD+, nicotinamide ade-
nine dinucleotide; RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary
progressive multiple sclerosis; TCA cycle, tricarboxylic acid cycle.
The disease course often begins with clinically isolated syn-
drome involving optic nerve, brain stem or spinal cord. The
70–80% of these patients experience relapsing-remitting events,
which at later stage are transformed into a secondary progressive
stage that causes irreversible neurologic worsening. This suggests
that the pathophysiology of progression is not solely inﬂammatory
in nature (4). To prevent disease progression investigators have
explored a possible role of energy metabolism in the CNS. Meta-
bolic disturbances have been implicated in neurodegenerative
disorders including Alzheimer’s, Huntington’s, and Parkinson’s
diseases. In demyelinating diseases particularly MS, investiga-
tions on the contribution of disturbed glucose metabolism in MS
pathology are limited. However, the existing literature hints to a
connection between disturbed glucosemetabolism andMSpatho-
genesis. In this context, this article will ﬁrst focus on some basic
aspects of brain’s energy balance, its regulation at cellular level,
and its role in normal and diseased conditions with a special focus
on MS. Before we discuss the cell-speciﬁc mechanisms underly-
ing brain energy metabolism, it seems pertinent to brieﬂy review
the metabolic pathways, which include glycolysis, the tricarboxylic
acid (TCA) cycle, and thepentose phosphate pathway (PPP). These
metabolic pathways are similar in brain and other tissues.
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GLYCOLYSIS
Glycolysis (Embden–Meyerhof pathway) is the metabolism of
glucose to pyruvate. Four ATP molecules are produced in the
processing of glucose to pyruvate, where two ATP molecules are
consumed in the pathway resulting in a net production of two
ATP molecules per glucose molecule. In the absence of oxygen
(anaerobic conditions),pyruvate is converted into lactate, allowing
the regeneration of nicotinamide adenine dinucleotide (NAD+),
which is necessary tomaintain a continued glycolytic ﬂux.Without
the regeneration of NAD+ the pathway could not have continued
beyond glyceraldehyde 3-phosphate.
TRICARBOXYLIC ACID CYCLE
Under aerobic conditions, pyruvate undergoes oxidative decar-
boxylation to yield acetyl-CoA in a reaction catalyzed by pyruvate
dehydrogenase.Acetyl-CoA in thepresence of citrate synthase con-
denses with oxaloacetate and forms citrate. This is the ﬁrst step of
the TCA cycle in which three molecules of NADH are formed from
NAD+ and one molecule of FADH2 is formed from ﬂavin ade-
nine dinucleotide (FAD) through four oxidation–reduction steps.
The reducing equivalents NADH and FADH2 transfer their elec-
trons to molecular oxygen via mitochondrial electron transport
chain (ETC). There are ﬁve enzyme complexes, denoted as I–V
that forms the ETC in mitochondria. Electron transfer from com-
plexes I and II to complex III and from complex III to complex
IV is accomplished by co-enzymes ubiquinone and cytochrome
c. During this process, protons are transported across the inner
mitochondrial membrane to the intermembrane space to gener-
ate an electrochemical gradient. The enzyme ATP synthase utilizes
this energy and produces ATP.
PENTOSE PHOSPHATE PATHWAY
Overall, glucose is completely oxidized to carbondioxide andwater
via three synchronized pathways namely glycolysis, the TCA cycle,
and the ETC, and ﬁnally produces energy in the formof ATP.How-
ever, there are conditions when extra metabolic energy is required
in the form of reducing power in addition to ATP. These are the
situations when precursors are in a more oxidized state than the
products. In PPP, glucose 6-phosphate is converted into ribulose
5-phosphate utilizing two molecules of NAD+. Thus,when ample
amount of energy is required, the level of NADPH falls down and
the pathway is activated to generate more reducing equivalents.
GLUCOSE SERVING AS THE MAIN FUEL IN BRAIN
The human brain represents only 2% of the body weight, yet 25%
of total body glucose is utilized by it. Energy requirement is high-
est in neurons of adult brain (5). Therefore, a continuous supply
of glucose is needed from bloodstream into the brain. With a few
exceptions, glucose is the main source of energy in mammalian
brain (6).Nevertheless, there are certain circumstanceswhen brain
uses ketone bodies as energy source including starvation, during
strenuous exercise and development (7). Metabolism of glucose
yields energy in the form of ATP that is used for neuronal and
non-neuronal cell survival and generation of neurotransmitters.
Therefore, tight regulation of glucose metabolism is necessary for
normal brain physiology and perturbation in any step of its regu-
lation pathway may form the pathophysiological nexus for many
brain disorders.
CELL-SPECIFIC MECHANISMS UNDERPINNING BRAIN
ENERGY METABOLISM
GLIA AND VASCULAR ENDOTHELIAL CELLS – ROLE IN BRAIN ENERGY
METABOLISM
Neurons are usually regarded the most important cells of the CNS
taking part in energy metabolism. However, other cells like glial
and vascular endothelial cells also play a critical role in the distrib-
ution of energy substrates to neurons. Glial cells constitute nearly
half of the brain volume. Out of many different cell types in the
brain, neurons represent only a small proportion for glucose uti-
lization. It has been seen that the presence of specialized end-feet
processes makes astrocytes the ﬁrst cellular barrier that glucose
entering the brain parenchyma come across and makes them a
probable site of glucose uptake and energy substrate distribution.
Besides possessing end-feet processes, astrocytes contain processes
that ensheathe synaptic contacts. The receptors and uptake sites
present on astrocytes allow neurotransmitters to communicate
with them. These structural and functional characteristics exhib-
ited by astrocytes makes them perfectly suitable to couple local
changes in neuronal activity with coordinated adaptations in
energy metabolism.
GLUCOSE METABOLISM IS TIGHTLY REGULATED IN ALL CELL TYPES OF
THE BRAIN – NEURONAL AND NON-NEURONAL
Due to enormous degree of cellular heterogeneity in brain, it is
quite cumbersome to understand the relative role of each cell
type in energy substrate ﬂux. However, usage of primary cultures
in vitro enriched in neurons, astrocytes or vascular endothelial
cells have proved very beneﬁcial in localizing the cellular sites
for glucose uptake and its consequent metabolic fate particu-
larly as regards glycolysis and oxidative phosphorylation. As it is
well understood that in situ cellular preparation does not exhibit
all the properties as observed in whole brain tissues many other
aspects of brain energy metabolism can be studied using cultures
in vitro.
Under basal conditions, glucose uptake and its utilization occur
in all cell types of the brain with a high speciﬁcity. This is due to
the presence of unique glucose transporters (GLUTs) on different
cell types. Due to low lipid solubility and lack of speciﬁc trans-
port carriers in the luminal membrane of the capillary endothelial
cell entry of neuroactive compounds such as glutamate, aspartate,
and glycine into the blood–brain barrier is limited. Glucose being
an obligatory fuel enters through facilitated transport mechanism
mediated by speciﬁc transporters. Six genes and one pseudogene
encoding glucose transporter proteins have been identiﬁed so far.
These are designated as GLUT1 to GLUT7 (8). In brain, GLUT1,
3, and 5 are preponderantly expressed in cell-speciﬁc manner (9).
Based on the degree of glycosylation, GLUT1 is expressed in two
forms in the brain with molecular weight 55 and 45 kDa (10,
11). The 55 kDa form of GLUT1 is expressed in choroid plexus,
ependymal cells, and vascular endothelial cells. The other form
with 45 kDa molecular mass is localized on astrocytes (12). Neu-
rons possess GLUT3 transporter on their membrane (13) whereas
microglial cells, the resident macrophages of the brain, are found
to have GLUT5 form of the transporter (9). So, it is apparent that
glucose enters the brain via 55 kDa GLUT1 receptor present on
endothelial cells. The uptake by astrocytes is mediated by 45 kDa
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form of GLUT1 while GLUT3 receptors mediate this process
in neurons. Ultimately, microglial cells uptake glucose from the
surrounding medium through GLUT5 receptor.
GLUCOSE METABOLISM AND MULTIPLE SCLEROSIS
Studies show that there is a possible role of impaired energy
metabolism in the CNS of MS patients (Figure 1). Initial stud-
ies describing the possibility of defective pyruvate metabolism
in MS were performed by Jones et al. (14). The group observed
elevated blood pyruvate level in both fasting and postprandial
times in MS patients with relapse. Similarly, other investigators
also reported increased fasting pyruvate level in this disease (15).
However, there were conﬂicting reports demonstrating normal
fasting lactate level, or increase in only a small number of patients
(16–18). On the other hand, Jeanes and Cumings (16) found an
abnormal rise in the blood pyruvate level after glucose intake.
These reports hint to a possible abnormality of pyruvate metabo-
lism in MS patients. In addition, increase in levels of Krebs cycle
acids like alpha-ketoglutarate in fasting and citrate after glucose
intake in MS patients further strengthened the connection of dis-
turbed pyruvate metabolism with MS progression (18). McArdle
et al. (19) found elevated levels of pyruvate and α-ketoglutarate
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FIGURE 1 | Schematic representation of glucose metabolism in MS
brain. Glucose enters cells through GLUTs and is phosphorylated by
hexokinase to produce glucose 6-phosphate. Glucose 6-phosphate can be
processed into three main coordinated metabolic pathways. First, it can be
metabolized through glycolysis giving rise to two molecules of pyruvate
and producing ATP and NADH. Pyruvate can then enter mitochondria,
where it is metabolized through theTCA cycle and oxidative
phosphorylation, producing ATP and CO2. Alternatively, pyruvate can be
reduced to lactate by Ldh. This lactate can be released into the
extracellular space through monocarboxylate transporters (MCTs). The
complete oxidation of glucose produces 30–34 ATP molecules in the
mitochondria. Alternatively, glucose 6-phosphate can be processed
through the PPP leading to the production of reducing equivalent in the
form of NADPH. Note that the PPP and glycolysis are linked at the level of
glyceraldehyde-3-phosphate (GLAP) and fructose 6-phosphate. Finally,
glucose 6-phosphate can be converted to glycogen through the process of
glycogenesis in astrocytes. Hk, hexokinase; Gpi, glucose-6-phosphate
isomerase; Pfk, phosphofructokinase-1; DHAP, dihydroxyacetone
phosphate; Tpi, triose phosphate isomerase; GAPDH,
glucose-6-phosphate dehydrogenase; Pgk, phosphoglycerate kinase;
Pgam, phosphoglycerate mutase; Eno, enolase; Pk, pyruvate kinase; Ldh,
lactate dehydrogenase; 6-PGL, 6-phosphoglucono-d-lactone.
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in MS. Increased activity of metabolic enzymes including enolase,
pyruvate kinase, lactate dehydrogenase (Ldh), and aldolase in the
CSF of patients with disseminated sclerosis make them a sensitive
indicator of active demyelination (20).
B cells and antibodies reactive with triose phosphate isomerase
(TPI) and GAPDH are produced intrathecally in CSF and lesions
of MS (21). BothTPI andGAPDHare essentialmetabolic enzymes
involved in ATP production. Another investigation by the same
group showed that these antibodies bind with TPI and GAPDH
and inhibit the glycolytic activity of GAPDH but not TPI in MS
patients (22). This inhibitory effect of antibodies on GAPDH was
not visualizedwhen anti-GAPDHIgGwas exhausted from theCSF
demonstrating the role of anti-GAPDH antibodies in impeding
the GAPDH enzyme activity in brain leading to neuronal apopto-
sis and cytotoxicity. In systemic lupus,an autoimmune rheumatoid
disorder, autoantibodies were found reactive to GAPDH (23).
Accumulating evidence indicates that inhibition of GAPDH activ-
ity in glycolytic pathway is associated with neuronal apoptosis. It
has been purported that GAPDHenzyme activity suppresses when
it reacts with other proteins in the CNS (24). Single chain variable
fragment antibodies (scFv-abs) obtained from clonally expanded
B cells binds speciﬁcally withGAPDHandTPI in activeMS lesions
(25). In addition, interaction of GAPDH with ß-amyloid protein
and Huntingtin protein well demonstrates the role of GAPDH in
neurodegenerative disorders (26).
A recent study demonstrated that a ligand-activated transcrip-
tion factor known as peroxisome proliferator-activated receptor
gamma (PPARγ) playing a pivotal role in regulation of glu-
cose and lipid metabolism is markedly increased in CSF of MS
patients (27). Furthermore, elevated expression of PPARγ has
been reported within the spinal cord of EAE mice (28) and in
an in vitro model of antigen induced demyelination (29). These
ﬁndings may contribute to our understanding about the role of
PPARγ in the pathogenesis of MS. William et al. studied the role
of CNS energy metabolism in MS disease progression. The group
measured the levels of lactate, sorbitol, and fructose, all metabo-
lites of extra-mitochondrial glucose metabolism, in the CSF of
relapsing remitting and secondary progressive MS patients (30).
Sorbitol and fructose are the metabolites of polyol pathway that
run parallel to glycolysis and lactate is the metabolite of anaer-
obic pathway. The ﬁnding demonstrated elevated levels of all
three metabolites in the CSF of SPMS patients and to a lesser
extent to RRMS patients (Figure S1 in Supplementary Mater-
ial). These alterations in energy metabolism may contribute to
mitochondrial dysfunction and neuroaxonal degeneration under-
lying MS progression. Taken together, the ﬁnding supports a
link between increased activity of extra-mitochondrial pathways
of glucose metabolism and MS disease progression. Other stud-
ies found that the activity of enolase, pyruvate kinase, Ldh, and
aldolase, all metabolic enzymes was increased in disseminated
sclerosis (20).
A recent investigation demonstrated differences in the gene
expression levels of various NADPH subunits between initial MS
lesions and control white matter brain. The group performed
whole genome proﬁling of MS brain tissue and observed signif-
icant up regulation of nicotinamide dinucleotide phosphate oxi-
dase I and nicotinamide dinucleotide phosphate oxidase organizer
I in active MS lesions (31). NADPH oxidase is a multi-subunit
enzyme complex that is activated under pathological condi-
tions in microglia and catalyzes the production of superoxide
from O2. Other studies have identiﬁed defects in mitochon-
drial electron transport gene expression and function in post-
mortem MS cortex (32, 33). These studies have found tran-
scriptional changes in important mitochondrial genes; however,
translational or post-translational changes in several other pro-
teins may also inﬂuence mitochondrial function and energy
production.
MITOCHONDRIAL DEFECTS IN MS
Mitochondrial dysfunction is implicated in various pathological
conditions like diabetes, anxiety disorders, neurodegenerative dis-
eases such as Alzheimer’s, Huntington’s, and Parkinson’s disease,
and cancer and fatigue (see for instance Table 1). It is only recently
that mitochondrial aberrations have been studied in MS. Unlike
nuclear DNA, mitochondrial DNA (mtDNA) is not surrounded
by histones, proteins that shield nuclear DNA from free radicals.
Therefore it is quite prone to damage. The number of mitochon-
dria in a cell is determined by its energy requirement. For instance,
there may be up to 200–2000 mitochondria present in a single
somatic cellwhereas thenumber is ﬁxed to 16 in spermatozoa germ
cells and 100,000 in oocytes. Metabolically active cells like skele-
tal muscle, cardiac muscle, and brain contain largest number of
mitochondria. It has been seen that the number of mitochondria
and their activity is increased in MS plaques (34). In demyeli-
nating diseases particularly MS, it is likely that cells need ample
energy to survive. Hence, metabolic activity of biomolecules in
mitochondria increases with concomitant impairment of Krebs
cycle and/or neuronal oxidative phosphorylation within the CNS.
Another study revealed a reduction in ATP synthase expression in
MS lesions (35). Mitochondrial proteins are expressed in greater
amounts in both active and inactive lesions. Activity of complex
IV found on mitochondrial membrane is increased dramatically
in MS lesions (30). Lu et al. (36) revealed defects in complex I
component of ETC in white matter lesions. Furthermore, reduced
functional activity of complex I and complex III and a decrease in
gene expression of complex I, complex III, complex IV, and ATP
synthase has been observed in non-lesional motor cortex (33).
A recent ﬁnding demonstrated changes in mitochondrial com-
plex enzyme activities and cytochrome c expression in platelets of
MS patients. Krebs cycle enzyme aconitase activity was higher in
patients without fatigue and all respiratory complex enzyme activ-
ities (complex I, II, III, IV, andV) were higher in MS patients com-
pared to controls. Complex II activity increased signiﬁcantly inMS
group between patients with and without fatigue (42). Interest-
ingly, a signiﬁcant reduction in the gene expression of cytochrome
c oxidase 5B subunit (COX5B) was observed in MS patients (46).
This data suggest that there is a down regulationof genes associated
withmitochondrial ETC.Analysis of a numberof respiratory chain
proteins reveals functionally important defects of mitochondrial
proteins [cytochrome c oxidase (COX) and its catalytic compo-
nent, COX-1] in complex III in MS (47). Different expressions of
mitochondrial proteins namely cytochrome c oxidase subunit 5b
(COX5b), hemoglobin ß, creatine kinase, and myelin basic protein
(MBP) were found in the brain of MS (48). Taken together, these
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Table 1 | Comparison of disturbed glucose metabolism in MS and other neurodegenerative disorders.
Glucose metabolism Multiple sclerosis Other neurodegenerative disorders
Glycolysis Elevated blood pyruvate level was observed in both fasting and
postprandial times in MS patients with relapse (14)
Impaired GAPDH function was observed in subcellular
fractions of ﬁbroblasts from Alzheimer and Huntington
patients (37)
GAPDH was found to be overexpressed in the neocortex
and caudate putamen neurons in a transgenic model of
Huntington’s disease (38)
The activity of GAPDH, hexokinase and pyruvate
kinase was increased in Alzheimer’s disease (AD) (39)
Pyruvate levels were found to be increased in MS (19)
The activity of metabolic enzymes including enolase and pyruvate
kinase was found to be increased in the CSF of MS patients (20)
Antibodies reactive with triose phosphate isomerase (TPI) and
GAPDH, bind with them and inhibit the glycolytic activity of
GAPDH in MS patients (22)
The levels of enolase, pyruvate kinase, Ldh, and aldolase, all
metabolic enzymes were increased in MS (20)
TCA cycle Krebs cycle proteins like α-ketoglutarate levels in fasting and
citrate levels after glucose intake were found to be increased in
MS patients (18)
Mitochondrial aconitase, succinyl-CoA synthetase β,
fumarase and malate dehydrogenase showed
decreased gene expression in hippocampal samples from
autopsy AD brains in two independent studies (40, 41)
Mitochondrial oxoglutarate dehydrogenase, showed
increased and decreased gene expression in moderate
and severe AD patients (40)
α-Ketoglutarate levels were found to be increased in MS (19)
Krebs cycle enzyme aconitase activity was found to be higher in
MS patients without fatigue (42)
Oxidative
phosphorylation
A reduction in the expression ofATP synthase gene was
observed in MS lesions (35)
Decreased mRNA expression levels of ETC proteins,
speciﬁcally FAD synthetase, riboﬂavin kinase (RFK),
cytochrome C1 (CYC1), and succinate dehydrogenase
complex subunit B were reported in amyotrophic lateral
sclerosis (43)
Decreased mRNA levels of the mitochondrial-encoded
cytochrome oxidase (COX) subunits I, II, and III were
observed in brains of AD patients (41, 44, 45)
Reduced expression of nuclear encoded subunits of
mitochondrial enzymes of oxidative phosphorylation
including subunit IV of COX and the beta-subunit of
the F0F1-ATP synthase was also observed in vulnerable
areas of AD brains (41, 44)
Activity of mitochondrial ETC complex IV was increased
dramatically in MS lesions (30)
Defects in complex I component of mitochondrial ETC were
observed in white matter lesions (36)
Furthermore, reduced functional activity of complex I and
complex III and a decrease in gene expression of complex I,
complex III, complex IV, and ATP synthase has been observed
in non-lesional motor cortex (33). In contrast, enzyme activities of
complex I, II, III, IV, andV were found to be higher in MS patients
compared to controls. Complex II activity increased signiﬁcantly
in MS group between patients with and without fatigue (42)
A signiﬁcant reduction in the gene expression of cytochrome c
oxidase 5B subunit (COX5B) was observed in MS patients (46)
Analysis of a number of respiratory chain proteins reveals
functionally important defects of mitochondrial proteins
[cytochrome c oxidase (COX) and its catalytic component,
COX-1] in complex III in MS (47)
Different expression of mitochondrial proteins namely
cytochrome c oxidase subunit 5b (COX5b), hemoglobin β,
creatine kinase, and myelin basic protein (MBP) was found in
the brain of MS (48)
studies show mitochondrial abnormalities that may cause func-
tional disturbance in the surviving demyelinated axons in MS and
may result in neurological dysfunction.
GLUCOSE METABOLISM AND NEURODEGENERATIVE
DISORDERS
A body of evidence indicates a link between disturbed meta-
bolic function and the progression of neurodegenerative diseases
like AD, Huntington’s disease and Parkinson’s disease. A report
documented that GAPDH glycolytic function is impaired in sub-
cellular fractions of ﬁbroblasts from Alzheimer and Huntington
patients whereas the gene expression remained unchanged (37).
This might have occurred due to post-translational modiﬁcation
of the GAPDH protein. In a transgenic model of Huntington’s
disease, GAPDH is seen to be overexpressed in speciﬁc neuronal
populations of several brain regions, such as the neocortex and
caudate putamen neurons. This study also revealed translocation
of GAPDH into the nucleus and the subsequent cell loss in the
neocortex and caudate putamen region of the brain (38). Sim-
ilar ﬁnding was observed by Bae et al. (49), who demonstrated
that GAPDH facilitates nuclear translocation of mutant Hunt-
ingtin protein (mHtt) and causes neurotoxicity. In Aβ (amyloid
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beta) resistant cells of Alzheimer’s brain, glycolytic pathway was
upregulated and hexose monophosphate shunt (HMS) was acti-
vated. The activity of GAPDH, hexokinase, and pyruvate kinase
was increased in both glycolysis andHMS(39). In amyotrophic lat-
eral sclerosis (ALS), abnormalities in ETC have been reported. The
study found decreased mRNA expression levels of ETC proteins,
speciﬁcally FAD synthetase, riboﬂavin kinase (RFK), cytochrome
C1 (CYC1), and succinate dehydrogenase complex subunit B
(SDHB) (43).
CONCLUSION
Despite extensive research being carried out for a decade the
underlying cause of MS still remains elusive. Perturbed glucose
metabolism is implicated in neurodegenerative disorders like
Alzheimer’s, Parkinson’s, and Huntington’s. However, little is
known about its role in MS pathology. The observations reviewed
in this article, especially those referred with mitochondrial aber-
rations and impaired glucose metabolism in MS, pointed to a
relationship between glucose metabolism and MS disease patho-
genesis. Although traditionally considered as an autoimmune,
inﬂammatory, and demyelinating disease of the CNS, the scenario
of MS pathogenesis associated with metabolic abnormalities is
speculated.
These observations open new perspectives for the understand-
ing of metabolic dynamics in MS yet many puzzling aspects and
critical questions need to be addressed. For instance, how does
defect in metabolic pathway contributes to demyelination? Does
metabolic pathway alter in other cell types in MS? The changes in
a cell type, may affect directly, through some unknown factor, or
indirectly, through global changes in metabolic intermediates lev-
els in CSF, to other cell types? Is disturbance in metabolic pathway
a mere cause or a consequence of MS? Could those genes be used
as a pharmacological target to alleviate MS pathology? Much more
research is required to fully unravel the disease mechanism, and a
proper understanding of the disease could eventually lead to new
treatments.
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Gene expression studies employing real-time PCR has become an intrinsic part of
biomedical research. Appropriate normalization of target gene transcript(s) based on
stably expressed housekeeping genes is crucial in individual experimental conditions to
obtain accurate results. In multiple sclerosis (MS), several gene expression studies have
been undertaken, however, the suitability of housekeeping genes to express stably in
this disease is not yet explored. Recent research suggests that their expression level
may vary under different experimental conditions. Hence it is indispensible to evaluate
their expression stability to accurately normalize target gene transcripts. The present
study aims to evaluate the expression stability of seven housekeeping genes in rat
granule neurons treated with cerebrospinal ﬂuid of MS patients. The selected reference
genes were quantiﬁed by real time PCR and their expression stability was assessed
using GeNorm and NormFinder algorithms. GeNorm identiﬁed transferrin receptor (Tfrc)
and microglobulin beta-2 (B2m) the most stable genes followed by ribosomal protein
L19 (Rpl19) whereas β-actin (ActB) and glyceraldehyde-3-phosphate-dehydrogenase
(Gapdh) the most ﬂuctuated ones in these neurons. NormFinder identiﬁed Tfrc as the
best invariable gene followed by B2m and Rpl19. ActB and Gapdh were the least
stable genes as analyzed by NormFinder algorithm. Both methods reported Tfrc and
B2m the most stably expressed genes and Gapdh the least stable one. Altogether our
data demonstrate the signiﬁcance of pre-validation of housekeeping genes for accurate
normalization and indicates Tfrc and B2m as best endogenous controls in MS. ActB
and Gapdh are not recommended in gene expression studies related to current one.
Keywords: housekeeping genes, multiple sclerosis, normalization, GeNorm, NormFinder
Introduction
Techniques employed for calibrating gene expression are paramount in studies directed toward
accurate analysis of transcriptomic proﬁles. Quantitative real time PCR (qRT-PCR) has gained
signiﬁcant momentum over the past decade to quantify gene expression proﬁles. Considering the
utmost sensitivity and reliability of qRT-PCR, a careful selection of a constitutively expressed gene
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is required to account for variation in the amount and quality
of starting RNA and cDNA synthesis eﬃciency. In general,
the expression of target gene transcripts is normalized with
an internal control, often referred to as a housekeeping gene.
Housekeeping (HK) genes are endogenous controls that are
required for the primary function of a cell hence their expression
should be constant in all conditions. However, recent research
has indicated that their expression may not necessarily be stable
in all cells/tissues. A gene showing consistent expression in one
condition may show unstable expression in another. Invariable
expression of the so-called housekeeping genes has been observed
during cellular development (Al-Bader and Al-Sarraf, 2005) and
under distinct experimental conditions (Zhong and Simons,
1999; Hamalainen et al., 2001; Deindl et al., 2002; Glare et al.,
2002; Torres et al., 2003; Radonic et al., 2004; Toegel et al., 2007;
Gubern et al., 2009). Therefore it is essential to pre-validate the
expression stability of reference genes to accurately normalize
the gene expression data. It is recommended that more than one
stably expressed gene should be used for precise normalization
procedure (Zhong and Simons, 1999; Tricarico et al., 2002;
Vandesompele et al., 2002; Ohl et al., 2005).
In this context, we aimed to evaluate the expression stability
of seven commonly used housekeeping genes in cerebellar
granule neurons (CGNs) treated with cerebrospinal ﬂuid (CSF)
from multiple sclerosis (MS) and neuromyelitis optica (NMO)
patients. Axonal damage is widely accepted as a major cause of
persistent functional disability in MS. Therefore to study primary
neuronal damage independent of secondary damage, resulting
from demyelination, we used primary cultures of unmyelinated
CGNs as a cellular model and exposed them to CSF derived
from MS patients. Prior to comprehending mechanisms involved
in axonal degeneration–regeneration, it was ﬁrst necessary to
identify best stably expressed housekeeping genes that can be
used to normalize target mRNA transcripts in our experimental
system. We therefore used a xenogeneic system comprising of
primary rat CGN cultures incubated with CSF from patients with
MS or controls and investigated the stability of reference genes in
these rat neuronal cells. Previous studies in similar xenogeneic
models showed that treatment with human CSF resulted in
neurotoxicity in culture, although the molecular mechanisms
remained unknown (Xiao et al., 1996; Alcazar et al., 2000).
Recently, Vidaurre et al. (2014) reported that ceramides present
in CSF from patients with MS disturb neuronal bioenergetics in
rat neuronal cultures.
Primary cultures of rat CGNs represent an excellent model
to study almost every aspect of neurobiology. While neuronal
cell lines have been very useful in the study of neuronal cell
cultures, there are certain drawbacks they exhibit. These cell
lines are derived from neuronal tumors and hence will show
many important physiological diﬀerences with the cell type
from which they were derived. For instance, the human SH-
SY5Y cell line, was derived by subcloning from the parental
metastatic bone tumor biopsy cell line SK-N-SH (Biedler et al.,
1973). Therefore, it is prudent to use primary cultures because
they are not tumor-derived and hence are more likely to
exhibit the properties of neuronal cells in vivo. Furthermore,
CGNs are small and the most numerous unmyelinated neurons,
therefore we used primary cultures of rat CGNs as a cellular
model and exposed them to diseased CSF to comprehend the
pathophysiological mechanisms implicated in MS and prior
to that validating the expression stability of commonly used
housekeeping genes for their use in future gene expression
experiments.
We selected some frequently used housekeeping genes
from literature to determine their expression stability in our
experimental setting. MS is a major cause of non-traumatic
neurological disability deemed to aﬀect more than 2 million
people worldwide (Blight, 2011). It manifests as a chronic
inﬂammation in central nervous system (CNS) that leads to
demyelination and neurodegeneration. The disease typically
manifests at 20–40 years of age when people are in their full
employment and sometimes develops into an aggressive stage
that alters the lives of patients and their families. Unfortunately
the current treatments are only eﬀective in preventing relapses
and slowing down progression but not completely ceasing
it. Although the pathogenesis of MS is not well understood,
accumulating evidence suggests a complex interplay of both
genetic and environmental factors (Al-Bader and Al-Sarraf,
2005; Compston and Coles, 2008; Oksenberg et al., 2008).
A plethora of gene expression studies have been undertaken
in peripheral mononuclear white blood cells (Der et al., 1998;
Ramanathan et al., 2001; Wandinger et al., 2001; Bomprezzi
et al., 2003; Koike et al., 2003; Sturzebecher et al., 2003;
Hong et al., 2004; Iglesias et al., 2004; Satoh et al., 2006),
in MS brain tissues (Becker et al., 1997; Whitney et al.,
1999; Chabas et al., 2001; Whitney et al., 2001; Lock et al.,
2002; Mycko et al., 2003; Tajouri et al., 2003; Lindberg et al.,
2004; Mycko et al., 2004) and in CSF (Brynedal et al.,
2010). Proteomic approaches have also been used to identify
diﬀerentially expressed proteins in the CSF of MS patients
(Dumont et al., 2004; Hammack et al., 2004; Noben et al.,
2006). However, the proteomics analysis of CSF obtained from
MS patient is relatively challenging. Since proteins are highly
abundant, diversiﬁed, and soluble, only some protein subgroups
may be detected and others important proteins may fail to be
identiﬁed by proteomics approach. Thus, it would be prudent
to use proteomic analysis along with other approaches such
as gene expression proﬁling using microarray. Another similar
but totally distinct neurological disease known as NMO shares
many pathological similarities with MS and therefore it was
previously considered as its variant. For this reason clinicians
often used to encounter diﬃculty in distinguishing MS from
NMO and hence similar treatment was provided to both the
category of patients. However, recent research shows that there
are some NMO speciﬁc IgG antibodies present in the sera of
NMO patients, which diﬀerentiate both the diseases (Lennon
et al., 2004).
In MS, axonal damage is widely accepted as the major cause of
persistent functional disability, although its origin is unknown.
During the relapsing-remitting disease course the patient’s brain
itself is capable of repairing the damage, remyelinating the axon
and recovering the neurological function. CSF is in contact
with brain parenchyma (Rossi et al., 2012, 2014) and a site of
deposition of cellular damaged products, which can inﬂuence
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the cellular physiology of brain cells. It is a promising bioﬂuid
in the search for biomarkers and disease associated proteins in
MS, both with respect to inﬂammatory and neurodegenerative
processes. Exposure of CGNs with CSF from diseased states can
allow us to understand the pathophysiology of MS but prior to
that evaluation of housekeeping genes to accurately normalize
target genes is a crucial step. Selected housekeeping genes were
quantiﬁed using real time PCR to accurately normalize target
genes in our experimental setting. The expression stability of
reference genes was further assessed by GeNorm andNormFinder
algorithms. GeNorm program deﬁnes the gene stability as the
average pairwise variation of a particular gene with all other
control genes and ranks the genes according to their average
expression stability denoted by M (Vandesompele et al., 2002).
The gene with minimum M value is considered to be highly
stable whereas the gene with highest M value is least stable
and can be excluded. An alternative program, NormFinder,
ranks the candidate reference genes based on the combined
estimates of both intra- and intergroup variations (Andersen
et al., 2004).
Materials and Methods
All procedures were approved by the Committee of Animal
Care of Prince Felipe Research Center (CIPF), Valencia, in
accordance with the regulations of the European Union and
Spanish legislation. Informed consent was obtained from all the
patients and controls for this study and authorized by the Ethical
Committee of the Institute.
Patient Cohort
Patient Population
A total of 59 patients were recruited and CSF samples were
obtained from the Department of Neurology, Hospital La Fe and
Hospital Clinico, University of Valencia. Out of 59 patients, 21
had inﬂammatory MS (11 IgM+/+ and 10 IgM +/−), 8 had
medullary subtype, 11 had PPMS, 9 had NMO, and 10 were non-
inﬂammatory neurological controls (NIND patients). In CSF,
apart from factors related to MS or NMO, there are factors from
other diseases that produce their action. This must be considered
as “background noise” as average population. Mixing of total
CSF samples in all clinical forms may potentiate the factors
related to MS. Therefore, we mixed CSF samples in all clinical
forms.
Multiple sclerosis patients were deﬁned and grouped in
diﬀerent clinical courses, according to the current criteria (Lublin
and Reingold, 1996) and diagnosed according to McDonald
criteria. They all met the following characteristics: oligoclonal
IgG bands (OCGB) present, not in a phase of relapse, and
have spent more than a month after the last dose of steroids.
Wingerchuk criteria were used to diagnose patients with NMO
disease (Wingerchuk et al., 2006). Patients suﬀered relapses of
optic neuritis and myelitis, and two of the three criteria, normal
MRI or that did not accomplish the Patty criteria for MRI
diagnosis of MS. Table 1 illustrates the clinical characteristics of
the patients.
Patient Characteristics
Inﬂammatory MS (RRMS and SPMS forms)
MS is categorized into: (1) Relapsing remitting MS (RRMS) that
later develops into secondary progressive stage (SPMS); and (2)
primary progressive MS (PPMS). Over 95% of patients with MS
show oligoclonal bands (OCBs) of IgG in CSF (G+) (Kostulas
et al., 1987) and 40% show IgM OCBs in CSF (M+) related to a
more aggressive course of disease (Sharief and Thompson, 1991).
In our project we also classiﬁed and named inﬂammatory MS
into “IgM+/−” and “IgM+/+ subtype” (see below) on the basis
of aggressivity and prognosis that is more complete than just
RRMS or PPMS. In addition we have studied separately a set
of patients with MS but with a predominant aﬀectation of the
spinal cord, because these patients have some peculiarities, and
we wanted to explore if they have some diﬀerences in light of our
experiments. The most aggressive cases termed as “medullary”
have more spinal injuries.
IgM+/− clinical form of MS
Patients named as “IgM+/− subtype” had IgG antibodies (+) but
no IgM (−) oligoclonal antibodies detected in the CSF of brain.
IgM+/+ clinical form of MS
Patients named as “IgM+/+ subtype” had both IgG antibodies
(+) and IgM (+) oligoclonal antibodies detected in the CSF of
brain.
Medullary clinical form of MS
All these patients were positive for OCGBs and negative for
oligoclonal IgM bands (OCMBs) in CSF of spinal region. The
patients accomplished the Swanton criteria for dissemination in
time.
Primary progressive MS
These patients are characterized by progressive decline in
neurological disability.
Neuromyelitis optica patients
Individuals diagnosed with NMO met at least two of the
following three features. (1) Long extensive transverse myelitis
(>3 vestibule bodies); (2) Antibodies against aquaporin-4; (3)
Normal brain at the ﬁrst event.
Controls [Non-Inﬂammatory Neurological Diseases
(NIND)]
Individuals who were suspected to have MS but were not
diagnosed with MS were classiﬁed as controls.
Cerebrospinal Fluid Samples of Patients
Cerebrospinal ﬂuid samples were obtained by lumbar puncture
at the time of diagnosis. Samples were centrifuged for 10 min
at 700 × g and aliquots were frozen at −80◦C until use. No
patient had received treatment with immunosuppressive drugs,
immunomodulators or corticosteroids for at least 1 month prior
to the extraction of CSF.
Cerebrospinal Fluid Studies
All the studies were performed by immunologists who were blind
to the clinical and MRI data.
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TABLE 1 | Clinical characteristics of the patients studied.
Case # Sex Working clinical form Clinical form Age (years) Evolution time Actual EDSS
1 Female RRMS (+/−) RRMS 23 5 1.50
2 Female RRMS (+/−) SPMS 21 18 4.00
3 Female RRMS (+/−) RRMS 36 4 1.50
4 Male RRMS (+/−) RRMS 22 6 1.50
5 Female RRMS (+/−) RRMS 21 3 3.00
6 Female RRMS (+/−) RRMS 30 22 4.00
7 Female RRMS (+/−) RRMS 29 10 1.50
8 Female RRMS (+/−) RRMS 29 7 1.50
9 Female RRMS (+/−) RRMS 28 10 5.50
10 Female RRMS (+/−) RRMS 28 4 1.00
11 Female RRMS (+/+) RRMS 37 7 3.50
12 Male RRMS (+/+) RRMS 32 4 1.00
13 Female RRMS (+/+) RRMS 44 5 2.00
14 Female RRMS (+/+) RRMS 26 5 2.00
15 Female RRMS (+/+) RRMS 14 18 3.50
16 Male RRMS (+/+) RRMS 25 11 2.00
17 Female RRMS (+/+) SPMS 21 25 8.50
18 Female RRMS (+/+) RRMS 17 16 2.00
19 Female RRMS (+/+) SPMS 23 18 6.50
20 Female RRMS (+/+) SPMS 22 5 4.00
21 Female RRMS (+/+) RRMS 29 5 2.50
22 Male MedMS SPMS 39 10 4.50
23 Female MedMS SPMS 25 6 7.00
24 Female MedMS SPMS 25 14 8.00
25 Male MedMS SPMS 34 9 6.00
26 Male MedMS SPMS 34 6 6.50
27 Female MedMS RRMS 23 5 4.00
28 Female MedMS SPMS 40 10 7.50
29 Female MedMS SPMS 23 28 6.50
30 Female PPMS PPMS 54 12 7.00
31 Male PPMS PPMS 40 23 6.00
32 Female PPMS PPMS 52 14 5.50
33 Female PPMS PPMS 38 11 5.50
34 Male PPMS PPMS 31 24 6.00
35 Female PPMS PPMS 47 14 5.50
36 Male PPMS PPMS 49 11 6.00
37 Female PPMS PPMS 26 13 6.50
38 Female PPMS PPMS 34 6 5.00
39 Female PPMS PPMS 39 8 8.50
40 Male PPMS PPMS 18 15 8.00
41 Female NMO NMO 39 5 9.00
42 Female NMO NMO 50 4 7.00
43 Male NMO NMO 15 17 4.00
44 Male NMO NMO 42 5 3.50
45 Female NMO NMO 22 5 2.50
46 Female NMO NMO 27 5 2.00
47 Male NMO NMO 9 14 1.00
48 Female NMO NMO 8 32 4.00
49 Male NMO NMO 19 20 8.50
50 Male CONTROL CONTROL 23 NA NA
51 Female CONTROL CONTROL 77 NA NA
52 Female CONTROL CONTROL 33 NA NA
53 Female CONTROL CONTROL 32 NA NA
54 Male CONTROL CONTROL 59 NA NA
(Continued)
Frontiers in Cellular Neuroscience | www.frontiersin.org 4 September 2015 | Volume 9 | Article 375
Mathur et al. Assessment of housekeeping genes in multiple sclerosis
TABLE 1 | Continued
Case # Sex Working clinical form Clinical form Age (years) Evolution time Actual EDSS
55 Female CONTROL CONTROL 36 NA NA
56 Female CONTROL CONTROL 57 NA NA
57 Male CONTROL CONTROL 37 NA NA
58 Female CONTROL CONTROL 21 NA NA
59 Male CONTROL CONTROL 13 NA NA
EDSS, Kurtzke expanded disability status scale (method of quantifying disability in MS); MedMS, medullary MS; RRMS, relapsing-remitting multiple sclerosis; PPMS,
primary progressive multiple sclerosis; NMO, neuromyelitis optica; +/−, presense of IgG but no IgM antibodies in the CSF; +/+, presense of both IgG and IgM antibodies
in the CSF; NA, not applicable.
Oligoclonal band studies
Paired CSF and serum samples were analyzed to detect
OCBs (OCGB and OCMB) by isoelectric focusing (IEF) and
immunodetection. We used a commercial kit to determine
OCGB (Helena BioScience IgG-IEF Kit) and the technique
described by Villar et al. (2001) to detect OCMB. Serum
samples were diluted in saline before the IEF in order to
reach the same concentration range as that of CSF samples. All
samples were incubated with 50 mmol/L dithiothreitol at pH
9.5 to reduce IgM. Focusing was performed on a Multiphor
II Electrophoresis System (GE Healthcare) at pH 5–8. Proteins
were then transferred to a PVDF membrane and analyzed
by Western blot. Finally, immunodetection was performed by
biotin-conjugate-goat anti-human IgM and streptavidin-alkaline
phosphatase (Sigma–Aldrich).
Serum studies
Anti-AQP4 antibody in NMO has a high speciﬁcity so as to
contribute to early diagnosis and optimized treatment of Devic
disease. Serum sample diluted 1:10 in PBS-Tween was used to
detect the presence of NMO speciﬁc IgG antibodies. Indirect
immunoﬂuorescence (IFI) was performed to diagnose NMO
(Figure 1B). Antibodies against aquaporin 4 were detected using
a cell line, which was molecular biologically modiﬁed to produce
large quantities of aquaporin 4. In this method (EuroImmun
IIFT) recombinantly transfected cells act as an antigen substrate
to be incubated with diluted serum samples for half an hour.
Animals
Wistar rats (Harlan Iberica) with weight between 200 and 250 g
were used. All animals were raised under controlled conditions
with cycles of light/dark (12/12 h), temperature of 23◦C and
humidity of 60%. Access to water and food (standard rodent
feed supplied by Harlan, Teklad 2014 Global 14% Protein
Rodent Maintenance Diet) was provided. To obtain oﬀspring,
pregnant females were separated and kept in isolated cages during
gestation. The maintenance of the animals was performed in the
animal facilities unit of Prince Felipe Research Center, Valencia,
Spain.
Primary Culture of Cerebellar Granule Neurons
All operations were performed under sterile conditions in vertical
laminar ﬂow chamber (Telstar AV-100 and Bio-II-A). The cells
were kept in an incubator at 37◦C in a humidiﬁed atmosphere
composed of 95% air and 5% CO2 (CO2 incubator Thermo
FIGURE 1 | (A) Immunodetection of oligoclonal bands (OCBs) in serum (S)
and cerebrospinal ﬂuid (CSF) (L). Pattern 1: No OCBs seen (negative,
polyclonal): No OCBs in CSF or serum. No intrathecal Ig synthesis; Pattern 2:
OCBs in CSF only (positive): OCBs present in CSF only. Intrathecal IgG
synthesis as seen in MS; Pattern 3: Identical OCBs in both (mirror images):
Bands in serum mirror those in CSF. This suggests systemic Ig synthesis;
Pattern 4: Identical OCBs in both with extra bands in CSF: Identical bands in
both serum and CSF with extra bands in CSF. Image demonstrates both
intrathecal and systemic Ig synthesis. This is identical as it is seen in MS.
(B) Indirect immunoﬂuorescence in cells transfected by aquaporin 4
(EUROIMMUN Aquaporin-4 IIFT). Panel I: Anti-AQP4 antibodies observed in
the serum of NMO patients (positive sample); Panel II: Absence of anti-AQP4
antibodies in serum sample (negative sample).
Form, model 371). Primary cultures of CGNs were obtained
according to previously described modiﬁed protocol (Minana
et al., 1998). Forebrains were collected from 8 days old Wistar
rats, mechanically dissociated and cerebellum was dissected.
Frontiers in Cellular Neuroscience | www.frontiersin.org 5 September 2015 | Volume 9 | Article 375
Mathur et al. Assessment of housekeeping genes in multiple sclerosis
Isolated cerebella were stripped of meninges, minced by mild
trituration with a Pasteur pipette and treated with 3 mg/ml
dispase (grade II) for 30 min at 37◦C in a 5% CO2 humidiﬁed
atmosphere. After half an hour, dispase was inactivated with
1mM EDTA. Granule cells were then resuspended in basal Eagles´
medium (BME, Gibco, ref. 41010) with 40 μg/ml of DNaseI.
The cell suspension was ﬁltered through a mesh with a pore
size of 90 μm and centrifuged at 1500 rpm for 5 min and
thereafter, cell suspension was washed three times with BME.
Finally, the cells were resuspended in complete BME medium
with Earles´ salts containing 10% heat inactivated FBS (fetal
bovine serum, Gibco), 2 mM glutamine, 0.1 mg/ml gentamycin
and 25 mM KCl. The neuronal cells were counted and plated
onto poly-L-lysine coated 6-well (35-mm) culture dishes (Fisher)
at a density of 3 × 105 cells/well and incubated at 37◦C in a
5% CO2/95% humidity atmosphere. After 20 min at 37◦C, the
medium was removed and fresh complete medium was added.
Since the purpose of our study was to obtain pure cultures of
CGNs, it was necessary to add a chemical that can prevent the
growth of non-neuronal cells. Twenty micro liter of cytosine
arabinoside (1 mM) was added to each culture plate after 18–24 h
to inhibit replication of non-neuronal cells. The cells were kept
in an incubator at 37◦C in a humidiﬁed atmosphere composed
of 95% air and 5% CO2 (CO2 incubator Thermo Form, model
371). Cells were fed every 3–4 days in culture with 5.6 mM
glucose.
Cerebellar granule neurons were stained with Texas Red and
FITC dyes. The nuclei of neuroﬁlaments were stained with DAPI.
Figure 2A shows pure cultures of granule neurons isolated from
cerebellum with stained neuroﬁlaments.
Confocal Microscopy
The living cells were always kept at 37◦C and 5% CO2.
Cells were analyzed on a Leica TCS SP2 confocal microscope
AOBS (Leica Microsystems) inverted laser scanning confocal
microscope using a 63× Plan-Apochromat-Lambda Blue 1.4
N.A. oil objective lens. All confocal images were obtained under
identical scan settings. Images of 1,024◦ × 1,024 pixels, 8-bits
were collected for each preparation. Best focus was based on
highest pixel intensity. Imaging conditions were identical for
all the images, and no images were saturated. Metamorph 7.0
(Molecular Devices, Downingtown, PA, USA) was used for image
analysis on the images collected.
Selection of Housekeeping Genes
Candidate housekeeping genes were selected from those
most commonly used in literature including β-actin (ActB),
hypoxanthine guanine phosphoribosyl-transferase (Hprt),
ribosomal protein L19 (Rpl19), lactate dehydrogenaseA
(Ldha), transferrin receptor (Tfrc), microglobulin beta-
2 (B2m), and glyceraldehyde-3-phosphate-dehydrogenase
(Gapdh). The function and references of the genes are
listed in Table 2. The primers for the selected reference
genes from 5′- to 3′- end were as follows: Actb forward
ATTGAACACGGCATTGTCAC, reverse ACCCTCATAGATGG
GCACAG; Hprt forward CCTCTCGAAGTGTTGGATACAG,
reverse TCAAATCCCTGAAGTGCTCAT;Rpl19 forward ACCT
FIGURE 2 | (A) Immunoﬂuorescence of primary cultures of CGNs. (a) DAPI
stained nuclei. Neuroﬁlaments stained with (b) Texas red and (c) FITC dyes. (d)
Merged images. (B) Analysis of β-actin (a) and Gapdh (b) expression by PCR:
(1) Electrophoretic bands; (2) Integrated density obtained by Image J software
quantiﬁcation. The values correspond with the fold change vs. control values
of the MS clinical forms, NMO, and control patients.
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TABLE 2 | Panel of seven candidate housekeeping genes selected for expression analysis.
Gene
symbol
Gene name mRNA accession
number
Function Reference
ActB β-Actin NM_031144 Cytoskeletal structural Protein Stürzenbaum and Kille, 2001
Hprt Hypoxanthine guanine
phosphoribosyl transferase
NM_012583 Metabolic salvage of purines Everaert et al., 2011
Rpl19 Ribosomal protein L19 NM_031103 Unclear Zhou et al., 2010
Ldha Lactate dehydrogenase A NM_017025 NADH dependent enzyme that
catalyzes reduction of pyruvate
to lactate
–
Tfrc Transferrin Receptor NM_022712 Iron delivery from transferrin to
cells
Gorzelniak et al., 2001
B2m Microglobulin-b-2 NM_012512 Major histocompatibility
complex class I
Yurube et al., 2011
Gapdh Glyceraldehyde-3-
phosphate-dehydrogenase




Fort et al., 1985; Harrison et al.,
2000; Medhurst et al., 2000;
Gorzelniak et al., 2001
GGATGCGAAGGATGAG, reverse CCATGAGAATCCGCTTG
TTT; Ldha forward AGGAGCAGTGGAAGGATGTG, reverse
AGGATACATGGGACGCTGAG; Tfrc forward GTTGTTGAG
GCAGACCTTCA, reverse ATGACTGAGATGGCGGAAAC;
B2m forward GTCGTGCTTGCCATTCAGA, reverse ATTTGA
GGTGGGTGGAACTG; Gapdh forward GGAAACCCATCA
CCATCTTC, reverse GTGGTTCACACCCATCACAA.
Treatment, Total RNA Isolation and cDNA
Synthesis
Neuronal cell cultures were incubated with 10% v/v CSF from
MS (IgM+/−, IgM+/+, medullary, PPMS) patients, NMO
patients and controls for 24 h. This step was performed
to identify transcriptional changes in future transcriptomic
experiments. Total RNA was isolated from cell cultures exposed
to the CSF of diﬀerent experimental conditions (IgM+/−,
IgM+/+, medullary, NMO, PPMS, Control) using Quick RNA
MicroPrep Kit (Zymo Research Corp.). The RNA concentration
was determined spectrophotometrically at 260 nm using the
Nanodrop 1000 spectrophotometer (V3.7 software) and RNA
purity was checked by means of the absorbance ratio at
260/280 nm. Isolated RNA was stored at −80◦ and later reverse
transcribed to cDNA. The cDNA was synthesized and stored
at −20◦C. Primers for selected genes were designed using
Primer 3 software. PCR was performed in a thermocycler
(BioRad) with cycling conditions (94◦ for 30 s, 40 cycles
at 59◦ for 30 s and 72◦ for 30 s). Each 25 μl reaction
contained 12.5 μl Master Mix (Applied Biosystems), 1 μl
gene-speciﬁc forward and reverse primers (0.5 μM), 1 μl
undiluted cDNA and 10.5 μl DEPC (nuclease free) treated water.
Negative controls with no template contained nuclease-free water
instead.
Agarose Gel Electrophoresis and Real-time
Polymerase Chain Reaction of Selected
Housekeeping Genes
The electrophoresis was performed in 1.5% agarose gels, and they
were run at 50 V, stained with ethidium bromide, photographed
and evaluated with ImageJ software. A DNA ladder control
(100 bp, Invitrogen) was also used in the electrophoresis to
evaluate DNA fragment size. Real time PCR was performed in a
96-well plate (Roche) incubated in thermocycler (LC480, Roche)
with cycling conditions (94◦ for 15 s, 45 cycles at 60◦ for 30 s and
72◦ for 30 s). Each 10ml reaction contained 5 ml SYBR Green
Master Mix (Applied Biosystems), 1 μl gene-speciﬁc forward
and reverse primers (0.5 μM), 1 μl undiluted cDNA and 3 ml
DEPC (nuclease free) treated water. Negative controls with no
template contained nuclease-free water instead. All samples were
run in duplicate and average values were calculated. Data was
analyzed using 7300 Sequence Detection Software (SDS) Version
1.3 (Software Roche). Following qRT-PCR, a dissociation curve
was run to check the PCR product speciﬁcity.
Determination of Reference Gene Expression
Stability
To determine the stability of these genes on the basis of
their Cp values, we employed comparative CT method. Data
are plotted as fold change values which were calculated by
2(Ctexp −Ctcontrol) . Cp value is deﬁned as the PCR cycle at which
the ﬂuorescent signal of the reporter dye crosses an arbitrarily
placed threshold. Invariable genes were later assessed by publicly
available software tools named GeNorm and NormFinder.
Results
Demographic and Clinical Proﬁles of MS, NMO
and NIND Groups
Patients were classiﬁed according to detection of OCBs
(Figure 1A) and of aquaporin antibodies (Figure 1B). Baseline
characteristics of the study population are described in Table 3.
Prevalence of MS was found more in women (75%) than in men.
Mean age of MS patients was 30.7 ± 9.7 whereas 25.6 ± 15 for
NMOpatients. According to the clinical classiﬁcation, the general
characteristics ofMS patients are described inTable 4. There were
signiﬁcant diﬀerences observed between the age at beginning
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% Females (n) 60.0 (6) 75.0 (30) 55.6 (5) 0.40 (χ2 )
Age (mean,
SD)
40.3 (19.5) 30.7 (9.7) 25.6 (15.0) 0.04 (ANOVA
test)
EDSS n.a. 4.5 (2.3) 4.6 (2.8) 0.94 (t-test)
Evolution time n.a. 11.1 (6.6) 11.8 (9.7) 0.79 (t-test)
of PPMS and the other two MS forms (p < 0.003); between
the EDSS of RRMS and the two other MS forms (<0.001); the
evolution time between PPMS and RRMS (p = 0.043) after
Bonferroni correction. Table 5 shows the characteristics of MS
patients according to new proposal and working classiﬁcation.
After Bonferroni correction, signiﬁcance was due to diﬀerences
between the age at beginning and the EDSS between medullary
MS and PPMS with the inﬂammatory MS.
We found signiﬁcant diﬀerences in the age at beginning
between PPMS and the other two MS forms (RRMS and
SPMS) after Bonferroni correction (p < 0.003) (Table 6). People
with PPMS are usually older at the time of diagnosis with an
average age of 40. Furthermore, diﬀerent subtypes of MS help
predict disease severity and response to treatment hence their
categorization is important. In our study, we found signiﬁcant
diﬀerences between the “Expanded Disability Status Scale”
(EDSS) of RRMS and the two other MS forms (SPMS and PPMS)
(p < 0.001) (Table 5). Although nerve injury always occurs, the
pattern is speciﬁc for each individual with MS. Disease severity
and disability increases from relapsing-remitting to secondary
progressive course and in PPMS subtype, symptoms continually
worsen from the time of diagnosis rather than having well-
deﬁned attacks and recovery. PPMS usually results in disability
earlier than relapsing-remitting MS. Signiﬁcant diﬀerences were
found in the evolution time from the ﬁrst to the second episode
between RRMS and PPMS (p = 0.043). In patients experiencing
a progressive course, evolution time was similar in secondary
progressive cases and in cases that were progressive from onset
(13.5 versus 13.8) (Table 5).
According to the new proposal and working classiﬁcation,
inﬂammatory MS subtypes shared similar age at disease onset
(mean= 26.7 versus 26.3 years; p= 0.005). Signiﬁcant diﬀerences
were found between the age at disease onset in medullary MS
and PPMS with the inﬂammatory MS (p < 0.005). The degree
of disability as measured by EDSS was similar in medullary MS
and PPMS (6.2 versus 6.3) whereas signiﬁcant diﬀerences were
found between disability extent in medullary MS and PPMS with
the inﬂammatory MS (p < 0.001). IgM+/− represents the less
aggressive inﬂammatory subtype with OCGB in CSF with poor
prognosis whereas IgM+/+ signiﬁes a more aggressive category
with OCGB and OCMB in CSF with worse prognosis. On the
contrary, medullary MS represents the most aggressive subtype
of MS with increased neurological disability and dysfunction
as compared to inﬂammatory subtypes. Disability in patients
experiencing PPMS worsens over time with no relapses and
remission.
Identiﬁcation of Stably Expressed
Housekeeping Genes
PCR of Gapdh and β-actin
We ﬁrst quantiﬁed ActB and Gapdh genes using conventional
PCR in treated neuronal samples and ran agarose gel
electrophoresis. We found that both β-Actin and Gapdh
genes, which are presumed to express at constant levels
showed varying band intensity in CGNs when treated with
the CSF from MS and NMO patients (Figure 2B). From this
data we conclude that both ActB and Gapdh genes are not
suitable to normalize gene transcripts in our experimental
conditions.
Quantitative PCR of Housekeeping Genes in our
Experimental Conditions
Quantitative real time PCR was performed for a group of
frequently used reference genes. GeNorm and NormFinder
algorithms were used to assess the most stably expressed genes.
Our data suggests Tfrc, B2m as the most stable genes followed
by Rpl19 using GeNorm software (Average expression stability
value denoted by M: 1.09 for Tfrc and B2m; M: 1.19 for Rpl19).
Similarly, Tfrc showed most stable expression as assessed by
NormFinder algorithm followed by Ldha and Rpl19 (M: 0.54
for Tfrc; M: 0.58 for Ldha and 0.97 for Rpl19) (Table 6). On
the other hand, β-Actin and Gapdh showed highest ﬂuctuation
in our experimental conditions with 2.9 and 4.2 as the average
expression stability value by GeNorm. Therefore their use is
strictly discouraged while normalizing gene expression data in
studies related to the current one.
Table 6 illustrates candidate housekeeping genes ranked in
CGNs treated with CSF from MS/NMO patients according to
their expression stability by GeNorm and NormFinder methods.
The Ct values of all the experimental conditions obtained from
qPCR experiment were normalized to control. Then we plotted
the fold change values for each reference gene tested in distinct
disease courses of MS and NMO patients (Figure 3). Fold change
was calculated by 2(Ctexp −Ctcontrol).
ActB
We found that the expression of ActB gene dropped to 0.2 folds in
neurons treated with IgM+/−MS patients and increased again to
1.4 folds in IgM+/+ treated neurons, as compared to control. In
neurons treated with medullary CSF the gene expression dropped
to 0.04 folds and 0.2 folds in PPMS and increased to 1.78 folds in
NMO patients compared to control. Although the variation in
the expression level of this gene in all the diﬀerent experimental
conditions is not large as seen by qPCR data, we employed
GeNorm software to compare the expression stability of all the
reference genes with each other and identify the best reference
gene out of a group of commonly used reference genes to avoid
getting biased results. The software GeNorm ranked ActB gene
as second last unstable gene as compared to the expression levels
of other selected reference genes (M value: 2.92 using GeNorm).
We conclude that this gene varies in our experimental conditions
with respect to other selected reference genes. Hence it should not
be used to normalize gene expression data in our experimental
conditions.
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TABLE 4 | Characteristics of MS patients according to the clinical classiﬁcation.
RRMS (n = 18) SPMS (n = 11) PPMS (n = 11) p
% Females (n) 83.3 (15) 72.7 (8) 63.6 (7) 0.48 (χ2 )
Age (mean, SD) 27.3 (7.2) 27.9 (7.3) 38.9 (11.2) 0.003 (ANOVA test)
EDSS 2.4 (1.2) 6.2 (1.5) 6.3 (1.1) <0.001 (ANOVA test)
Evolution time 8.1 (5.4) 13.5 (7.8) 13.8 (5.7) 0.043 (ANOVA test)
After Bonferroni correction, signiﬁcance were due to differences between the age at beginning between PPMS and the other two MS forms; between the EDSS of RRMS
and the two other MS forms; the evolution time between PPMS and RRMS.
TABLE 5 | Characteristics of MS patients according to new proposal and working classiﬁcation.
Inﬂammatory MS (n = 21) Medullar MS (n = 8) PPMS (n = 11) p
G+/M− (n = 10) G+/M+ (n = 11)
% Females (n) 90 (9) 81.8 (9) 62.5 (5) 63.6 (7) 0.40 (χ2 )
Age (mean, SD) 26.7 (4.8) 26.3 (8.7) 31.4 (7.0) 38.9 (11.2) 0.005
EDSS 2.5 (1.5) 3.4 (2.2) 6.2 (1.4) 6.3 (1.1) 0.000
Evolution time 8.9 (6.3) 10.8 (5.9) 8.5 (3.1) 13.8 (5.7) 0.154
After Bonferroni correction, signiﬁcance was due to differences between the age at beginning and the EDSS between Medullar MS and PPMS with the inﬂammatory MS.
TABLE 6 | Candidate housekeeping genes ranked in cerebellar granule neurons treated with CSF of MS/NMO patients according to their expression
stability by Genorm and Normﬁnder methods.
Genorm Normﬁnder
Ranking order Gene name Average M value Ranking order Gene name Stability value
1 Tfrc 1.092 1 Tfrc 0.546
1 B2m 1.092 2 Ldha 0.589
2 Rpl19 1.198 3 Rpl19 0.972
3 Ldha 1.253 4 B2m 1.102
4 Hprt 1.318 5 Hprt 1.379
5 ActB 2.929 6 ActB 6.099
6 Gapdh 4.201 7 Gapdh 6.953
M, average expression stability measure of seven reference genes with Tfrc the most stable gene and Gapdh the least stable. Lower M value of average expression
stability indicates more stable expression while the highest M value indicates variable expression. Bold indicates most stably expressed genes.
Hprt
The data indicates that Hprt gene was 0.23 folds downregulated
in neurons treated with IgM+/−CSF ofMS patients as compared
to control. The expression was up regulated 1.7 times in IgM+/+
treated neurons and again down regulated by 0.1 folds, 0.27 folds
and 0.4 folds in neurons treated with the CSF of medullary, PPMS
and NMOpatients as compared to control. According toGeNorm
program, Hprt was ranked third last unstable reference genes
with respect to other reference genes (Average expression stability
value: 1.3).
Rpl19
Rpl19 gene expression was down regulated by 0.2 and 0.5 folds in
IgM+/− and IgM+/+ treated neurons as compared to control.
There was only 0.1 folds decrease in Rpl19 gene expression when
neurons were treated with medullary, PPMS and NMO patients
as compared to control. Hence, there is a negligible variation in
all the experimental conditions as indicated by qPCR data. In
agreement with this data GeNorm identiﬁes this gene as the third
most stable gene (M value: 1.19).
Ldha
There was 0.5 folds downregulation of Ldha gene in neurons
treated with the CSF of IgM+/− patients with respect to
control. The expression level increased up to fourfolds in neurons
treated with IgM+/+ treated neurons. In medullary, there was
a 0.17 folds decrease in gene expression and we found 0.28
folds and 0.54 folds decrease gene expression in PPMS and
NMO patients. The data signiﬁes that the expression of this
gene is not constant in all the experimental conditions. The
average expression stability (M) value of this gene was 1.25
and was ranked as the fourth stable gene according to GeNorm
software.
Tfrc
Tfrc gene was up regulated by 1.2 folds in neurons treated with
IgM+/− treated neurons as compared to control. In IgM+/+
treated neurons the expression level almost remained the same
as compared to control. In medullary patients the expression
was reduced by 0.2 folds and in PPMS treated neurons the
level was increased by only 1.1 folds which was almost similar
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FIGURE 3 | Fold change for each reference gene tested in distinct disease courses of multiple sclerosis (MS). IgM+/+ and IgM+/−: Inﬂammatory forms
of relapsing remitting MS; Med: medullary form; NMO: neuromyelitis optica; Control: other non-inﬂammatory neurological diseases (NIND).
as compared to control. There was a downregulation of this
gene by 0.4 folds in neurons treated with the CSF of MS
patients. Overall, there was a negligible variation in the gene
expression in diﬀerent experimental conditions. According to
the GeNorm algorithm the average expression stability value was
1.092 and it was ranked the best reference gene with respect to
others.
B2m
The data indicates that there was 1.2 folds up regulation of B2m
gene in IgM+/− treated neurons as compared to control. The
expression was down regulated by 0.9 folds in IgM+/+ treated
neurons which was not a large variation as compared to control.
It dropped to 0.2 folds in medullary treated neurons and 0.4 folds
in PPMS treated neurons. The expression decreased by 0.8 folds
in NMO treated neurons as compared to control. According to
the GeNorm algorithm the average expression stability value was
similar to Tfrc average expression stability (M: 1.092) and it was
also ranked the best reference gene with respect to others. We
conclude that both Tfrc and B2m with similar average expression
stability values should be used to normalize gene expression data
in our experimental conditions.
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Gapdh
The expression level of Gapdh gene was 0.89 folds lower in
IgM+/− treated neurons as compared to control. The expression
level increased by twofolds in IgM+/+ treated neuons as
compared to control. In neurons treated with the CSF of
medullary MS patients the gene downregulated by 0.02 folds
and by 0.1 fold in neurons treated with the CSF of PPMS
patients. Similarly the expression level declined by 0.38 folds in
NMO treated patients. According to qPCR data that there is a
huge ﬂuctuation in Gapdh gene expression in our experimental
conditions. Normally, Gapdh is used as a housekeeping gene but
we ﬁnd that it is not a housekeeping gene in our experimental
conditions. GeNorm ranked this gene as the least stable gene with
4.2 as the average expression stability value.
Discussion
Quantitative RT-PCR has recently become the most widely
accepted method of quantiﬁcation for its sensitive, accurate and
reliable determination of gene expression levels in cells and
tissues. To avoid sample-to-sample variation, normalization of
gene transcripts is required. The conventional way to perform
normalization is to select a housekeeping gene whose expression
is believed to remain stable in all cell types/tissues, during
cellular development and under various experimental conditions
then relate the expression of gene of interest to that of a
housekeeping gene. For many years it has been assumed that
the genes such as β-Actin and Gapdh express constitutively in
all cells and tissues. β-Actin (ActB) is a cytoskeletal protein
that maintains the structure and integrity of cells. GADPH,
on the other hand, is a key glycolytic enzyme involved mainly
in the production of energy. Since both ActB and Gapdh are
involved in maintaining the basic metabolic functions of a
cell, they are presumed to express at stable levels. Therefore,
they are employed as common internal controls in most of
the laboratories. However, several lines of evidence show that
their rate of transcription is aﬀected by a variety of factors
such as epidermal growth factor, transforming growth factor-β
and platelet-derived growth factor while constitutively expressed
(Elder et al., 1984; Leof et al., 1986; Keski-Oja et al., 1988).
Therefore, their expression may not necessarily be constant
in all conditions. Furthermore, GADPH is implicated in non-
metabolic processes independent of its metabolic function, such
as transcription activation, vesicle transport from endoplasmic
reticulum to Golgi apparatus and polymerization of tubulin into
microtubules (Kumagai and Sakai, 1983; Durrieu et al., 1987;
Muronetz et al., 1994; Zheng et al., 2003; Tisdale and Artalejo,
2007). Previous literature reveals that neuronal apoptosis is
associated with suppressed glycolytic activity of GADPH (Burke,
1983; Dastoor and Dreyer, 2001; Makhina et al., 2009). It has been
observed that GADPH interacts with other proteins which results
in reduced glycolytic activity (Hara et al., 2005). This process may
lead to neuroaxonal damage in neurodegenerative diseases such
as Huntington’s, Parkinson’s, and Alzheimer’s disease (Vécsei and
Pál, 1993; Mazzola and Sirover, 2003; Senatorov et al., 2003;
Li et al., 2004; Tsuchiya et al., 2005; Kolln et al., 2010). The
realization that these reference genes may ﬂuctuate in diﬀerent
experiments has led to their pre-validation for their expression
stability.
This is the ﬁrst study to the best of our knowledge that
reports the most stable HK genes in CGNs treated with CSF from
MS/NMO patients. Seven commonly used housekeeping genes
were chosen from the available literature. Expression levels of HK
genes in diﬀerent MS clinical forms were quantiﬁed by qRT-PCR.
Our results reveal that Gapdh expression levels changed in all
forms (RRMS, PPMS, NMO) as compared to controls. This gene
was not among the best reference genes therefore it is strongly
advised not to employ it as a control in studies related to current
one. Moreover, β-Actin, that is often used as a loading control
also showed unstable expression in all conditions, though to a
lesser extent than Gapdh. Transferrin receptor (Tfrc) gene was up
regulated by 1.2 folds in neurons treated with IgM+/− treated
neurons as compared to control. In IgM+/+ treated neurons
the expression level almost remained the same as compared to
control. In medullary patients the expression was reduced by
0.2 folds and in PPMS treated neurons the level was increased
by only 1.1 folds which was almost similar as compared to
control. There was a downregulation of this gene by 0.4 folds
in neurons treated with the CSF of MS patients. Overall, we
see from the data that there was a negligible variation in the
Tfrc gene expression in diﬀerent experimental conditions. Tfrc is
required for iron delivery from transferrin to cells. Microglobulin
beta-2 (B2m), a component of MHC class I molecule, showed
higher expression in IgM+/− treated neurons as compared to
control. The expression was down regulated by 0.9 folds in
IgM+/+ treated neurons which was not a large variation as
compared to control. It dropped to 0.2 folds in medullary treated
neurons and 0.4 folds in PPMS treated neurons. The expression
decreased by 0.8 folds in NMO treated neurons as compared
to control. According to the GeNorm algorithm the average
expression stability value was similar to Tfrc average expression
stability (M: 1.092) and it was also ranked the best reference
gene with respect to others. We conclude that both Tfrc and B2m
with similar average expression stability values should be used to
normalize gene expression data in our experimental conditions.
Hypoxanthine guanine phosphoribosyl-transferase (Hprt) gene
showed ﬂuctuated expression level in diﬀerent experimental
conditions. It plays an important role in purine salvage pathway.
According to GeNorm program, Hprt was ranked third last
unstable reference genes with respect to other reference genes
(Average expression stability value: 1.3). Ribosomal protein L19
(Rpl19) showed negligible down regulation in all the diﬀerent
experimental conditions. GeNorm identiﬁes this gene as the third
most stable gene (M value: 1.19). On the contrary, Ldha gene
was upregulated in IgM+/+ but down regulated in IgM+/− and
medullar clinical form of RRMS. Its expression further lowered
in PPMS and NMO. The data signiﬁes that the expression of this
gene was not constant in all the experimental conditions and not
suitable for normalization of gene transcripts in studies related to
the current one.
Overall, geNorm and NormFinder algorithms identiﬁed Tfrc
and B2m the best housekeeping genes and Gapdh and ActB the
most unsuitable genes in our experimental model of MS and
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therefore the current study demonstrates the necessity for pre-
validation of HK genes for any experimental system. Since both
the algorithms are based on diﬀerent mathematical approaches,
the order of genes was not exactly similar. However, both geNorm
and NormFinder rank the traditional reference genes GAPDH
and β-actin as most unstable genes. Therefore, we strongly advise
to check the expression stability of these genes before using them
for normalization purposes.
We conclude from data provided in this study that transferrin
receptor (Tfrc) and microglobulin beta-2 (B2m) as the most
stably expressed housekeeping genes in CGNs treated with CSF
of MS patients. On the other hand, Gapdh and β-actin showed
highly ﬂuctuated expression indicating their unsuitability for
such studies. This study demonstrates the usefulness of pre-
validating the expression stability of housekeeping genes for
normalization of target gene transcripts in gene expression
studies. Our data suggest that it is required to determine
the suitability of any common HK genes to be used for
normalization in “Omic” studies, and even such pre-selection
should be a routine step for any experimental system in a
laboratory.
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